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Basic concepts of pain
Pain is a subjective experience. Two individuals with exactly the same cause of pain, can 
feel different intensities of pain. In fact, pain can be present without a clear anatomical 
substrate.
The International Association for the Study of Pain (IASP) defines pain as: “An unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage”.1 Following this definition, pain requires the integration 
of sensory, cognitive, and affective information. Pain research is complicated by this 
multidimensional and subjective character of pain. Commonly used instruments to 
quantify pain in individuals, such as the visual analogue scale (VAS) and numeric rating 
scale (NRS), assess the amount of pain, but are sensitive to various kinds of bias.2,3
Acute pain is an important protective function of our body, that normally disappears when 
the injury has subsided. However, in some situations, acute pain becomes chronic often 
for unclear reasons. Pain is then no longer protective, but maladaptive, resulting from 
abnormal functioning of the peripheral and central nervous system.
Chronic pain is defined as: “any pain that persists beyond the anticipated time of healing”.4 
Usually pain is regarded as chronic when it lasts or recurs for more than 3 months.5 Chronic 
pain of moderate to severe intensity occurs in 19% of adult Europeans, seriously affecting 
their daily activities, social and working lives.6 Chronic pain can be classified in different 
categories including chronic visceral pain, such as chronic pancreatic pain, and chronic 
postsurgical pain. 
Chronic pancreatic pain
Chronic pancreatitis (CP) is a major source of morbidity in European countries, with 
an annual incidence of approximately 6.0 per 100.000 inhabitants.7 CP is a disease 
characterised by progressive destruction of the pancreatic gland, usually resulting in 
impairment of exocrine and endocrine function.8 Abdominal pain is the most frequent and 
dominant symptom in CP, and most patients develop recurrent episodes of chronic pain 
during the course of their disease. The pain is typically described as a constant, severe, dull 
pain in the epigastrium, which often radiates to the flanks and back. However, this classical 
pain pattern is not universal and differs among patients in character, location and severity.9 
Currently, the main treatment methods for chronic pancreatitis are focused on correction 
of pancreatic insufficiency, management of complications, and pain management.10
The pathophysiology causing pain in CP is incompletely understood and multifactorial. 
Several underlying mechanisms have been suggested: 1) increased intrapancreatic 
pressure within the pancreatic duct or parenchyma resulting in tissue ischemia; 2) 
inflammation in the pancreas; 3) extrapancreatic causes of pain such as bile duct 
and duodenal stenosis due to extensive pancreatic fibrosis and inflammation, and 4) 
maladaptive plasticity within the nervous system including alterations in peripheral 
nerves and central sensitisation.11-13 Because these underlying pain mechanisms are 
poorly understood, treatment is challenging and often unsatisfactory.14 Therefore, 
pancreatic pain carries a high burden of morbidity because of its long duration and 
recurrent attacks.
Chronic postsurgical pain
Chronic postsurgical pain (CPSP) is increasingly recognized as a potential adverse 
outcome of surgery, in particular after limb amputation, breast surgery, thoracotomy 
and inguinal hernia repair.15-17
CPSP is defined as pain developing after surgery and persisting for at least three months.4 
However, many debate this timeframe, as wound healing and postsurgical inflammation 
can still persist and pain complaints may decline up to over a year.18-20
Incidences of moderate to severe CPSP at 12 to 36 months after surgery range from 12% - 
18% in European countries.21,22 In 23% of the patients visiting chronic pain clinics, surgery 
is considered the cause of pain, that is most frequently (48%) located in the abdomen.23 
Abdominal CPSP is often refractory to treatment and thought to be the result of a 
combination of factors. Some researchers suggest that intra-abdominal adhesions 
are the primary cause for this pain.24 Adhesions are fibrous bridges that connect two 
(abdominal) tissues that normally freely move along each other and develop after nearly 
every abdominal surgery. In studies following patients with chronic postoperative pain 
after previous surgery, adhesions were identified as the most likely cause of pain during 
diagnostic laparoscopy in 57% of patients.25 An alternative hypothesis for explaining 
persistent postsurgical abdominal pain is that pain results from nerve injury (i.e. 
neuropathic pain). Hence, neuropathic pain develops as a result of a lesion or disease 
affecting the somatosensory nerves system either in the peripheral or central nervous 
system.26 Moreover, CPSP is associated with changes in pain sensibility originated from 
plasticity of the central nervous system,27 and decreased inhibitory pain modulation.28,29
Neural reorganization of chronic pain
A complex neural reorganization from the periphery to the neocortex seems to occur 
for different types of chronic pain.30 First, pain chronicity is associated with peripheral 
reorganization of afferent signalling, changing sensitivity for nociceptors, and possibly 
for tactile afferents.30 Chronic pain is also associated with increased responsiveness 
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of nociceptive neurons in the central nervous system, termed central sensitization.31 
Changes to nociceptive signal processing in the central nervous system are typically 
expressed as hyperalgesia, i.e. increased pain in response to noxious stimuli, and 
allodynia, i.e. pain in response to a non-nociceptive stimulus. Additionally, accumulating 
evidence shows that the human brain undergoes extensive reorganization in chronic 
pain conditions.32 Several characteristic changes in central pain processing are also 
observed in patients with painful CP and CPSP,12,13 but need to be further investigated.
Pharmacological pain management
The standard extrapolated guideline for analgesic treatment follows the principles of the 
“pain relief ladder” provided by the World Health Organisation.33 However, satisfactory 
pain relief is often lacking or incomplete, which can be attributed to the different 
multidimensional pain mechanisms underlying the individual chronic pain condition. 
Because central sensitization alters the properties of neurons in the central nervous 
system, the pain is frequently no longer reliably coupled to the presence of particular 
peripheral stimuli. Therefore, research is increasingly focused on (adjuvant) analgesics, 
that modify these underlying pain processes. 
Cannabis-based drugs as potential analgesic
The medical use of cannabis has received increasing attention since the discovery of delta-
9-tetrahydrocannabinol (THC) in 1964, which is the principal psychoactive compound 
of the Cannabis sativa plant.34 Interest in the therapeutic potential of cannabinoids has 
escalated further with the discovery and cloning of the endocannabinoid system in 
the early 1990s. THC induces its effects by binding to two types of G-protein-coupled 
cannabinoid receptors, termed CB1 and CB2.35,36 CB1 receptors are predominantly found 
in the brain and spinal cord, in particular highly expressed in brain regions critical for 
emotion processing including the amygdala, hippocampus, and anterior cingulate 
cortex.37 Although CB2 receptors are also found in the central nervous system, CB2 is 
mainly considered a peripheral cannabinoid receptor. CB2 receptors are mostly observed 
on cells of the immune system, including the pancreas, and is therefore speculated to 
play a part in immunoregulatory responses.38
Patients who use medicinal cannabis these days, usually take in THC by means of 
smoking or vaporizing. Inhalation is known to produce a reliable pharmacokinetic 
profile, however it has some obvious disadvantages. Additionally, whole plant extracts 
of cannabis contain a complex mixture of natural cannabinoids and other chemical 
compounds. These may interact to provide a superior therapeutic profile, but on the 
other hand, may also induce unintended adverse events. To avoid adverse events, new 
pharmaceutical products were developed containing either natural or synthesized 
THC (dronabinol is the international non-proprietary name (INN) of THC). One of these 
pharmaceutical products is Namisol® (Echo Pharmaceuticals, Weesp, The Netherlands), 
which is an oral tablet containing pure, natural THC isolated from the Cannabis sativa 
plant. It was developed using a novel drug delivery technology, AlitraTM, to improve the 
absorption and bioavailability of poorly soluble lipophilic compounds. A previous phase 
I study of single doses THC demonstrated reliable pharmacokinetic and tolerability 
profiles in healthy young volunteers.39 
Neurophysiological assessment of pain
Several techniques have been used to study the complex reorganisation of chronic 
pain in the central nervous system, e.g. quantitative sensory testing (QST), positron 
emission tomography (PET), (functional) magnetic resonance imaging ((f )MRI) 
and electroencephalography (EEG). Each technique, has greatly contributed to our 
knowledge of underlying pain mechanisms and provided new insights for the diagnoses 
and treatment of chronic pain. These techniques are also increasingly used to evaluate 
the efficacy and mechanisms of (novel) analgesics.
QST comprises a standardized sensitivity test consisting of thermal, mechanical 
or electrical stimuli. Calibrated stimuli are applied to capture perception and pain 
thresholds, thus providing information on the presence of sensory loss as well as a gain 
of function (e.g. hyperalgesia),40 linked to different levels of the nervous system. QST has 
the disadvantage that it is a psychophysical test, reflecting the subjective report from 
a patient to a objective stimulus, making QST susceptible to various kind of biases and 
measurement errors. 
Neuroimaging tools such as fMRI and PET have a high spatial resolution, but measure 
indirect measures of neuronal activity, resulting in a relatively poor temporal resolution. 
EEG directly measures the brain’s electrical activity, giving high temporal resolution but 
low spatial resolution. Other advantages of EEG are the relatively low costs and portable 
and easy to apply equipment compared to neuroimaging equipment. This allows EEG-
based methods more easily for clinical use. 
Electroencephalography
In 1924, Hans Berger recorded the first human EEG on the surface of the scalp.41 He 
observed that EEG consistently changed with the general status of the subject, e.g. 
from relaxation to alertness. Berger also concluded that brain activity could be seriously 
affected by certain pathologic conditions such as convulsive seizures.42 Since then, EEG 
measurements are commonly used for both clinical and research purposes. 
EEG is described as electrical activity of an oscillating type generated by brain structures 
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recorded from the scalp surface. Neurons are specialized cells that are able to transmit 
electrical signals from one cell to another and produce local current flows. EEG measures 
mainly the electrical currents that flow during synaptic excitations of the dendrites of 
many pyramidal neurons in the cerebral cortex. Only large populations of active neurons 
can generate electrical activity recordable on the scalp surface by amplification strategies.
The EEG originates from the difference between the electric potential of a surface 
electrode with respect to a reference surface electrode. The peak to peak amplitude of the 
EEG is relatively small, normally ranging from 0.5 to 100 μV in amplitude, when measured 
on the scalp. EEG recordings are generally divided into two types: spontaneous EEG at a 
resting state and evoked EEG in response to a stimulus.
Frequency analysis of spontaneous brain activity 
The spontaneous EEG, also called resting state EEG, is recorded during a state of awake 
rest and characterized by sinusoidal oscillations. Several signal processing techniques, 
such as Fast Fourier Transform (FFT), are applied to extract specific characteristics from 
the raw EEG signal. FFT transforms a signal from the time domain into the frequency 
domain. Basically, the raw EEG signal consists of multiple slow and rapid oscillations, that 
can be broken down in sinusoids at each different frequencies and plotted in a frequency 
power-spectrum. The bandwidth ranges from 1 Hz to about 80 Hz and is typically 
described in distinct frequency bands, such as delta (1-4 Hz), theta (4-7.5 Hz), alpha (7.5-
13 Hz), beta (13-32 Hz), and gamma (32-80 Hz). The resting state EEG with eyes closed is 
dominated by oscillations in the alpha-band, most prominently recorded at the parietal 
and occipital cortex.43
Evoked brain potentials
Evoked potentials (EPs) involve voltage polarity changes in the EEG in response to 
the onset of a stimulus. EP amplitudes tend to be low compared to amplitudes of the 
spontaneous EEG activity components, so single EPs are difficult to recognize from the 
raw EEG signal. Therefore, EP recordings are averaged across epochs of EEG time-locked 
to a set of repeated stimuli. This signal averaging improves the signal to noise ratio, 
whereby the stimulus-specific activity becomes visible as an EP.44 An EP thus reflects, with 
high temporal resolution, only that brain activity which is consistently associated with 
the stimulus processing. EPs can be elicited by stimuli of various modalities, which may 
be electric, auditory, visual, somatosensory, etc., resulting in different stimulus-specific 
EP patterns. An EP is characterised by different peaks with corresponding latencies and 
amplitudes. It is generally assumed that early components of EPs largely depend on the 
physical parameters of the stimulus, whereas late components of EPs are related to the 
manner in which the subject evaluates the stimulus.45
Aims of this thesis
The first goal of this thesis was to investigate potential neuroplastic changes in brain 
activity associated with chronic pain using both spontaneous and evoked EEG recordings. 
The second goal of this thesis was to evaluate the therapeutic potential of a novel oral 
tablet containing purified THC for the treatment of chronic abdominal pain. Therefore, 
several phase II clinical drug studies were performed in order to evaluate the efficacy, 
safety and tolerability of oral THC in patients with chronic abdominal pain. Beyond 
these clinical outcome measures of analgesia, we aimed to investigate experimental 
pain measures utilizing EEG in order to study potential antinociceptive effects of THC in 
chronic pain management. 
Thesis outline
The aims of this thesis have been elaborated in observational EEG studies, phase 2 
clinical drug studies using several clinical and experimental outcomes and a review. The 
thesis can be subdivided into three consecutive parts: 
PART I: Cortical processing in chronic (postsurgical) pain
Changes in brain activity have been observed in several chronic pain conditions, 
suggesting that chronic pain involve changes in central pain processing mediated 
through mechanisms of neural plasticity. This concept of central plasticity has been 
further explored in the first part of this thesis utilizing different EEG techniques.
In Chapter 2, we described the cortical processing of painful stimuli recorded in the EEG 
in patients with persistent pain after breast cancer surgery compared with those patients 
without persistent pain after breast cancer surgery. Changes in cortical processing 
were recorded in the EEG utilizing pain related EPs to noxious electrical stimuli. We 
hypothesized that chronic pain is associated with an enhanced brain response to painful 
stimuli in supposed neuropathic pain.
Alterations in central pain processing were also studied in patients with painful 
CP, a serious form of visceral pain, which is described in Chapter 3. In this study, we 
investigated the brain’s resting state activity within the alpha frequency band in chronic 
pain patients related to CP in order to explore novel potential EEG biomarkers for chronic 
pain. The clinical usefulness of EEG biomarkers for CP pain and the relation to disease 
progression were also addressed.
PART II: Efficacy and safety of tetrahydrocannabinol in chronic abdominal pain
The majority of clinical trials assessing the efficacy of THC for pain treatment have been 
focused on cancer-related pain, central neuropathic pain syndromes, and acute pain 
conditions. We aimed to investigate the therapeutic potential of THC in patients with 
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chronic abdominal pain.
Chapter 4 describes the results of a randomized, single dose, double-blinded, placebo 
controlled crossover study in patients with painful CP. We present the analgesic efficacy, 
pharmacokinetic profiles, pharmacodynamic effects and safety results of a single dose 
oral THC in CP patients with chronic abdominal pain subdivided into opioid and non-
opioid users.
The results of a randomized, double-blind, placebo-controlled trial evaluating the 
analgesic efficacy, pharmacokinetics, and tolerability of oral THC in patients with chronic 
abdominal pain during a treatment period of 50-52 days are described in chapter 5. THC 
was administered 3 times daily during a treatment period of 50-52 days.
Chapter 6 provides an overview of clinical trials that have been conducted to investigate 
the analgesic efficacy of cannabis-based products with standardized THC content for 
chronic non-malignant pain. Furthermore, common limitations in clinical trials and 
a mechanism-oriented approach to evaluate the therapeutic potential of THC are 
discussed in this review. 
PART III: Neuronal mechanisms of tetrahydrocannabinol 
The experimental outcome measures of the clinical trials comparing THC and placebo are 
discussed in the last part of this thesis. Chapter 7 addresses the antinociceptive effects 
of THC by investigating underlying pain related cortical activity in a crossover study. We 
investigated whether a single dose of orally administrated THC alters the resting state 
EEG and EPs to pain related electrical stimuli in patients with chronic pancreatic pain. 
Additionally, the reproducibility of EEG patterns over a two week period was evaluated 
within this study.
Neural correlates of THC in relation to its analgesic potency were further explored and 
reported in chapter 8. We evaluated the long term effects of THC after a treatment period 
of 50-52 days using similar pain related EEG indices in patients with chronic abdominal 
pain due to CP or surgery. We hypothesized that THC would decrease theta activity at 
a resting state and reduce evoked brain amplitudes. The relation between clinical pain 
intensities and objective EEG outcomes were also analyzed and discussed in this chapter. 
Chapter 9 addresses the main findings with respect to literature and future perspectives. 
Part of this general discussion is a narrative on mechanism-oriented approach to pain in 
chronic pancreatitis. 
Chapter 10 provides a summary of the studies presented in this thesis in English and 
Dutch.
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PART I
Chapter 2
Patients with persistent pain after breast cancer 
surgery show both delayed and enhanced cortical 
stimulus processing
Van den Broeke EN, de Vries M, van Goor H, Vissers KC, van Rijn CM, Wilder-Smith OH. 
Journal of Pain Research. 2012;5:139-50.
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ABSTRACT
Background: Women who undergo breast cancer surgery have a high risk of 
developing persistent pain. We investigated brain processing of painful stimuli using 
electroencephalogram (EEG) to indentify event-related potentials (ERPs) in patients with 
persistent pain after breast cancer treatment. 
Methods: Nineteen patients (eight women with pain, eleven without persistent 
pain), who were treated more than 1 year previously for breast cancer (mastectomy, 
lumpectomy, and axillary lymph node dissection) and/or had chemoradiotherapy, were 
recruited and compared with eleven healthy female volunteers. A block of 20 painful 
electrical stimuli was applied to the calf, somatopically remote from the initially injured 
or painful area. Simultaneously the EEG was recorded, and a visual analogue scale (VAS) 
pain rating obtained.
Results: In comparison with healthy volunteers, breast cancer treatment without 
persistent pain is associated with accelerated stimulus processing (reduced P260 
latency) and shows a tendency to be less intense (lower P260 amplitude). In comparison 
to patients without persistent pain, persistent pain after breast cancer treatment is 
associated with stimulus processing that is both delayed (ie, increased latency of the ERP 
positivity between 250-310 ms [P260]), and enhanced (ie, enhanced P260 amplitude). 
Conclusion: These results show that treatment and persistent pain have opposite effects 
on cortical responsiveness.
INTRODUCTION
In recent years interest has grown in the alterations in brain processing present in 
patients with persistent pain. Brain imaging techniques like fMRI and PET have been 
used to investigate brain function by measuring the evoked response to applied 
somatosensory stimuli.1,2 The results regarding altered pain processing by the brain in 
the context of persistent pain are highly incongruent, perhaps due to large variability 
between the patients regarding pain history, pain etiology, pain distribution and 
psychological characteristics.1,2
Use of a postoperative model may help overcome some of these problems, because 
it permits study of a homogenous patient population regarding pain etiology, pain 
distribution and treatment. Furthermore this model makes it possible to differentiate 
between the effect of treatment and the effect of pain because a comparative patient 
group (same treatment, but no pain) can be included for comparison.
It has been shown that women who undergo surgery for breast cancer have a high risk 
of developing persistent postsurgical pain.3-6 This pain persistence is difficult to treat 
and is accompanied by a significantly diminished quality of life.5,7
The often used generic term “postmastectomy pain syndrome” in cases of persistent 
pain after breast cancer treatment might suggest a homogeneous disease category. 
But this is debatable.8 In fact, different types of pain have been observed after breast 
cancer treatment, like phantom breast pain3,9, scar pain10, neuropathic pain6, complex 
regional pain syndrome11, pain arising from the axillary web syndrome12 and the 
more recently prospectively investigated myofacial pain syndrome, which is typically 
observed during the first year after breast surgery including axillary lymph node 
dissection (ALND).13
The etiology of persistent pain after breast cancer treatment is probably multifactorial.8 
This is because breast cancer treatment includes different types of surgical interventions 
(ie, mastectomy, lumpectomy, sentinel lymph node biopsy, and ALND), and adjuvant 
therapies like chemotherapy, radiation and endocrine therapies. All these interventions 
may contribute to the development of the persistent pain, and could have their own 
characteristics. However, nerve damage and radiotherapy appear to be significant risk 
factors.8
A frequently observed phenomenon in persistent postsurgical pain conditions, and 
also in patients after breast cancer surgery, is a change in the sensitivity of tactile and 
pain processing. This change consists of a combination of sensory loss, particularly in 
the skin innervated by the possibly damaged nerves, and hypersensitivity.4,6,8,14,15
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To our knowledge, studies investigating the evoked brain response using 
electroencephalography (EEG) in the context of persistent postsurgical pain are scarce.2,16 
In contrast to fMRI and PET, EEG directly measures neuronal activity; furthermore it makes 
it possible to study the sequential activation of different brain structures in time. The 
aim of this study is to investigate brain processing of painful stimuli using EEG (or more 
specifically, event-related potentials [ERPs]) in patients with persistent pain after breast 
cancer surgery. To investigate possible changes in ERPs as result of the presence of pain, 
these results (ie, from patients with pain) are compared with those in women without 
persistent pain after breast cancer surgery. In addition, we aim to investigate possible 
ERP changes as result of breast cancer treatment by comparing the results of the patients 
without pain with healthy female volunteers. Our main hypothesis is that persistent pain 
is associated with an enhanced brain response to painful stimuli.
MATERIALS AND METHODS
Participants
Nineteen patients (eight women with pain and eleven without pain) who had been 
treated for breast cancer were recruited from a clinical database of the Radboud University 
Nijmegen Medical Centre. Approval for the study was obtained from the Medical and 
Ethical Review Board Committee region Arnhem-Nijmegen, Nijmegen, The Netherlands 
(NL 30189.091.09). All subjects signed an informed consent form. At the moment of 
inclusion none had evidence for metastases or disease recurrences. All patients (with and 
without pain) had been operated ≥ 1 year ago at the time of participating. Patients all 
underwent a mastectomy or lumpectomy and ALND but no breast reconstruction. The 
rationale for investigating this population of patients is the high incidence of persistent 
pain after this type of surgery (mastectomy or lumpectomy + ALND).3,4 Only patients who 
had unilateral breast cancer were included. Persistent pain was defined as pain persisting 
continuously or intermittently for more than 3 months after surgery.17
Besides patients, eleven healthy female volunteers were also recruited from the Nijmegen 
area. Patients as well as healthy volunteers were excluded from the study if they:
1) had undergone breast reconstruction,
2) had a psychiatric or neurological condition (for patients; neurological signs 
 as a result of the treatment were excepted),
3) used pain medication or other medication that potentially affects 
 brain processing like anti-depressants, anti-psychotics, anti-epileptics and 
 benzodiazepines (hormone therapy as adjuvant therapy used by the 
 patients excepted),
4) suffered from any pre-existing pain or pain syndrome.
Subjects were instructed not to consume caffeine-containing beverages for twelve hours 
before the recording session. This was to avoid the caffeine-induced theta decrease in 
EEG.18
Variables measured
Demographic and clinical characteristics
The composition of the two breast cancer surgery groups (with and without pain) was 
based on a standardized question (obtained via an interview by telephone) whether the 
patient experienced ongoing pain (yes or no) as a result of the breast cancer treatment. 
For confirmation, the same question was asked again on the day of measurement, 
together with an additional standardized question (only if the patient experienced 
pain) regarding pain intensity as a measure of past experienced pain load (‘What is the 
averaged intensity of the breast treatment-related pain during the last three months on 
a numeric 0-10 rating scale (NRS)?’).
Other demographic and clinical characteristics obtained were age, menopausal status, 
surgical treatment, and chemotherapy, radiation, and/or hormone therapy.
Patients who undergo ALND during breast cancer treatment are at risk for developing 
lymphedema.19 Hypothetically, this could contribute to the persistence of pain. Therefore 
we measured limb volume differences (unaffected compared to. affected limb) as an 
indirect reflection of the possible presence of lymphedema. To do so, we measured the 
limb volume of both sides (arms) via water displacement.20 Subjects were instructed to 
lower their arm slowly into a fully filled volume meter and asked to stop when the top 
of the volume meter came in contact with the axilla.20 The amount of spilt water was 
collected in a measuring cup (ml). The volume of the opposite (control) arm was also 
measured. The difference in volume of spilt water between the two sides (affected and 
control) was calculated. This test was also performed in the healthy volunteers to test if 
there are normally differences in volume between the two sides.
Data about the type of pain and pain-related sensory signs in the patients with pain were 
collected using the Douleur Neuropathique 4 (DN4) questionnaire.21,22 This questionnaire 
includes pain descriptors as well as three clinical tests reflecting altered somatosensory 
processing. The tests were performed by a physical therapist. For measuring hypoesthesia 
to touch, a brush (SENSElab, brush-05; Somedic, Horby, Sweden) was applied on different 
skin sites in the location of the pain. For measuring hypoesthesia to pinprick, a Semmes-
Weinstein monofilament (nr. 5.07, 10.0 g) was applied to different skin areas in the 
location of the pain. For measuring brush evoked or increased pain within the location of 
pain, the same brush as for hypoesthesia was used. The effects of stimulation of the first 
two clinical tests (hypoesthesia to touch and pinprick) were quantified by comparing the 
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skin sites in the location of pain to a control site on the contralateral body site.
It is important to mention that, in this study, the DN4 questionnaire is not used as a 
screening or diagnostic instrument for neuropathic pain, because at present it is not 
validated for this purpose in this population of surgical patients. Thus we used the DN4 
exclusively to collect data regarding the clinical qualitative characteristics of the pain 
syndrome.
Patients of both groups (with and without persistent pain) were asked if they had 
experienced tactile hypaesthesia or numbness since their treatment. If they did, they 
were asked to draw on a map the size and anatomical area of hypaesthesia.
Electrophysiological measures
A multi-channel electroencephalogram (EEG) (BrainVision, Brain Products GmbH, 
Waldkirch, Germany) was recorded during the experiment (band-pass 0.1-100 Hz, sample 
frequency 2000 Hz) with 64 active electrodes mounted in an elastic electrode cap. The 
electrodes were arranged according to the international 10-20 system and electrode 
CPz was used as common reference. Eye movements were detected by horizontal and 
vertical electrooculogram (EOG) recordings. Horizontal EOG was measured from the 
outer canthus of the left eye, and vertical EOG supra orbital to the left eye. Impedance 
was kept under 20 kΩ for all leads.
Painful stimulation
Subjects received painful stimulation on the calf, between the medial and lateral head of 
the gastrocnemius, using a concentric electrode (CE).23 Because of its concentric design 
and small anode–cathode distance this stimulating electrode produces a high current 
density at relatively low current intensities. In this way, depolarization is more limited 
to the superficial layer of the dermis (where nociceptive [Aδ] fibers are present) with 
less recruitment of deeper lying non-nociceptive fibers. Stimulation with this electrode 
produces a pinprick-like painful sensation. The stimulated site was balanced across 
patients with regard to the affected side. In healthy subjects, balancing was according 
to lateral dominance.
The stimulation protocol consisted of 20 double pulses (monopolar square wave; 
duration 0.5 ms and double-pulse interval 5 ms) with a random inter-pair interval ranging 
from 7 to 10 seconds. The double pulses were delivered through the CE using a constant 
current stimulator (Twister®, Dr. Langer Medical GmbH, Waldkirch, Germany) and with 
an intensity of 150% of the individual pain threshold. This individual pain threshold was 
determined by an ascending sequence of increasing current intensities starting from 
0 mA and in steps of 0.5 mA. This procedure stopped when the pain threshold was 
achieved, as verbally reported by the subjects. This threshold determination protocol 
was performed twice and the mean was used in the experiment to set intensity of 
stimulation.
During stimulation, subjects were comfortably seated in a chair and were instructed to 
passively perceive the stimuli with eyes closed (as this condition is less prone to artifacts), 
without making any movements. A computer display was placed in front of the subject 
(0.5 m) together with a computer mouse. The display was used to show the visual 
analogue scale (VAS) (see Behavioral measure), preceded by a tone (65 dB). Participants 
were instructed to open their eyes after the tone and use the mouse to mark the VAS, 
after which they closed their eyes again.
Behavioral measure
In order to quantify the amount of pain as a result of the painful stimulation, subjects 
were asked to rate, at random times within a train of 5 double pulses, the amount of pain 
caused by the last received stimulus on a VAS. The VAS ranged from 0 cm = ‘’no pain” to 
10 cm = ‘’unbearable pain” and was rated by the subject by moving the mouse pointer 
(vertical line) on a horizontal bar.
Procedure 
At the beginning of the experiment, demographic and clinical characteristics were 
collected. Next, the individual pinprick-like pain thresholds for the double pulse 
stimulation were determined. Finally, subjects received the experimental painful 
stimulation with simultaneous recording of the EEG.
Signal analysis
Event-related potentials
The EEG was analyzed offline using the software Brain Vision Analyzer sotware (v. 2.0; 
Brain Products GmbH, Gliching, Germany) and Matlab (2011a; MathWorks, Natick, MA). As 
a first step, the continuous EEG was referenced to a common average (ie, all electrodes). 
Next, the EEG signal (2500 Hz) was high-pass filtered at 1 Hz and low-pass filtered at 30 
Hz. Based on the onset of the stimulus, the EEG was segmented into epochs from -100 
ms pre-stimulus to 1000 ms post-stimulus with a total period of 1100 ms. Bad segments 
containing ocular artifacts were corrected using the Gratton-Coles method.24 Segments 
were also inspected for other artifacts like muscle or jaw and line noise activity and were 
removed if necessary. As a last step baseline correction (-100 – 0 ms) was applied to all 
segments.
For each subject separately, all segments were averaged to obtain an averaged subject-
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specific event-related potential waveform. ERP components were defined in terms of 
their latency and topographic distribution. Subsequently the grand average global 
field power (GFP) of all subjects was calculated.25,26 Next, we calculated the topographic 
voltage distribution corresponding to the ERP latencies identified in the GFP plot. Then we 
identified the electrode in the topographic plot which shows the maximal activity and used 
this electrode for subsequent analysis. To insure accurate identification of point of maximal 
activity we also inspected the grand average ERPs (of all electrodes) for all subjects.
Individual ERP latencies were determined in the individual GFP plot corresponding to the 
windows of the grand average GFP latencies.26 The mean amplitude of each ERP component 
was calculated at the individual GFP-latency ± 5 ms at the electrode of maximal activity.26 
The rationale for using the mean activity instead of the more commonly used maximal 
peak value (baseline-to-peak) is that, the fewer trials included in the subject-specific 
average, the more residual noise is superimposed on the maximal peak, and thus the more 
the maximal peak of the subject-specific average will be determined by residual noise 
rather than by the peak of interest. Therefore, we calculated the mean amplitude instead of 
the maximal peak amplitude because the former value is more stable and representative 
of evoked activity.27
Statistical analysis
The software package Graphpad Prism 5 (Graphpad, San Diego, CA) was used for statistical 
analysis. Because of the small sample sizes and non-Gaussian distributions, nonparametric 
test statistics were used for between-group comparisons. A Kruskall-Wallis test statistic (H) 
was used for ratio variables. In the present study only two pairs of post-hoc comparisons 
were tested; healthy volunteers compared to patients without pain (effect of treatment) 
and patients without pain compared to patients with pain (effect of pain). The Dunn’s 
multiple comparisons test, which corrects for the number of statistical tests, was used as 
post-hoc test. The effect size r was calculated as the Z-score divided by the square root of 
the total number of observations. Categorical variables were tested using the Chi-squared 
(χ2) test statistic (p < 0.05).
RESULTS
Clinical and demographical characteristics
Clinical and demographical characteristics are shown in Table 1 A-C and 2.
No statistically significant differences were observed between the three groups with 
respect to age and limb volume differences. Median (and interquartile ranges) age and 
limb volume differences scores are shown in Table 1 A-C.
Table 1 Demographic and clinical characteristics of the patients (A) with pain, (B) without pain and (C) healthy 
volunteers
(A)
Patient Age 
(years)
Menopausal 
status
Surgical treatment Additional treatment
Chemotherapy Radiation 
therapy
Hormone 
therapy
1 52 post Mast  + ALND (II) Yes (FEC) Yes Yes (TAM)
2 50 post Mast  + ALND (II) Yes (TAC) Yes No
3 63 post Mast  + ALND (II) Yes (TAC) Yes Yes (TAM)
4 46 post Mast  + ALND (II) Yes (TAC) Yes Yes (TAM)
5 57 post Mast  + ALND (II) Yes (FEC) No Yes (TAM)
6 49 post Lump + ALND (II) Yes (FEC) Yes Yes (TAM)
7 65 post Mast  + ALND (II) Yes (TAC) Yes Yes (TAM)
8 52 post Mast  + ALND (II) No No No
Median 52
I-Q range 49 - 61
(%) 87.5 75.0 75.0
Patient Arm volume 
difference (ml)
Location of pain Intensity pain 
(NRS)
Affected side - 
unaffected side
Mean score of last 
3 months
1 200 Arm + chest 6
2 -50 Arm 6
3 -60 Small area arm + chest (nipple and armpit) 6
4 20 chest 3
5 170 Upperarm + chest 6
6 -40 arm 3
7 60 Small area arm + chest 4
8 -110 Armpit (upperarm + top) + chest (scar) 4
Median -10 5
I-Q range (%) -57 - 142 3 - 6
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(B)
Patient Age 
(years)
Menopausal 
status
Surgical 
treatment
Additional treatment Arm volume 
difference (ml)
Chemo
therapy
Radiation 
therapy
Hormone 
therapy
Affected side -
unaffected side
1 32 post Mast  + ALND (II) Yes (TAC) No Yes (TAM) 30
2 49 post Mast  + ALND (III) Yes (TAC) Yes Yes (TAM) 260
3 58 post Mast  + ALND (II) Yes (FEC) No Yes   (ARI) -50
4 45 post Mast  + ALND (II) Yes (TAC) Yes Yes (TAM) -80
5 42 post Mast  + ALND (II) Yes (FEC) No Yes (TAM) 0
6 53 post Mast  + ALND (II) Yes (TAC) Yes Yes (TAM) 170
7 58 post Mast  + ALND (II) Yes (TAC) No Yes (TAM) 100
8 56 post Mast  + ALND (III) Yes (TAC) Yes Yes (TAM) 330
9 47 post Mast  + ALND (III) Yes (TAC) Yes Yes   (ARI) 140
10 65 post Lump + ALND (II) No Yes Yes   (ARI) 200
11 68 post Lump + ALND (II) No Yes Yes (TAM) 
and  (ARI)
100
Median 53 100
I-Q range 45 - 58 0 - 200
(%) 81.8 63.6 100.0
 
(C)
Control subject Age 
(years)
Menopausal 
status
Arm volume 
difference (ml)
Positive difference between 
left and right side
1 63 post 60
2 40 pre 20
3 50 post 70
4 61 post 30
5 46 pre 10
6 41 pre 20
7 42 pre 80
8 56 post 30
9 62 post 40
10 60 post 70
11 61 post 190
Median 56 40
I-Q range 42 - 61 20 - 70
Abbreviations: MAST, mastectomy; LUMP, lumpectomy; ALND, axillary lymph node dissection with between 
brackets the level of axillary dissection I, II, or III28; TAC, docetaxal (Taxotere®) + doxorubicin (Adriamycin®) + 
cyclophosphamide; FEC, fluorouracil + epurobicin + cyclophosphamide; ARI, Arimidex®; TAM, tamoxifen.
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A significant association (χ2 (2) = 7.972, p = .019) was observed between condition 
(healthy volunteers and patients) and menopausal status (pre- and post-). As can be 
seen in Table 1 A-C, all patients (with and without pain) are postmenopausal, whereas 
44% of healthy volunteers are premenopausal. 
No significant associations were observed between the two patient groups (with and 
without pain) regarding the type of surgical intervention (mastectomy + ALND or 
lumpectomy + ALND) and incidences of adjuvant therapies (chemotherapy, radiation, or 
hormone therapy), see also Table 1 A-C for incidences. The results from obtained from the 
DN4 questionnaire are shown in Table 2. Figure 1 shows the topography of hypaesthesia 
(numbness) drawn by the patients (with and without pain).
Figure 1 Area of tactile hypoesthesia (numbness).
Notes: This figure shows the topographical map of areas of tactile hypoesthesia (numbness) drawn by the 
patients without pain and with pain. The scale of percentages shown in the legend represents the number of 
patients (converted to percentages) who marked that area as hypoesthetic.
Stimulation intensity
No statistically significant differences were observed between the three groups regarding 
the applied stimulation intensities for noxious stimulation for ERPs. Median (and inter-
quartile ranges) stimulation intensities were: healthy volunteers 3.0 (2.7 - 4.2) mA, patients 
without pain 3.3 (3.0 – 3.7) mA, patients with pain 3.9 (2.7 - 4.7) mA.
Behavioral tests
No statistically significant differences were observed between the three groups regarding 
the VAS-scores obtained during the noxious stimulation. Median (and inter-quartile 
ranges) VAS-scores were: healthy volunteers 4.2 (2.5 - 4.7) cm, patients without pain 3.0 
(2.4 – 5.9) cm, patients with pain 2.5 (1.6 - 4.2) cm.
Event-related potentials
Based on the grand average Global Field Power (GFP) and corresponding topographic 
representations of all subjects (N=30) shown in Figure 2, we defined four distinctive ERP 
components: 
1. A negative voltage between 110-180 milliseconds (ms), maximal at electrode 
 FCz, which we label as N150,
2. A positive voltage between 190-230 ms, maximal at Cz, which we label as P200,
3.  A positive voltage between 250-310 ms, maximal at FCz, which we label as 
 P260,
4. A positive voltage between 310-380 ms, maximal at Cz, which we label as P350.
Figure 3 shows the topographic representations of the ERP components for each group at 
the ERP latencies.
ERP amplitude
There were no statistically significant differences regarding N150, P200 and P350 between 
groups. Median and interquartile ranges are shown in Table 3. A statistical difference was 
observed for the P260 between the three groups (H (2) = 6.490, p = .039). Dunn’s post-hoc 
tests revealed a statistically significant difference between patients with pain vs. patients 
without pain (p < .05; effect size r = -.49). Grand average ERPs of P260 are shown in Figure 4. 
ERP latency
A statistically significant difference was observed between the three groups (H (2) = 9.367, 
p = .009) regarding P260 latency. Dunn’s post-hoc tests revealed a statistically significant 
difference between patients without pain and healthy volunteers (p < .05; effect size r = 
.58) but also between patients with pain vs. patients without pain (p < .05; effect size r = 
-.56). Median and inter-quartile ranges are shown in table 3.
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Table 3 Event-related potential (ERP) amplitude and latencies
Healthy volunteers Patients without pain Patients with pain
Amplitude (μV) Latency (ms) Amplitude (μV) Latency (ms) Amplitude (μV) Latency (ms)
N150 
(FCz)
-2.2
(-7.0-2.4)
133.2
(128.0-159.6)
-4.6
(-6.7-1.1)
148.8
(123.2-176.4)
-3.4
(-8.1-0.8)
156.2
(146.8-161.8)
P200 
(Cz)
2.7
(-1.9-4.1)
196.8
(190.0-218.4)
-1.5
(-5.0-1.5)
208.0
(196.4-224.4)
0.5
(-0.9-4.9)
203.4
(198.2-227.7)
P260 
(FCz)
4.0
(2.9-6.8)
279.2
(266.8-302.8)
1.3
(-0.6-4.1)
255.6
(250.0-266.0)
5.7
(2.5-8.2)
284.4
(265-305.2)
P350 
(Cz)
3.6
(2.5-7.3)
355.6
(320.8-380.0)
3.0
(0.6-5.1)
348.4
(332.0-372.4)
4.3
(3.0-8.9)
336.8
(327-351.5)
Figure 2 Grand average global field power (GFP) and corresponding topographic representations. (A) Grand 
average GFP (N = 30). The dotted lines indicate peak latency of the different event-related potential (ERP) 
components. Four different components can be identified: a negative voltage between 110–180 ms, maximal 
at FCz, labeled as N150, a positive voltage between 190–230 ms, maximal at Cz, labeled as P200, a positive 
voltage between 250–310 ms, maximal at FCz, labeled as P260, and a positive voltage between 310–380 
ms, maximal at Cz and labeled as P350. (B) Topographic representations of the ERP components at the ERP 
latencies (N = 30). To best illustrate the maximal activity in each representation, we adjusted the scale to its 
maximal absolute values (for increases and decreases in voltages). As a result the scale differs between the 
different representations and is therefore left out.
Figure 3 Group-specific topographic representations. Shown are the topographic representations of the 
different event-related potential (ERP) components at the different ERP latencies (Figure 2).
Notes: To best illustrate the maximal activity in each representation, we adjusted the scale to its maximal 
absolute values (for increases and decreases in voltages). As a result the scale differs between the different 
representations and is therefore left out.
Figure 4 Event-related potential (ERP) waveforms. Grand average ERPs observed from FCz showing the P260 
differences (A) effect of treatment, (B) effect of pain.
Notes: Upward deflection is positive charge and downward is negative charge. Representations of ERPs are 
with respect to common reference.
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DISCUSSION
To our knowledge, this is the first study to investigate cortical processing by means of EEG 
and with this kind of stimuli in this group of patients. In comparison to patients without 
persistent pain, persistent pain after breast cancer treatment is associated with delayed 
and enhanced stimulus processing as reflected in an increased latency and enhanced 
amplitude of the ERP positivity between 250-310 ms (P260). Moreover, in comparison 
to healthy volunteers, breast cancer treatment is associated with a speeding of (reduced 
P260 latency) and a tendency towards a less intense (smaller P260 amplitude) stimulus 
processing. These results suggest that the two conditions, ie, treatment and pain 
persistence, have opposite effects regarding cortical responsiveness.
Breast cancer treatment and cortical processing
The comparison between patients without pain and the healthy volunteers reveals 
the effect of treatment on cortical processing. This comparison revealed a speeding of 
stimulus processing (reduced P260 latency) in patients without pain compared to the 
healthy volunteers. Moreover, there is a smaller late ERP amplitude (P260) in patients 
without pain vs. the healthy volunteers, however, not statistically significant according 
to the Dunn’s post hoc test. This is probably due to the small sample sizes and the fact 
the p value has to be corrected for multiple comparisons. Indeed the effect size is r = -.45.
Kreukels et al.29 did observed a lower ERP amplitude in disease-free breast cancer 
survivors who were treated for breast cancer (including surgery and radiotherapy). All 
patients underwent surgery and radiotherapy. In this study the authors investigated 
the effect of different chemotherapy regimens on ERP activity in response to auditory 
stimuli (by using an oddball paradigm). Overall they observed a significantly reduced 
late ERP (i.e. P3) amplitude between patients that received chemotherapy as compared 
to matched control patients who had not received chemotherapy. Moreover, a shorter 
P3 latency was observed after chemotherapy. The authors did not find any changes in 
mid-latency N1 ERP amplitude or latency between the two groups (with and without 
chemotherapy), a finding in agreement with the present study.
Are there alternative factors that can explain the reduced brain activity? Regarding 
hormone therapy, Kreukels et al.29 performed an additional sub analysis on their data 
in which they compared the ERP P3 amplitude between current, past and never users 
of tamoxifen. They found no significant difference in P3 amplitude between the three 
groups, suggesting that tamoxifen (and perhaps also other hormone therapy regimens) 
cannot explain the observed ERP reduction.
An as yet undefined pathophysiological process subsequent to amputation, e.g. 
deafferentation, might also change EEG activity.30 This argument is based on the study of Karl 
et al.30 Although not statistically significantly different, a lower P3 amplitude was observed in 
the amputees without pain compared to the healthy controls.
When we look at the clinical and demographic characteristics (Table 1) the proportion of 
premenopausal status between healthy women compared to the patients without pain 
is different. Theoretically, this could be a further factor explaining the differences in P260 
amplitude between the two groups.
Persistent pain and cortical processing
The comparison between patients with and without pain reveals the effect of the presence 
of persistent post-surgical pain on cortical processing. Based on the results mentioned in 
the previous section, we suggest that breast cancer treatment (ie, chemotherapy) affects 
late ERP activity, ie, lower ERP amplitude and shorter latency. The larger ERP amplitude (and 
increased latency) seen in the patients with pain compared to the patients without pain is 
likely the result of the presence of pain additionally to the effect of breast cancer treatment. 
Therefore we conclude that persistent pain after breast cancer treatment is associated with 
delayed (increased P260 latency) and enhanced (larger P260 amplitude) stimulus processing.
Interestingly, Karl et al.30, using an oddball paradigm, compared the visual P3 amplitude 
between upper limb amputees with and without persistent pain and healthy volunteers. 
Patients with pain showed significantly higher P3 amplitudes than patients without pain, 
but neither group were statistically different from the healthy volunteers. The latter result 
could be due to the small sample sizes (patients with pain N= 5, patients without pain N=5 
and healthy volunteers N=10). However, the ERP findings observed in the study of Karl et al. 
appear to involve later ERP activity (between 300-500 ms) than in our study (between 250-
310 ms). Possible explanations for the fact that in the two studies different ERP activities are 
affected are type of stimulus and paradigm used.
Methodological considerations
Defining (late) ERP components
The positivity around 260 ms (ie, P260) shares the same time course and topographic 
distribution as the previously described SP5 component (233-277 ms) evoked after painful 
electrical stimulation.31 This ERP component seems to overlap with the more later positivity 
SP6 or pain related P2.
The positivity around 350 ms, labeled as P350, might be the pain related P2 evoked after 
painful electrical stimulation.31,32 By comparing laser stimulation with electrical sural nerve 
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stimulation Dowman showed that this P2, evoked after painful stimulation, has similar 
properties as the commonly described P2, associated with selective A-delta fiber activation, 
and evoked after painful laser stimulation.33-36 
However, Mouraux et al.35 recently compared electrical intra-epidermal, electrical non-
nociceptive transcutaneous and laser stimulation for their selectivity in generating A-delta 
fiber associated evoked brain responses. They showed that only laser and low intensity 
electrical intra-epidermal stimulation are able to evoke A-delta associated evoked brain 
responses. Additionally, they showed that intra-epidermal stimulation loses its selectivity 
with increasing stimulus intensity, something that occurred above intensities of 2.5 mA.35 In 
the present study we used transcutaneous electrical stimulation with stimulation intensities 
around 3.0 mA, which tends to argue against the possibility that we selectively evoked 
A-delta associated brain responses.
Alternatively, the P350 could be a P3a-like component.31,37,38 This hypothesis can be 
supported by the fact that:
1.  A “single stimulus” paradigm as used in the present study, in which only 
 target but no standard stimuli are delivered with long, variable and random 
 interstimulus intervals, is able to evoke a P3a-like component,39,40 also after 
 painful electrical stimulation,31 and
2.  this positivity shares the same generators in the brain as the classic P3a, 
 as is demonstrated via intracranially-recorded cortical responses evoked 
 after painful electrical stimulation. These generators include the dorsolateral 
 and medial prefrontal cortices, temporal-parietal junction and posterior 
 hippocampus.37
Area of stimulation
In the present study, the painful stimuli were applied to a body part somatopically remote 
from the initially injured or painful area. We choose to do this because we wished to investigate 
cortical changes in pain processing (which one would expect to be generalized). For this, 
we need to stimulate in an area remote from the spinal segment undergoing nociceptive 
input due to breast cancer treatment. Our study therefore reflects only generalized but not 
localized effects of surgery or radiation therapy.
Sample size
An important methodological limitation of this study is the small sample size. This was the 
result of our opting for more strict inclusion and exclusion criteria (to avoid confounding 
factors), but has the advantage that the resulting patient groups are very homogenous. 
Nevertheless, the ERP effects observed in the present study should be confirmed in a new 
future study with larger sample sizes.
Conclusions 
This observational study shows that the two conditions, ie, treatment and persistent 
pain, have opposite effects regarding cortical responsiveness. Breast cancer treatment 
is associated with a speeding of and a tendency to a less intense stimulus processing. 
Persistent pain after breast cancer treatment is associated with delayed and enhanced 
stimulus processing. To our knowledge, this is the first study to investigate cortical 
processing by means of EEG and with this kind of stimuli in this group of patients.
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ABSTRACT
Objectives: Electroencephalography (EEG) may be a promising source of physiological 
bio markers accompanying chronic pain. Several studies in patients with chronic 
neuropathic pain have reported alterations in central pain processing, manifested as 
slowed EEG rhythmicity and increased EEG power in the brain’s resting state. We aimed 
to investigate novel potential markers of chronic pain in the resting state EEG of patients 
with chronic pancreatitis.
Participants: Resting state EEG data from 16 patients with persistent abdominal pain 
due to chronic pancreatitis (CP) were compared to data from healthy controls matched 
for age, sex and education.
Methods: The peak alpha frequency (PAF) and power amplitude in the alpha band 
(7.5–13 Hz) were compared between groups in four regions of interest (frontal, central, 
parietal, and occipital) and were correlated with pain duration.
Results: The average PAF was lowered in CP patients compared with that in healthy 
controls, observed as a statistically significant between-group effect (mean 9.9 versus 9.5 
Hz; P=0.049). Exploratory post hoc analysis of average PAF per region of interest revealed 
a significant difference, particularly in the parietal and occipital regions. In addition, we 
observed a significant correlation between pain duration and PAF and showed increased 
shifts in PAF with longer pain durations. No significant group differences were found in 
peak power amplitudes.
Conclusion: CP pain is associated with alterations in spontaneous brain activity, 
observed as a shift toward lower PAF. This shift correlates with the duration of pain, 
which demonstrates that PAF has the potential to be a clinically feasible biomarker for 
chronic pain. These findings could be helpful for assisting diagnosis, establishing optimal 
treatment, and studying efficacy of new therapeutic agents in chronic pain patients.
INTRODUCTION
Diagnosis and treatment of chronic pain is challenging because, by definition, pain 
is a subjective experience and can be measured only by self-report.1 Identification of 
physiological pain biomarkers for 1) disease severity, 2) disease progression, 3) disease 
prognosis, and 4) treatment effects including indication and responder identification, 
could help us to improve pain diagnostics and treatment. Increasing evidence supports 
the idea that chronic pain can be understood not only as an altered perceptual state, 
but also as a consequence of alterations in peripheral and central neuronal processing. 
Electroencephalography (EEG) can be a useful method to detect such alterations in 
central pain processing.2-4
The resting state EEG with eyes closed is dominated by oscillations in the alpha-band 
(7.5-13 Hz), which are widely distributed in the cerebral cortex and more prominent in 
the parietal and occipital regions. Resting EEG is commonly analyzed by transforming 
data from the time domain to the frequency domain. A measure derived from such 
analysis is the peak alpha frequency (PAF). The PAF is defined by two parameters: (i) the 
frequency at which it occurs on the frequency axis, and (ii) its amplitude on the power–
density axis. 
Sarnthein et al.2 observed increased power amplitude differences in the alpha band, 
and a shift towards lower frequencies of the dominant peak in patients with mixed 
neurogenic pain syndromes. These results are supported by other resting state EEG 
studies investigating alterations in central pain processing in various chronic pain 
states.3,5-7 Olesen et al. reported similar alterations in EEG activity in patients with chronic 
pancreatitis, observed as an increase in power amplitude in the θ and α frequency band.4,8 
However, they neither calculated PAF nor studied its relation to clinical pain parameters.
Chronic pancreatitis (CP) is a disease characterized by inflammation and progressive 
destruction of the pancreatic gland, which results in irreversible morphologic changes 
that typically cause pain and/or exocrine and endocrine insufficiency.9 The most 
important symptom of CP is abdominal pain, present in 80-90% of patients in the time 
course of the disease.10 Pancreatic pain is typically intense, long-lasting and difficult to 
treat. 
Alterations in pancreatic nerves, including an increased number and diameter of nerve 
fibers and increased amount of neurotransmitters,11,12 as well as alterations in central 
pain processing, including supraspinal sensitization, somatotopic reorganization and 
pro-nociceptive pain modulation were proposed as possible mechanisms underlying 
chronic pain in CP. 13-15 Altered central pain processing was demonstrated in a previous 
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study in CP patients using Quantitative Sensory Testing (QST), manifested as a 
widespread hyperalgesia (i.e. an increased pain sensitivity16) in distant, non-damaged 
tissues. This can be interpreted as a sign of spinal, supraspinal (cortical), or combined 
sensitization.17 These observations support the role of central neuronal plasticity in 
the pain accompanying CP. If so, therapies exclusively directed at the pancreas as the 
nociceptive source are unlikely to be effective in achieving pain relief. Therefore, patients 
who may benefit from a treatment targeting central pain mechanisms need to be 
identified.
In the current study, we aim to investigate the brain’s resting state activity within the 
alpha frequency band in patients with chronic pain resulting from CP in order to: (1) 
research novel potential EEG biomarkers, (2) investigate biomarker scalp localization, (3) 
study effects of disease progression on biomarkers, and (4) address the clinical usefulness 
of EEG biomarkers for CP pain.
METHODS
Subjects
Sixteen patients with persistent abdominal pain as a result of CP were randomly selected 
from the outpatient clinic of the Radboud University Nijmegen Medical Centre. CP was 
diagnosed based on medical history, laboratory tests and radiological findings according 
to the Marseille and Cambridge Classification System.18 All patients had typical pancreatic 
pain, which is characterized as severe, dull epigastric pain, eventually radiating to the back. 
Intake of analgesics including opioids and centrally-acting medication was permitted. 
Patients with present alcohol use were excluded. Sixteen healthy participants were 
matched by age, gender and years of education. Previous studies suggest that this is an 
appropriate sample size to investigate the resting state EEG.2,6,19
Medical ethical approval was obtained for the measurements in healthy controls 
(Committee on Research involving Human Subjects, Region Arnhem-Nijmegen nr. 
2002/008). The patients were all referred by their physician in charge for neuropsychological/ 
neurophysiological testing, as part of their medical follow up. The neurophysiologic testing 
results have already been published and revealed a decline in cognitive performance in 
the CP group.20 Both patients and healthy participants gave written informed consent to 
use the data for scientific purposes. 
EEG recording 
EEG data were collected according to a standardized protocol using a Quickcap (NuAmps) 
with 26 scalp electrodes located according the international 10-20 electrode system (Fp1, 
Fp2, F7, F3, Fz, F4, F8, FC3, FCz, FC4, T3, C3, Cz, C4, T4, CP3, CPz, CP4, T5, P3, Pz, P4, T6, O1, 
Oz, O2).21 Electrooculogram (EOG) data were recorded from electrodes above and below 
the left eye and lateral to the outer canthi of each eye. Additional physiological data were 
obtained from the orbicularis oculus and the masseter muscles. Data were recorded at a 
sampling rate of 500 Hz and offline referenced to the mean of the signals recorded at the 
mastoids. The ground electrode was placed at Fpz. Electrode impedance was kept below 
5 kΩ for all electrodes.
The spontaneous EEG or resting EEG was recorded during eyes closed and eyes open. 
Each recording lasted 2 minutes. All results presented in this study refer to the eyes closed 
condition to avoid artifacts and alpha activity is typically present during this condition. 
During the recording in eyes closed condition, participants were seated in a comfortable 
chair and were asked to close their eyes and relax. No further task was given.
EEG analysis
Brain Vision Analyzer 2.0 software was used for EEG analysis. 
EEG data were band-pass filtered (1-120 Hz; phase shift-free Butterworth filters), and 
corrected for ocular artifacts according to the Gratton and Coles algorithm.22 Each EEG 
recording was segmented into 12 epochs of 10 sec each. Subsequently, epochs were 
inspected for artifacts and rejected from further analysis if data exceeded an amplitude 
of 200 µV or exceeded the maximal allowed voltage step of 50 µV. This resulted in 1.7% 
rejection of all epochs, mainly concerning temporal electrodes. The power amplitudes of 
the EEG frequencies were computed using a Fast Fourier Transformation (FFT). To this end, 
epochs were multiplied by a Hanning window (10%), Fourier transformed and spectral 
distributions were averaged across all epochs for each participant and electrode separately. 
Data analysis and statistics
Grand average power spectra were computed by averaging all scalp electrodes for each 
participant. These grand averages were averaged per group in order to obtain the overall 
power. Peak power amplitudes were determined as the maximum value between 7.5-
13 Hz within empirically defined regions of interest (ROI). Positively skewed peak power 
amplitudes were log-transformed to normalize the data. A lack of lateralization, as shown 
in topographical distribution plots, provides the opportunity to average individual 
electrodes in ROI in order to obtain a more stable but targeted analysis. Hence, four 
horizontally arranged ROI were composed: frontal (Fp1, Fp2, F3, Fz, F4), central (FC3, FCz, 
FC4, C3, Cz, C4), parietal (CP3, CPz, CP4, P3, Pz, P4), and occipital (O1, Oz, O2) ROI.
Different methods can be used to quantify the variation of spectral distribution within 
the alpha range.23 First, peak alpha frequency (PAF) can be measured by calculating 
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the frequency with the highest magnitude within the alpha range. Second, the center 
of gravity, rather than peak, can be measured. This gravity method has been used as 
a different, and possibly more stable measure of spectral distribution than the peak 
method.23,24 Particularly if there are multiple peaks in the alpha range, the gravity method 
appears the more adequate estimate of PAF.23 In the current study, a few participants 
demonstrated low-voltage EEG without clear peaks within the alpha band. The center of 
gravity method was assumed to be most appropriate since this method enables analysis 
of the entire dataset without excluding low-voltage EEG subjects from analysis. All 
participants demonstrated at least some peak, within 7.5-13 Hz range, assumed as the 
alpha frequency band, and were included for further analyses. The PAF is the weighted 
sum of spectral estimates, divided by alpha power, given in this equation (1).25
PAF = Σ(af x f ) / Σaf       (1)
af  = Amplitude of frequency f
f   = Frequencies within 7.5-13 Hz range (per 0.1 Hz)
For statistical analysis SPSS software for Windows v. 16.0 was used. 
All variables were visually inspected and Kolmogorv Smirnoff Test was applied to test 
data distributions. A t-test for independent samples was applied on normally distributed 
data, otherwise a non-parametric Mann-Whitney U-Test was used. A General Linear 
Model (GLM) repeated measures ANOVA analysis was used to test whether there were 
statistically significant differences regarding PAF and peak power amplitudes between 
CP patients and healthy controls with respect to the ROI (frontal, central, parietal and 
occipital). Our dependent variable, the PAF, was normally distributed allowing parametric 
testing. Mauchly’s test indicated that the assumption of sphericity had been violated. 
Therefore, degrees of freedom were corrected using Greenhouse-Geisser estimation. 
Post hoc analyses included exploratory pair-wise testing of each ROI separately using 
two-sided unpaired t-tests. A GLM repeated measures ANOVA was used to test whether 
there were significant differences between opioid and non-opioid users, and between 
the different etiologies of CP, with respect to the ROI. In addition, pain duration was 
correlated with EEG parameters using the non-parametric Spearman test. Controls did 
not have pain and were allocated zero scores on pain duration, and included in this 
analysis. In all tests the significance level was set at p < .05.
RESULTS
Research population
CP patients had a mean pain duration of 5.4 years, 8 patients had a history of alcohol 
abuse and 9 patients used opioid medication for pain relief (table 1). Matched controls 
did not use centrally-acting medication, and were all pain free expressed as zero scores 
on pain duration. No differences were observed between the CP and HC group with 
respect to age, gender and years of education (table 2).
Table 1. Demographic and clinical characteristics of individual patients with chronic pancreatitis.
No Age 
(years)
Sex Etiology Pain 
(years)
Opioids Other drugs
1 28 F hereditary 6 MS Contin PPI
2 50 M idiopathic 5 - PPI
3 57 F alcohol abuse 10 Durogesic -
4 40 M alcohol abuse 6 Morphine PM; NSAID
5 51 M alcohol abuse 6 Temgesic -
6 54 M alcohol abuse 8 Morphine AD
7 58 M alcohol abuse 4 Tramadol PM; AE
8 39 F idiopathic 10 Durogesic/ pethidine -
9 46 F idiopathic 2 Oxycontin -
10 72 M idiopathic 6 - PPI; NSAID
11 50 M alcohol abuse 10 - PM
12 48 M biliary 4 Oxycontin AE; BZ; PM
13 56 M alcohol abuse 2 - PM; PPI
14 24 F idiopathic 2 - -
15 52 F alcohol abuse 5 - AE; BZ; PM; Li
16 59 M idiopathic 1 - PPI
mean (SD) 5,4 (2,9)
Notes: Relevant drugs include antiepileptics (AE), benzodiazepines (BZ), antidepressants (AD), lithium (Li), non-
steroidal anti-inflammatory drugs (NSAID), paracetamol (PM) and proton pump inhibitors (PPI).
Table 2. Demographic and clinical characteristics of healthy controls and chronic pancreatitis patients.
HC CP p
N 16 16
Male / Female 10 / 6 10 / 6 NS
Mean (SD) age (years) 48.0 (11.27) 49.5 (11.91) NS
Mean (SD) education (years) 11.9 (2.86) 11.8 (3.09) NS
Abbreviations: healthy controls (HC); chronic pancreatitis patients (CP); not significant (NS)
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Figure 1. Grand average frequency power distributions averaged across all channels in patients with chronic 
pancreatitis (CP) compared to healthy controls (HC). This figure shows a shift towards lower frequencies and an 
increased amplitude in CP patients compared to HC.
Figure 2. Individual pain durations and grand average peak alpha frequencies of both chronic pancreatitis 
(CP) and healthy controls (HC). HC were all pain free expressed as zero scores on pain duration. A significant 
correlation was found (r = -0.379; p= 0.032), indicating that an increase in pain duration is correlated with an 
increased shift of PAF.
Abbreviation: Peak alpha frequency (PAF)
Grand average power spectra
Absolute values of grand average power spectra amplitudes within the α-band are 
summarized for CP patients and HC in figure 1. No significant group differences were 
found in the logarithmically transformed peak power amplitudes. The corresponding 
PAF was significantly shifted towards lower EEG frequencies in the CP group compared 
to the HC group (mean ± SD: 9.9 ± .4 vs. 9.5 ± .5 Hz; 95% confidence interval of mean diff 
(CI) = -.68 to -.01 Hz; P < .05). Moreover, pain duration was significantly correlated with 
the grand average PAF (r = -0.379; p= 0.032), showing increased reductions in PAF with 
longer pain durations (figure 2).
Topographical power distributions
Differences in grand average power spectra between both groups were restricted to the 
frequency range between 7.5 to 10 Hz (figure 1). Thus we restricted the topographical 
analysis of EEG power to this part of the α-band (figure 3a-f ). The topographical 
distribution plots showed maximum EEG alpha power in both groups as well as maximum 
group differences to be situated in parietal and occipital regions.
Power spectra
The average power frequency distributions were plotted separately per ROI (figure 4a-
d). This figure suggests increased peak power amplitudes in CP patients compared to 
the HC group in each ROI, particularly parietal and occipital. However, logarithmically 
transformed peak power amplitudes did not differ significantly in any of the ROIs (table 3). 
Table 3. Peak alpha frequency (PAF) and logarithmized peak power in healthy controls (HC) and chronic 
pancreatitis patients (CP).
 Mean (SD) p
HC CP
Frontal ROI 
PAF 9.7 (0.50) 9.4 (0.46) 0.190
Logarithmized peak power -0.39 (0.98) -0.19 (1.09) 0.586
Central ROI 
PAF 9.8 (0.42) 9.5 (0.49) 0.091
Logarithmized peak power -0.31 (1.08) -0.04 (0.97) 0.462
Parietal ROI 
PAF 9.9 (0.41) 9.6 (0.50) 0.037*
Logarithmized peak power 0.21 (0.97) 0.31 (1.34) 0.811
Occipital ROI 
PAF 10.0 (0.47) 9.6 (0.59) 0.019*
Logarithmized peak power -0.24 (1.59) 0.32 (1.59) 0.332
Note: *P<0.05.
Abbreviations: regions of interest (ROI); standard deviation (SD).
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Figure 3a-f. Average topographical power distributions of the resting electroencephalogram. The average 
topographical distributions of EEG power showed the maximum amplitudes in the parietal-occipital regions in 
both chronic pancreatitis (CP) patients and healthy controls (HC). Scalp distributions are shown for frequency 
spectra within the alpha band.
Figure 4a-d. Averaged power distributions within the frontal (a), central (b), parietal (c), and occipital (d) regions 
of interest (ROI) in chronic pancreatitis patients compared to healthy controls. The grey square represents the 
area within the alpha band.
Figure 5. Peak alpha frequency in four regions of interest shown for patients with chronic pancreatitis compared 
with healthy controls. Red squares correspond to mean PAF in patients, green triangles correspond to mean 
PAF in controls, and short lines represent corresponding standard deviations. Asteriks indicate significant 
differences.
Abbreviations: ROI, region of interest; PAF, peak alpha frequency.
Peak alpha frequency
The mean PAF per ROI is shown in figure 5. A statistically significant between group effect 
was observed regarding the PAF in CP patients compared to HC (F= 4.20; p= 0.049). Within 
groups testing revealed a statistically significant difference of ROI (F= 11.62; p< 0.001). No 
significant interaction was observed between the effects of group and ROI on the PAF (F= 
2.785; p= 0.085). Exploratory post hoc testing resulted in significant differences between 
patients and controls regarding the PAF in the parietal and occipital ROI (table 3).
The mean PAF in CP patients using opioid medication and non opioid medication were 
similar, 9.5 ± 0.5 Hz and 9.5 ± 0.5 Hz, respectively. Opioid use as between group factor in 
the RM-ANOVA indicated no significant differences regarding PAF (F= 0.015; p= 0.904) 
or peak power amplitudes (F= 1.593; p= 0.228). Opioid use as covariate did not modify 
the main between group effect. Subgroups of patients with or without alcohol abuse in 
history did not show significant differences regarding PAF (F= 0.063; p= 0.806) or peak 
power amplitudes (F= 1.984; p= 0.181).
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DISCUSSION
We observed a significant shift towards lower frequencies in patients with CP compared 
to healthy controls, observed as a decrease in PAF over all scalp electrodes. These results 
are consistent with other studies investigating the brain’s default state in chronic pain 
patients including CP reporting slowing of EEG oscillations.2-5,7 Exploratory post hoc 
analysis of average PAF per ROI reveals a significant difference particularly in parietal and 
occipital regions. Furthermore, this study shows that longer pain durations are associated 
with greater declines in PAF, indicating that PAF might be a marker for disease progression.
Alpha oscillations in the resting state EEG
Continuous EEG is dominated by alpha-band oscillations (7.5-13 Hz), which are widely 
distributed in the cerebral cortex and recorded with larger amplitudes over posterior 
regions with eyes closed.25 The exact role of alpha oscillations remains unclear, but several 
factors have been identified affecting the alpha activity in some way. The PAF, a primary 
measure of alpha activity, starts to decline with increasing age,26 and is known to increase 
with cognitive processing, attentional demand and arousal.27 Several studies found PAF to 
be a stable measure, showing a high intra-individual stability. 28, 29
Spontaneous alpha oscillations in chronic pain
Multiple studies report that phasic as well as tonic painful stimuli suppress spontaneous 
oscillations over the cortex in healthy participants,19,30 but only a few studies have 
investigated the brain default state in patients with chronic pain. Sarnthein et al.2 
reported an increased EEG power and a slowed dominant peak frequency in patients with 
severe neuropathic pain of various origins. Maximal differences appeared in the 7-9 Hz 
band in all electrodes. These results were explained by the concept of thalamocortical 
dysrhythmia (TCD), which is proposed as a general mechanism to explain the generation 
of neuropathic pain and other neurological symptoms.2,3,31 TCD is based on diminished 
excitatory or increased inhibitory input of neurons in the thalamus, resulting in the 
presence of a persistent low-frequency, thalamocortical resonance during the awake 
state.3 This mechanism has been supported by the finding that therapeutic surgical 
lesions in the thalamus resulted in normalization of EEG activity as well as pain relief.2
Two studies in patients with neuropathic pain following spinal cord injury (SCI) support 
the TCD theory. In both studies, peak frequency was shifted towards lower frequencies in 
SCI patients with pain compared to SCI patients without pain. In contrast, no differences 
were observed in power amplitudes.5,7 Interestingly, this is not the case in patients with 
chronic low back pain, who did not demonstrate any statistically significant TCD effect. 
Only in a subsample of these patients with evidence for root damage was a trend for 
significant effect observed. The authors of this study suggest that only patients with 
severe pain or neuropathic pain develop the typical TCD pattern.32 As stated earlier, 
pancreatic pain is typically intense and long-lasting, and secondly, because pancreatic 
pain may be of neuropathic origin.8,33
A previous study in CP patients with pain showed slowing of EEG rhythms based on 
increased normalized power amplitudes in the lower frequency bands including the alpha 
band.4 The present study confirms these results in a similar population of CP patients. 
It extends these results to additional EEG parameters, better quantifying alpha slowing 
using PAF, and establishes a relation to clinically relevant factors such as pain duration. 
Interestingly, based on our PAF, maximum differences between groups were located 
over the posterior regions, whereas Olesen et al.4 reported that mainly frontal electrodes 
contributed to the difference based on normalized amplitude strengths. However, 
both studies observed slowing of EEG rhythmicity, which suggests that pancreatic pain 
originates from a disturbance in thalamocortical rhythmia. 
Toward a biomarker for chronic pain 
A simple self-evaluation of pain is not sufficient to provide insight into underlying 
mechanisms since multiple factors potentially affect pain experience. Therefore, 
development of a physiological measure reflecting underlying pain mechanisms is 
desirable. First, it may improve pain diagnostics through addition of a mechanism-oriented 
parameter reflecting central neuronal involvement in pain genesis and maintenance. 
Second, it may improve pain treatment by identification of patients who may benefit 
from a treatment targeting central pain mechanisms. Graversen et al.34 showed that 
quantitative pharmaco-EEG can be used to monitor the central analgesic mechanisms 
of pregabalin, and suggest that this approach may be used to predict effect of treatment 
leading to pharmaco-diagnostic testing.
Clinical applications of EEG 
Besides the fact that EEG measures different phenomena regarding brain function than 
fMRI or PET, EEG has several advantages: (1) PET and fMRI are based on the measurement of 
secondary metabolic changes in brain tissue, but not of primary electrical effects of neural 
excitation, (2) EEG equipment costs significantly less than neuro-imaging equipment, 
and (3) EEG equipment, including electrodes, a signal amplifier and a computer with 
EEG software, is portable and easy to apply. This enables us to record the EEG near the 
patient’s bed. On the other hand, it usually takes a long time to apply numerous electrodes 
at the scalp. Thus it would be desirable to reduce the number of required electrodes in 
clinical practice. But which electrodes are superfluous? Our study showed the maximum 
alpha-band oscillations in both groups to be located in the parietal and occipital regions. 
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More importantly, differences between groups in PAF, the only discriminative parameter 
observed in our study, were located over the same posterior regions. This suggests that 
PAF is best measured in the parietal and occipital regions of the scalp for chronic pain 
diagnostics. 
Methodological considerations 
Future research should concentrate on limitations within the current study. First, we 
did not collect pain scores during or just preceding the measurements, or average pain 
scores over the past few months. Therefore, it was not possible for us to correlate pain 
intensities with EEG parameters. Second, we made a comparison of CP patients with pain 
vs. healthy participants to study the differential influence of chronic pain. We recruited 
a homogeneous group of patients, all suffering from persistent visceral pain due to 
diagnosed CP. Although these patients were homogeneous regarding the cause of pain, 
it is difficult to ascribe the observed changes in the resting EEG to just one underlying 
cause. Variations in pain duration as well as differences in etiology (history of alcoholism), 
comorbidity (e.g. exocrine and/or endocrine failure), surgical treatment history, and 
actual medication use may be contributing factors. Thus, it might be interesting to 
investigate the influence of these factors based on a third group of CP patients without 
pain. However, it will be challenging to find CP patients having no pain and matched by 
age, level of education and medication intake, which are evident factors effecting the 
resting EEG.
Centrally-acting medication might influence the brain resting state activity. Many 
patients with CP use analgesics, including opioids, for pain treatment. This presents an 
ethical dilemma, as patients could potentially face severe pain if their medication was 
discontinued. In our study, more than half of the patients used opioids at the time of 
measurements. A comparison between subgroups of patients with and without opioids 
did not reveal any significant difference. Hence, the slowed PAF observed in our study is 
unlikely to have been caused by centrally-acting medication. 
Conclusions
The present study shows a shift of the alpha peak towards lower frequencies in CP patients 
with chronic pain compared to healthy controls. This shift correlates with the duration of 
pain, which demonstrates that PAF deserves to further study regarding its potential as a 
clinically useful biomarker for chronic pain. . The subdivision in four ROIs showed that this 
biomarker is best measured in the parieto-occipital regions of the scalp, which reduces 
the number of electrodes necessary; of benefit for clinical practice. Accordingly, this 
method appears promising in supporting diagnosis and prognosis, establishing optimal 
treatment and studying efficacy of new therapeutic agents in chronic pain patients.
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ABSTRACT
AIM: We aimed to assess the analgesic efficacy, pharmacokinetics, tolerability and safety 
of a single dose of Δ9-THC in patients with chronic abdominal pain resulting from chronic 
pancreatitis (CP).
METHODS: This was a randomized, single dose, double-blinded, placebo-controlled, 
two way crossover study in patients suffering from abdominal pain as result of CP (n=24), 
post hoc subdivided into opioid and non-opioid users. Δ9-THC (8 mg) or active placebo 
(5mg / 10mg diazepam) was administered orally in a double dummy design.
RESULTS: No treatment effect was shown for delta VAS pain scores after Δ9-THC compared 
with diazepam. Δ9-THC was well absorbed with a mean tmax of 123 min. No significant 
differences were found between Δ9-THC versus diazepam for alertness, mood, calmness 
or balance. Feeling anxious and heart rate were significantly increased after Δ9-THC 
compared with diazepam. Most frequently reported adverse events (AEs) after Δ9-THC 
administration were somnolence, dry mouth, dizziness and euphoric mood.
CONCLUSIONS: A single dose of Δ9-THC was not efficacious in reducing chronic pain 
resulting from CP, but was well tolerated with only mild or moderate AEs. The PK results 
in CP patients showed delayed absorption and an increased variability compared to 
healthy volunteers.
INTRODUCTION
Chronic pancreatitis (CP) is a disease characterized by inflammation and progressive 
destruction of the pancreatic gland, which results in irreversible morphologic changes 
that typically cause endocrine and/ or exocrine dysfunction.1 The most important 
symptom of CP is abdominal pain, present in 80-90% of patients during the disease 
course.2 Pancreatic pain is described by most patients as severe abdominal pain, 
frequently radiating to the back. The pain is typically recurrent, intense and long-lasting, 
and is extremely difficult to treat.3 Initial treatment of CP consists of low fat diet and 
non-narcotic analgesics, which can be supplemented by oral pancreatic enzymes and 
proton pump inhibitors. If an acceptable level of pain relief is not obtained with these 
drugs, opioids are the next stage in the management of pain. Opioids have a number 
of well-known adverse effects including elevation of smooth muscle tone (affecting 
gastrointestinal motility), toxicity in the central nervous system, opioid-induced 
hyperalgesia and tolerance, and risk of addiction.4,5 Alternatives to medicinal treatment 
exist in the form of nerve blockade, lithotripsy and surgical treatment. However, results 
from studies of non-medicinal treatment modalities are equivocal and these treatments 
are only applicable in a minority of patients. Therefore, medicinal analgesic therapy must 
still be considered as the first choice in the management of painful CP.6
Underlying pain mechanisms of CP are poorly understood and multifactorial, and 
therefore, treatment is often empirical and insufficient. Several intra- and extrapancreatic 
causes of pain have been suggested. However, most research is focused alterations 
in pain processing, with peripheral causes including an increase in nerve fibers and 
neurogenic inflammation,7 and central causes including central sensitization and 
somatotopic reorganization.8,9 Furthermore, Olesen et al. demonstrated activation of 
descending inhibition in early CP patients, and loss of diffuse noxious inhibitory control 
(DNIC) in more advanced CP patients.10 It should be noted in this context that when 
opioid treatment becomes less effective the more central sensitization an individual 
has.11 Thus there is a clear need for alternatives (or adjuvants) to opioid treatment in CP 
patients with pain, targeting changes in (central) pain processing.
Delta 9 tetrahydrocannabinol (Δ9-THC) is the most potent psychoactive cannabinoid 
from the plant Cannabis Sativa, and has been used to treat pain for many centuries. 
However, the therapeutic potential of cannabinoids in current pain management 
remains unclear. To date, a wide range of products containing Δ9-THC are available for 
medicinal purposes, including: 1) crude medicinal cannabis containing several active 
compounds; 2) pharmaceutical products with standardized natural or synthetic Δ9-THC 
content containing whole cannabis plant extract, a defined combination of Δ9-THC 
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and cannabidiol (CBD) or pure Δ9-THC, and 3) synthetic analogues interacting with 
cannabinoid receptors.12 The pharmacokinetics (PK) of the different administration 
routes of herbal cannabis and cannabis-based medicines are variable and dosing is 
difficult to regulate. The development of pharmaceutical products for oral administration 
with pure and defined Δ9-THC content may offer a favorable alternative. Namisol® 
(Echo Pharmaceuticals, The Netherlands) is a novel formulation for oral administration, 
containing purified Δ9-THC isolated from the Cannabis Sativa plant, with a reliable PK 
profile as demonstrated in phase I healthy volunteer study.13
Δ9-THC induces pharmacological effects by binding non-selectively to cannabinoid 
receptors. Two cannabinoid receptors have been identified, the CB1 and CB2 receptor.14-16 
CB1 receptors are most densely present in the brain, particularly in the hippocampus, 
cerebellum and striatum, and occur in several areas providing targets through which 
cannabinoids could modulate pain. These areas include the periaqueductal gray (PAG), 
the rostral ventrolateral medulla, the superficial layers of the spinal dorsal horn, and the 
dorsal root ganglion from which they are transported to both central and peripheral 
terminals of primary afferent neurons.17-19 CB2 receptors are expressed in high quantities 
in human immune tissues and cells, e.g. in the spleen, tonsils and leucocytes.
Apart from potential direct analgesic effects, it is suggested that cannabis might further 
be useful to treat pain through possible synergistic interactions with opioid analgesics 
or by improving the efficacy of pain treatment in patients with a tolerance to opioids.20
In this phase 2 study, we aimed to study the analgesic efficacy, PK, pharmacodynamics 
(PD) and safety of a single dose oral Δ9-THC in patients with chronic abdominal pain 
resulting from CP, subdivided into opioid and non-opioid users.
METHODS
This was an equally randomized (1:1 ratio), single-dose, double-blind, placebo-
controlled, cross-over study to evaluate the analgesic efficacy, PK, PD, pharmacogenetics 
and safety of a single dose of Δ9-THC. The study population consisted of 24 subjects with 
CP, subdivided into daily opioid (n=12) and non-opioid users (n=12). The Medical Ethical 
Committee and Competent Authority approved the study (2011/114). The study was 
conducted according to the principles of the Declaration of Helsinki, and in accordance 
with the International Conference on Harmonization guidelines of Good Clinical Practice. 
All subjects provided oral and written consent before conduct of any protocol-related 
procedures. Clinicaltrials.gov identification number NCT01318369.
Study population
Eligible patients were adults (age >18 years) diagnosed with CP according to the 
Marseille and Cambridge Classification System. All patients had chronic abdominal pain, 
persistent or intermittent on a daily basis during the past 3 months, and considered their 
pain as severe enough for medical treatment (NRS ≥ 3). Patients in the opioid subgroup 
took stable doses of prescribed opioids, whereas patients in the non-opioid subgroup 
had not taken opioids or occasionally for pain flares in the past 2 months. The study took 
place at the Radboud university medical centre, the Netherlands, from October 2011 to 
May 2013. Patients were recruited by their physician or by advertisement.
Key exclusion criteria were: cannabis use in previous year; history of hypersensitivity 
to THC; BMI <18.0 or >31.2 kg/m2; serious painful conditions other than CP; significant 
medical disorder or concomitant medication that may interfere with the study or may 
pose a risk for the patient; major psychiatric illness in history; epileptic seizure in history; 
diabetic neuropathy; significant exacerbation in illness within two weeks; more than 1 
daily defined dose (DDD) benzodiazepines 6 hours prior to or following intake of study 
medication in the opioid subgroup, or more than 1 DDD benzodiazepines according 
to prescription in the non-opioid subgroup (1 DDD was defined as 20mg oxazepam); 
positive urine drug screen or alcohol test at screening or on study days; clinically relevant 
abnormalities in ECG or laboratory results; pregnant or breastfeeding females; intending 
to conceive a child; or participation in another investigational drug study within 90 days 
before study entry.
Randomization
Eligible patients were stratified into opioid and non-opioid users, then randomly assigned 
to one of two treatment sequences in a 1:1 ratio using a computer-generated list of 
random numbers. Patients, staff and investigator were all blinded by a double dummy 
design. Each study day, patients were given either a single dose Δ9-THC (Namisol® 8mg 
simultaneously with placebo Diazepam) or a single dose Diazepam (placebo Namisol® 
simultaneously with Diazepam (5mg non-opioid group/ 10mg opioid group)). Each 
patient subsequently received the alternative after at least a 14-day washout period. 
Namisol® or matching placebos were taken in three tablets (1x5mg + 2x1.5mg). The 
previous phase I study demonstrated that the maximal tolerable dosage with acceptable 
adverse events was 8 mg Namisol®. With respect to the expected THC-mediated sedative 
effects of cannabis, as demonstrated by frequently reported AEs such as somnolence 
and fatigue,21 low dose Diazepam was used as “active placebo” to prevent unblinding 
of patient and investigator. A study in healthy male subjects found no central effects 
after a single oral dose of 2 mg Diazepam, but intermediate effects after 5 mg and 
highly significant effects after 10 mg Diazepam.22 Opioid users are generally more used 
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to sedative (side) effects due to their regular medication use. Therefore, a dosage of 10 
mg Diazepam was chosen in order to induce similar sedative effects in this subgroup. 
Diazepam was packaged in capsules, which were identically prepared for the placebo 
Diazepam. Oral administration was performed using 200 ml of water.
Study procedures
The study consisted of a screening and two treatment days, with a telephone follow-up 
after each study day. Screening included demographics, medical history, NRS pain score, 
physical examination, 12-lead electrocardiogram (ECG), standard laboratory tests, and 
urine drug screening in order to assess the overall eligibility of the patient. Screening 
was carried out a maximum of 40 days before the first day of drug administration. All 
patients received a pain diary to fill in five days in a row, starting on the first day after 
screening in order to obtain a more convenient description of the pain status of the 
study population.
Use of illicit drugs and use of opioids were both tested using urine drug screening tests 
prior to drug administration. In addition, patients were not allowed to consume alcohol 
within 24 hours or caffeine within 6 hours prior drug administration. Urine pregnancy 
tests and saliva alcohol tests were performed at the beginning of both study days.
Study days were carried out at the research department of the hospital, where each 
patient stayed in a separate quiet room. Patients consumed as much as they preferred 
from a standardized menu on the first study day, but had to consume exactly the same 
on the second study day. The same applied to co-medication; patients used their regular 
medication, including painkillers, according to prescription on both study days. Every 
food and medication intake was recorded.
Analgesic efficacy
A visual analogue scale (VAS) was used to quantify pain intensity. VAS scores at rest and 
on movement after 5 sit-ups were marked on a 10 cm line. The boundaries of these lines 
were “no pain” on the most left side and “unbearable pain” on the most right side. The VAS 
was measured predose and postdose at 0:35, 1:05, 1:40, 2:05, 3:05, 4:10, and 5:00 hours 
after administration of study medication.
Pharmacokinetics
Plasma concentrations of THC and its active metabolite 11-OH-THC were determined 
in serial venous blood samples, which were collected in 4ml EDTA tubes predose at 
–0:15 hours and at 0:10, 0:30, 0:45, 1:00, 1:30, 2:00, 3:00, 4:00, and 6:00 hours postdose. 
Immediately after collection, samples were wrapped in aluminum foil and kept on ice. 
Samples were centrifuged within 30 minutes at 2000 g for 10 minutes at 4°C. The handling 
of THC samples was done avoiding direct light. The separated plasma was divided 
into primary and backup samples, and stored at –80°C until bioanalysis. Bioanalysis 
(Analytisch Biochemisch Laboratorium b.v., Assen, the Netherlands) was performed 
using a validated liquid chromatography/mass spectrometry/mass spectrometry (LC/
MS/MS) assay method according to good laboratory practice procedures. The lower limit 
of quantification for THC and 11-OH-THC was 0.100 ng ml−1.
Non-compartmental analysis to determine plasma PK parameters of the active 
compounds, THC and 11-OH-THC, was performed using the WinNonlin modeling 
and analysis software (version 2.1 a; Pharsight Inc., Apex, NC). The maximum plasma 
concentration (Cmax), the time to reach Cmax (Tmax), and the AUC from 0 up to the last 
measurement (AUC0–6h, using the linear log trapezoidal rule) were calculated from the 
individual plasma concentration-versus-time profiles. The terminal half-life (t1/2) was 
calculated only if there were two or more points (excluding Cmax) in the elimination phase 
of the plasma concentration–time curve with r2 > 0.80. For that reason, five patients were 
excluded from this part of the analysis for both THC and 11-OH-THC. Subsequently, 
the areas under the plasma concentration curves extrapolated to infinity (AUCinf) were 
calculated using the linear log trapezoidal rule and extrapolation to zero.
Pharmacogenetics
Genotyping of cytochrome P450 enzymes CYP2C9 and CYP2C19 was performed in 
order to investigate the effect of genetic polymorphisms on the pharmacokinetics of 
Δ9-THC.23,24 Two variants in genetic CYP2C9 polymorphisms (CYP2C9*2 and CYP2C9*3) 
and three variants in genetic CYP2C19 polymorphisms (CYP2C19*2, CYP2C19*3 and 
CYP2C19*17) were genotyped. To this end, saliva from 21 participating subjects was 
collected from which DNA extraction and genotyping was done.
Pharmacodynamics
Predose and postdose at 0:35, 1:05, 2:05, 3:05, and 5:00 hours, drug effects on mood and 
behavior were explored with a set of 16 individual Bond & Lader visual analogue scales. 
Three main factors were calculated as described by Bond and Lader: alertness (from nine 
scores), mood (from five scores), and calmness (from two scores).25 Potential subjective 
psychotomimetic (psychedelic) effects were evaluated using the Bowdle questionnaire. 
The Bowdle questionnaire consists of thirteen visual analogue lines ranging from ‘not 
at all’ to ‘extremely’ quantifying psychedelic effects.26 Subjects were asked to fill in both 
questionnaires predose and postdose at 1:05, 2:05, 3:05, and 5:00 hours after drug 
administration.
Left-right (roll) and anterior-posterior (pitch) postural oscillations were measured using 
a gyroscope-based measurement system (SwayStar™, Balance International Innovations 
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GmbH, Switzerland), which was attached to the waist of the patient. Patients stood, 
without shoes, as still as possible in a standardized base of support with their arms 
hanging at both sides of their body. Body sway was measured predose and at 1:25, 2:25, 
3:25, and 5:30 hours postdose for one minute with eyes open and one minute with eyes 
closed. During the task with eyes open patients were asked to fixate at one point. The 
computerized measures used for analysis reflect the 90% range roll and pitch excursion 
in degrees from the centre of gravity.
Safety and Tolerability
Safety and tolerability were evaluated using spontaneously reported adverse events 
(AEs) recorded at study days until follow-up, measurements of vital functions, ECG and 
laboratory tests. Blood pressure and heart rate were measured at screening and on both 
treatment days (predose and repeatedly postdose). ECG was recorded at screening, 
predose and at the end of each treatment day. Hematology, blood chemistry, and 
urinalysis were performed at screening and at the end of the study.
Statistical Methods
This was an exploratory study for which no sample size calculation was performed. 
Patients withdrawn prior to the first study day were replaced in order to have a total 
number of 24 evaluable patients for the analysis. The placebo treatment was considered 
as equal between opioid and non-opioid users, despite the distinction in dose treatment 
across both groups. For statistical analysis SPSS software for Windows v.20 was used. All 
statistical tests were performed two-tailed, and the limit for statistical significance was 
set at P<0.05.
Differences between Δ9-THC versus diazepam in VAS scores at rest at time point 2:05H 
were the primary outcome of this study. This was based on the assumption that Cmax is 
reached within two hours after medication intake. Differences between both treatments 
were statistically analyzed using a linear mixed model analysis with two fixed factors 
(period and treatment) and a random subject effect (random intercept). A period * 
treatment interaction was absent. The effect of treatment (Δ9-THC vs. placebo) was 
exploratory post hoc evaluated for both subgroups (opioid vs. non-opioid).
Statistics of repeated measures data were analysed using the area under the curve 
(AUC) of difference with baseline as summary measure. The AUC was computed using 
the trapezoid rule, ΔX*(Y1+Y2)/2, repeatedly for each adjacent pair of points defining 
the curve from zero until the last measurement. Differences between Δ9-THC versus 
diazepam were statistically analysed using a linear mixed model analysis. Opioid users 
and non-opioid users were compared in a subgroup analysis. The pharmacokinetics of 
patients with genetic polymorphisms were compared observationally.
RESULTS
Twenty-five patients were enrolled according to the flowchart in figure 1. One patient 
was not treated because of a positive drug screening on the first study day and was 
replaced. Two patients in the opioid subgroup were lost to cross over after the first 
study day, one female patient due to mild AEs and one male patient after withdrawal 
of consent. Consequently, 24 patients received a single dose Δ9-THC, and 22 patients 
received a single dose Diazepam.
Patient demographics and baseline characteristics are described in table 1. The mean age 
at screening was 52 years, mean BMI was 23.0 kg/m2, and 9 of 24 patients were female. 
Patients reported a mean NRS at screening of 6.0, whereas the mean VAS reported in 
the pain diary was 3.9. The average abdominal pain duration was 8.3 years at screening. 
Figure 1: Participant flowchart
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Table 1: Baseline demographics and disease characteristics
Sex
(M/F)
Age 
(years)
BMI
(kg/m2)
Etiology
CP
Pain
screen
(NRS)
Pain
diary
(VAS)
Pain 
duration
(years)
Concomitant 
medication
Opioid subgroup
1 M 54 25,7 Post ERCP 6 4,2 5 SOPI, PCM, AC
2 M 48 26,9 Idiopathic 4 4,5 2 SOPI, PCM, AC
3 M 46 26 Idiopathic 7 2,2 21 SOPI, AC, PE
4 F 61 26,6 Idiopathic 5 5,2 15 SOPI, PE
5 M 44 18,8 Neoplasm 3 4,5 0 SOPI, PE
6 M 42 22,5 Alcohol 6 5,1 14 WOPI, PCM, PE
7 M 45 22 Idiopathic 6 7,2 4 SOPI, WOPI, PCM
8 F 42 21,5 Hereditary 6 4,9 13 SOPI, PCM
9 M 52 22,2 Alcohol 5 4,4 1 SOPI, NSAID, PCM
10 M 50 26,2 Idiopathic 8 2,5 2 SOPI, PE
11 F 34 19,5 Idiopathic 4 4,0 11 SOPI, PCM
12 F 52 19,2 Idiopathic 8 4,6 8 SOPI, AC
mean 
(SD) 8/4
47,5 
(7,0)
23,1 
(3,1)
5,7 
(1,6)
4,4 
(1,3)
8,0 
(6,7)
Non-opioid subgroup
13 F 52 26,2 Idiopathic 8 6,9 11 PCM, AC
14 M 69 26,2 Hereditary 6 5,1 4 -
15 M 56 20,6 Neoplasm 8 4,0 8 AC, PE
16 M 71 23,6 Idiopathic 5 2,1 6 PCM, PE
17 M 51 26,3 Idiopathic 7 4,7 3 NSAID, PCM, PE
18 M 53 24,2 Idiopathic 3 2,5 9 PE
19 M 39 18,4 Idiopathic 7 2,5 6 NSAID, PCM, PE
20 F 54 18,1 Idiopathic 6 3,0 22 PCM, PE
21 F 57 23,8 Idiopathic 6 1,0 6 PE
22 M 44 18,5 Alcohol 9 2,1 6 PCM, PE
23 F 62 23,3 Alcohol 5 3,2 15 PE
24 F 65 26,3 Idiopathic 5 2,7 7 PCM
mean 
(SD)  7/5
56,1 
(9,5)
23,0 
(3,2)  
6,3 
(1,7)
3,3 
(1,6)
8,6 
(5,3)
Total
mean 
(SD) 15/9
51.8
(9.3)
23.0
(3.1)
6.0
(1.6)
3.9
(1.5)
8.3
(5.9)
SOPI Strong opioids including pethidine; WOPI Weak opioids including tramadol en codein; NSAID Non-steroidal 
anti-inflammatory drugs including diclofenac and ibuprofen; PCM Paracetamol; AC Anticonvulsants including 
pregabalin and gabapentin; AD Antidepressants; PA Pancreatic enzymes
 
Analgesic efficacy
Primary linear mixed model analysis at time point 2:05H showed no treatment effect of 
Δ9-THC compared with Diazepam on delta VAS pain at rest (mean diff Δ9-THC - diazepam 
-.17; 95% CI diff [-.95 to .61]; p=.65). Figure 2 shows the VAS pain at rest and on movement 
compared to baseline from 0:35H until 5:00H after administration of Δ9-THC as well as 
diazepam. The AUC VAS pain at rest (mean diff 18.37; 95% CI diff [-60.49 to 97.23]; p=.63) 
and AUC VAS pain on movement (mean diff -18.14; 95% CI diff [-168.31 to 132.03]; p=.80) 
after Δ9-THC were both not significantly decreased compared with diazepam. These 
parameters were similar for opioid vs. non-opioid users.
Pharmacokinetics
Mean plasma concentration-versus-time curves of THC and 11-OH-THC are shown in 
figure 3 and table 2 summarizes the PK of THC and its active metabolite 11-OH-THC. 
The PK parameters were similar between opioid and non-opioid users. One patient 
demonstrated a clearly enhanced Cmax compared to the rest of the population, which 
could not be explained by genetic polymorphism.
Table 2: Pharmacokinetic parameters of THC and 11-OH-THC
THC 11-OH-THC
Mean SD Mean SD
Cmax Group (n=24) 4,01 3,39 4,38 1,50
(ng/mL) Opioid (n=12) 4,44 4,40 4,51 1,62
Non-opioid (n=12) 3,58 2,08 4,25 1,44
Tmax Group (n=24) 122,80 87,99 135,70 77,50
(min) Opioid (n=12) 126,60 90,49 142,10 86,66
Non-opioid (n=12) 119,10 89,26 129,30 70,44
AUC 0-Last Group (n=24) 477,50 381,80 764,90 241,30
(ng*min/mL) Opioid (n=12) 507,90 506,70 777,70 298,10
Non-opioid (n=12) 447,20 214,70 752,20 180,50
AUC 0-inf Group (n=24) 532,20 442,50 920,70 316,40
(observed) Opioid (n=11) 577,70 571,10 954,00 400,00
(ng*min/mL) Non-opioid (n=8) 469,70 173,20 883,70 205,90
T1/2term Group (n=24) 67,12 20,37 110,10 26,57
(min) Opioid (n=11) 67,89 19,71 111,70 29,51
Non-opioid (n=8) 66,05 22,57 108,40 24,55
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Figure 2: VAS pain. Differences (mean and SD) in VAS pain compared to baseline were shown for Δ9-THC and 
diazepam measured at rest (A) and on movement (B) in patients with pancreatic pain (n=24). Abbreviation: 
PD= predose, maximal 1 hour prior drug administration.
Figure 3: Mean plasma concentration-time curves of THC (A) and 11-OH-THC (B) after a single dose of Δ9-
THC in CP patients subdivided in opioid (n=12) and non-opioid (n=12) users. Error bars represent standard 
deviation (SD).
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Pharmacogenetics
Several genetic polymorphisms were observed. Two patients were heterozygote 
carriers of CYP2C9*2 (C>T) and four patients were heterozygote carriers of CYP2C9*3 
(A>C). One patient was found to be AA homozygote and four patients GA heterozygote 
for CYP2C19*2 (G>A). No CYP2C19*3 (G>A) polymorphisms were observed. Genetic 
polymorphisms in CYP2C19*17 (C>T) were found for five subjects who were heterozygote 
CT carriers. Genetic CYP2C9 and CYP2C19 polymorphisms did not evidently effect the 
pharmacokinetics of Δ9-THC.
Pharmacodynamics
Figure 4 shows the effects of Δ9-THC and diazepam for alertness, mood and calmness 
obtained by the VAS Bond and Lader questionnaire. No significant differences were 
found between Δ9-THC vs. diazepam. Feeling anxious obtained by the VAS Bowdle 
questionnaire was significantly increased after Δ9-THC compared with diazepam (mean 
diff 166,92; 95% CI diff [10,86 to 322,97]; p=.037).
Overall 10 body sway measurements (4% of all measurements), from which 6 in the 
eyes closed condition and 8 after Δ9-THC administration, could not be conducted 
due to adverse events at that particular moment. There were no group differences in 
balance outcomes in both the eyes open and eyes closed condition between Δ9-THC 
and diazepam. However, balance performance was considerably disturbed in certain 
individuals after both Δ9-THC and diazepam. These individuals were found in both 
subgroups. Heart rate was significantly enhanced after Δ9-THC compared to diazepam 
(at time point 1:40H mean diff -5.5 BPM; 95% CI diff [-9.0 to -1.9]; p=.004). In one 
patient, heart rate in rest was measured above 100 BPM after Δ9-THC intake. Δ9-THC 
and diazepam did not affect diastolic or systolic blood pressure. Alterations in heart rate 
were not associated with PK parameters such as Cmax and AUCinf. All pharmacodynamic 
parameters were similar for opioid vs. non-opioid users and did not affect the treatment 
effect.
Safety and Tolerability
All related, probably related and possibly related AEs are presented in table 3. Overall, 
there was a higher frequency of AEs following Δ9-THC administration compared to 
diazepam (54 AEs in 24 patients vs. 36 AEs in 22 patients, respectively), although fewer 
patients reported at least one AE after Δ9-THC administration compared to diazepam 
(71% vs. 91% respectively). The most frequently reported AEs after Δ9-THC administration 
were somnolence, dry mouth, dizziness, and euphoric mood. Somnolence, dizziness, and 
fatigue were most commonly related or possibly related to diazepam administration. 
All AEs were mild or moderate, and equally divided between opioid and non-opioid
Table 3: Summary of adverse events
Adverse Event Diazepam (n=22) Δ9-THC (n=24)
  N % N %
General
Fatigue 8 36% 7 29%
Nervous system symptoms
Somnolence 11 50% 8 33%
Dizziness 6 27% 4 17%
Headache 3 14% 2 8%
Balance disorder 0 0% 2 8%
Amnesia 0 0% 1 4%
Paraesthesia 1 5% 2 8%
Depressed level of conciousness 1 5% 0 0%
Psychiatric symptoms
Confusional state 0 0% 2 8%
Indifference 0 0% 1 4%
Euphoric mood 2 9% 4 17%
Derealisation 0 0% 1 4%
Disorientation 0 0% 1 4%
Tension 0 0% 1 4%
Gastro-intestinal system symptoms
Nausea 1 5% 3 13%
Vomiting 0 0% 1 4%
Steatorrhoea 0 0% 1 4%
Constipation 1 5% 0 0%
Abdominal discomfort 0 0% 1 4%
Dry Mouth 0 0% 5 21%
Throat irritation 0 0% 1 4%
Vision symptoms
Visual impairment 1 5% 3 13%
Cardiac symptoms
Heart rate increased 1 5% 1 4%
Eye symptoms
Dry eye 0 0% 1 4%
Photophobia 0 0% 1 4%
TOTAAL 36   54  
users. The number of AEs was not associated with PK parameters such as Cmax and AUCinf. 
However, the subject showing the highest Cmax also had the greatest number of AEs. There 
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were no serious AEs during the study. One patient was withdrawn after administrating 
Δ9-THC on the first study day due to somnolence, dizziness, increased heart rate, nausea, 
paraesthesia, and feelings of tension. There were no clinically relevant changes in vital 
signs, ECG parameters, or safety laboratory parameters (hematology, biochemistry, and 
urinalysis).
Figure 4: VAS Bond and Lader questionnaire. Mean scores for alertness (A), mood (B), and calmness (C) 
were shown for Δ9-THC and diazepam in CP patients (n=24). Error bars represent standard deviation (SD). 
Abbreviation: PD= predose.
DISCUSSION
Our study investigated the analgesic efficacy, pharmacokinetics, pharmacodynamics and 
safety of a single dose Δ9-THC in patients with chronic abdominal pain related to CP. We 
demonstrated in an exploratory study, that a single dose of 8 mg Δ9-THC is not efficacious 
in reducing chronic pancreatic pain compared to the active placebo diazepam. Δ9-THC 
was absorbed with an average Tmax of 123 minutes, which was similar for opioid and 
non-opioid users, but slower than observed in a previous study in healthy subjects.13 
We observed a small, but significant increase in feeling anxious after Δ9-THC compared 
to diazepam. Other pharmacodynamic outcomes did not differ between Δ9-THC and 
diazepam. A single dose of Δ9-THC was well tolerated resulting in mild to moderate AEs.
Analgesic efficacy
Several RCTs investigated the analgesic efficacy of different products containing THC in 
various pain states.12,27-30 In a majority of these studies, THC treatment resulted in pain 
reduction in chronic pain, whereas the data in acute pain were less conclusive. Most studies 
in chronic non-malignant pain conditions demonstrated analgesic efficacy in chronic 
non-malignant pain using a single dose or treatment periods of 2 to 15 weeks.20,31-42 The 
majority of studies with cannabis-based medicines were conducted in patients suffering 
from central neuropathic pain in multiple sclerosis. Ours is the first study in patients with 
chronic abdominal pain resulting from CP, which is generally recognized as difficult to 
treat and associated with high opioid use.
Narang et al. demonstrated that patients who received a single dose THC experienced 
decreased pain intensity compared with placebo in patients taking opioids for chronic 
non-malignant pain of various origin (e.g. low back, lower extremity, cervical, and 
abdominal/pelvic pain), suggesting that THC may have an additive effect on pain relief.20 
Preclinical evidence also suggests that THC may act synergistically with opioids.43,44 
However, in the present study we did not observe any analgesic effect of Δ9-THC 
compared to diazepam nor a difference between opioid users and non-opioid users. 
Although pain was decreased after Δ9-THC administration, the same effect was observed 
after diazepam administration. As for diazepam no analgesic efficacy is described and 
is used in other pain studies as active placebo,45 it is assumed that the pain relief after 
diazepam is a placebo effect. It is well known that placebo and nocebo effects are present 
in chronic pain populations.46
Several explanations for the lack of analgesic effect in our study can be proposed:
1)  a single dose of Δ9-THC is insufficient to achieve adequate exposure duration. 
 THC is lipophilic and will diffuse to the fatty tissues immediately. The question 
 is whether the THC concentration at target site is sufficient to modulate pain. 
 
Figure 4: VAS Bond and Lader questionnaire. Mean scores for alertness (A), mood (B), and 
calmness (C) were shown for Δ9-THC and diazepam in CP patients (n=24). Error bars 
represent standard deviation (SD). Abbreviation: PD= predose  
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 Therefore, long-term treatment studies are necessary to achieve sufficient 
 exposure duration and evaluate the efficacy of Δ9-THC.
2)  the dosage of 8 mg Δ9-THC is inadequate for each individual patient. 
 The dosage should be adjusted for individual patients according to genetic, 
 mechanistic, and other patient-related factors that potentially influence the PK 
 and clinical effects.47,48
3)  Δ9-THC is effective only in certain types of pain, e.g. chronic vs. acute, or 
 visceral vs. neuropathic. It is difficult to specify responders, because the 
 working mechanism of how THC potentially modulates pain is unclear. It should 
 be noted that several previous clinical trials demonstrated analgesic efficacy in 
 chronic pain, particularly in multiple sclerosis, whereas the data in acute pain 
 were less conclusive.12
4)  sensitization of nociceptive pathways (e.g. central sensitization) and alterations 
 in central cognitive and autonomic processing, which are all associated with 
 chronic pancreatic pain,49-51 impedes analgesic efficacy in this particular 
 research population.
5)  THC in general is ineffective for pain relief. However, the absence of a significant 
 pain relief in current study, after only one single dose, does not give evidence 
 that supports this suggestion.
Pharmacokinetics
The mean plasma concentration curves demonstrate that THC was generally well 
absorbed and further metabolized to 11-OH-THC in this group of CP patients. However, 
it should be noted that, according to the mean plasma concentration curve of THC, the 
time to reach maximal THC concentration was 45-90 min, whereas the computed mean 
Tmax of THC was 119-127 min. This phenomenon can be explained by the observation that 
subjects with an early Tmax have a much higher Cmax compared to those subjects with a late 
Tmax which show a relatively low Cmax. The previously mentioned phase I study reported a 
time to reach maximal THC concentration of 39–56 min, but these subjects were young, 
healthy and fasted before Δ9-THC administration.13 Thus, the absorption of Δ9-THC was 
delayed in a subgroup of CP patients, resulting in an increased variability.
CP is associated with malabsorption,52,53 which potentially affects drug absorption and 
could explain the inter-individual PK variation in patients with CP.54 Drug absorption in 
CP patients might further be affected by alterations in gastrointestinal intraluminal pH, 
gastrointestinal motility, bacterial overgrowth and changed pancreatic gland secretion.54 
In addition, bowel dysfunction is a common adverse effect of prolonged opioid use,55 
which may affect the absorption of drugs as well. Therefore, the role of these factors in 
modulating the pharmacokinetic profile of THC should be further studied.
Pharmacogenetics
We aimed to evaluate the effects of CYP2C9 and CYP2C19 polymorphism on the 
pharmacokinetics of Δ9-THC, which is subsequently relevant for its efficacy and adverse 
effects. Sachse-Seeboth et al. found that the homozygous CYP2C9*3 variant affected the 
pharmacokinetics of THC, resulting in a three folded area under the plasma concentration 
curve of THC, as well as a trend towards increased sedation after oral administration of 
THC.23 In the current study, we did not observe significant differences between wild-type 
subjects and subjects with homozygous or heterozygous CYP polymorphisms. This can 
be explained by the small number of subjects with a genetic variant. However, it cannot 
be precluded that genetic polymorphisms may have contributed to the inter-individual 
variation in the pharmacokinetics of Δ9-THC. 
Pharmacodynamics
Several psychological outcomes such as alertness, feelings of unreality, control of 
thoughts, feeling high, and feeling drowsy seem to be affected after administration of 
both Δ9-THC and diazepam. Feeling anxious was the only outcome with a significant 
difference between Δ9-THC and diazepam, which is not surprising considering the 
anxiolytic properties of diazepam. Similar results were observed for the body sway 
measurements. Balance disturbances were found in several individuals after both 
Δ9-THC as well as diazepam. After 1:40 hours postdose, heart rate was significantly 
enhanced with 5.5 beats per minute after Δ9-THC compared to diazepam. This is in line 
with previous studies and for most patients not clinically relevant.13
Adverse effects
Δ9-THC was generally well tolerated resulting in only mild to moderate adverse events, 
which were very similar compared to those observed in healthy volunteers.13 However, 
we observed an inter-individual variation with certain subjects experiencing no single 
side effect while others experienced several side effects at the same time. This could not 
be explained by subgroups of (non)opioid users or pharmacogenetic polymorphisms, 
and could not be associated with pharmacokinetic parameters such as Cmax or AUClast. 
However, side effects of THC are considered to be dose-related,13 and therefore, adverse 
events should be avoidable by adjusting the dosage or by adequate dosage titration.
Methodological considerations
The similarities in the pharmacodynamics of Δ9-THC compared to diazepam clearly 
demonstrate that we succeeded in adequate blinding of subjects by giving the 
impression of an active psychotropic drug in both periods. Additionally, with respect 
to the sedative effects of THC, diazepam was used to control for indirect pain relief 
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through the sedative effects on the experienced pain. Diazepam is more often chosen as 
active placebo for THC and other central working analgesics.45,56 However, it should be 
mentioned that the role of GABA in mediating the transmission and perception of pain 
is not evidently clear. GABAergic neurons are widely distributed throughout the central 
nervous system, including regions of the spinal cord dorsal horn known to be important 
for transmitting pain impulses to the brain.57 GABA receptor agonists demonstrate 
antinociceptive properties in a variety of pain models in animal studies,58 and showed 
possible anti-hyperalgesic effects in experimental human pain models.59 However, 
benzodiazepines largely lack clear analgesic efficacy in humans,57,60 and diazepam is thus 
unlikely to affect the primary outcome. The comparison with diazepam, however, may 
have complicated the evaluation of PD effects of Δ9-THC. Several psychedelic outcomes 
such as alertness, feelings of unreality, control of thoughts, feeling high, feeling drowsy, 
and feeling anxious were affected after administration of both drugs.
Conclusion
This study demonstrates that a single dose of 8 mg Δ9-THC was not efficacious in 
achieving pain relief. At this dose, Δ9-THC was generally well tolerated with mostly 
mild AEs. The PK results in CP patients showed delayed absorption and an increased 
variability compared to healthy volunteers, most probably due to underlying pathology 
and concomitant medication use. Further long-term treatment studies are necessary to 
evaluate the efficacy and tolerability of Δ9-THC in chronic pancreatitis and other chronic 
visceral pain conditions.
Acknowledgements
The authors thank all participating patients and Simone Hins-deBree (research nurse) for 
all kind of study-related work.
Conflict of interest
All authors have completed the Unified Competing Interest form at www.icmje.org/coi_
disclosure.pdf (available on request from the corresponding author) and declare: HvG 
received a grant from the European Union, the European Fund for Regional Development 
(EFRO, ‘Here is an investment in your future’) for the submitted work; no financial 
relationships with any organisations that might have an interest in the submitted work 
in the previous 3 years; no other relationships or activities that could appear to have 
influenced the submitted work.
REFERENCES
1. Sarles H. Definitions and classifications of pancreatitis. Pancreas. 1991;6(4):470-474.
2. Andren-Sandberg A, Hoem D, Gislason H. Pain management in chronic pancreatitis. Eur J 
Gastroenterol Hepatol. 2002;14(9):957-970.
3. Warshaw AL BP, Fernandez-Del Castillo C. American Gastroenterological Association 
Medical Position Statement: treatment of pain in chronic pancreatitis. Gastroenterology. 
1998;115:763-764.
4. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS. Do opioids induce hyperalgesia in humans? 
An evidence-based structured review. Pain Med. 2009;10(5):829-839.
5. Tompkins DA, Campbell CM. Opioid-Induced Hyperalgesia: Clinically Relevant or Extraneous 
Research Phenomenon? Curr Pain Headache Rep. 2011.
6. Chauhan S, Forsmark CE. Pain management in chronic pancreatitis: A treatment algorithm. 
Best Pract Res Clin Gastroenterol. 2010;24(3):323-335.
7. Di Sebastiano P, di Mola FF, Bockman DE, Friess H, Buchler MW. Chronic pancreatitis: the 
perspective of pain generation by neuroimmune interaction. Gut. 2003;52(6):907-911.
8. Buscher HC, Wilder-Smith OH, van Goor H. Chronic pancreatitis patients show hyperalgesia 
of central origin: a pilot study. European journal of pain. 2006;10(4):363-370.
9. Drewes AM, Gratkowski M, Sami SA, Dimcevski G, Funch-Jensen P, Arendt-Nielsen L. Is 
the pain in chronic pancreatitis of neuropathic origin? Support from EEG studies during 
experimental pain. World journal of gastroenterology : WJG. 2008;14(25):4020-4027.
10. Olesen SS, Brock C, Krarup AL, et al. Descending inhibitory pain modulation is impaired in 
patients with chronic pancreatitis. Clin Gastroenterol Hepatol.8(8):724-730.
11. Edwards RR, Ness TJ, Weigent DA, Fillingim RB. Individual differences in diffuse noxious 
inhibitory controls (DNIC): association with clinical variables. Pain. 2003;106(3):427-437.
12. de Vries M, van Rijckevorsel DC, Wilder-Smith OH, van Goor H. Dronabinol and chronic pain: 
importance of mechanistic considerations. Expert opinion on pharmacotherapy. 2014:1-10.
13. Klumpers LE, Beumer TL, van Hasselt JG, et al. Novel Delta(9) -tetrahydrocannabinol 
formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic 
effects. British journal of clinical pharmacology. 2012.
14. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for 
cannabinoids. Nature. 1993;365(6441):61-65.
15. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid 
receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-564.
16. Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 5th edition. 
British journal of pharmacology. 2011;164 Suppl 1:S1-324.
17. Hohmann AG, Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat 
lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett. 1998;252(1):13-16.
Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.Chapter 4
9190
4
18. Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger 
RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization 
study. Neuroscience. 1999;90(3):923-931.
19. Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid 
and mu opioid receptors in rat spinal cord. Brain research. 1999;822(1-2):17-25.
20. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for 
chronic pain patients on opioid therapy. J Pain. 2008;9(3):254-264.
21. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review 
and Meta-analysis. Jama. 2015;313(24):2456-2473.
22. Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of 
oral diazepam: effect of dose, plasma concentration, and time. Clinical pharmacology and 
therapeutics. 1992;52(2):139-150.
23. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics 
of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clinical 
pharmacology and therapeutics. 2009;85(3):273-276.
24. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. 
Clinical pharmacology and therapeutics. 2005;77(1):1-16.
25. Bond A, Lader M. The use of analogue scales in rating subjective feelings. British Journal of 
Medical Psychology. 1974;47(3):211-218.
26. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic 
effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. 
Anesthesiology. 1998;88(1):82-88.
27. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic 
review of randomized trials. British journal of clinical pharmacology. 2011;72(5):735-744.
28. Russo EB. Cannabinoids in the management of difficult to treat pain. Therapeutics and clinical 
risk management. 2008;4(1):245-259.
29. Beaulieu P, Ware M. Reassessment of the role of cannabinoids in the management of pain. 
Current opinion in anaesthesiology. 2007;20(5):473-477.
30. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. Journal of 
ethnopharmacology. 2006;105(1-2):1-25.
31. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for 
chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia. 2004;59(5):440-452.
32. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, 
parallel-group study of THC/CBD oromucosal spray in combination with the existing 
treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. 
Journal of neurology. 2013;260(4):984-997.
33. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully 
treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-
controlled clinical trial. Pain. 2007;133(1-3):210-220.
34. Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM. Effect of dronabinol on central neuropathic 
pain after spinal cord injury: a pilot study. American journal of physical medicine & 
rehabilitation / Association of Academic Physiatrists. 2010;89(10):840-848.
35. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind 
clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: 
depression is a major confounding factor. Diabetes care. 2010;33(1):128-130.
36. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain 
in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Bmj. 
2004;329(7460):253.
37. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief 
of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled 
trial. Pain. 2004;112(3):299-306.
38. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, 
tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain 
caused by rheumatoid arthritis. Rheumatology. 2006;45(1):50-52.
39. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for 
neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year 
extension trial. Clinical therapeutics. 2007;29(9):2068-2079.
40. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts 
have general or specific effects on symptoms in multiple sclerosis? A double-blind, 
randomized, placebo-controlled study on 160 patients. Multiple sclerosis. 2004;10(4):434-
441.
41. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine 
whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. 
Clinical rehabilitation. 2003;17(1):21-29.
42. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms 
related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. 
Lancet. 2003;362(9395):1517-1526.
43. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life 
sciences. 2004;74(11):1317-1324.
44. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-
tetrahydrocannabinol and morphine. European journal of pharmacology. 2006;530(1-2):54-
58.
Chapter 4
92
45. Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia by oral standardized cannabis 
extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 
2008;109(1):101-110.
46. Capurso G, Cocomello L, Benedetto U, Camma C, Delle Fave G. Meta-analysis: the placebo 
rate of abdominal pain remission in clinical trials of chronic pancreatitis. Pancreas. 
2012;41(7):1125-1131.
47. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clinical pharmacology 
and therapeutics. 2007;81(6):807-816.
48. Bruehl S, Apkarian AV, Ballantyne JC, et al. Personalized medicine and opioid analgesic 
prescribing for chronic pain: opportunities and challenges. The journal of pain : official 
journal of the American Pain Society. 2013;14(2):103-113.
49. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain 
in clinical chronic pain. Pain. 2011;152(3 Suppl):S49-64.
50. Baliki MN, Petre B, Torbey S, et al. Corticostriatal functional connectivity predicts transition to 
chronic back pain. Nature neuroscience. 2012;15(8):1117-1119.
51. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 
2011;152(3 Suppl):S2-15.
52. Forsmark CE. Chronic pancreatitis and malabsorption. The American journal of 
gastroenterology. 2004;99(7):1355-1357.
53. Pezzilli R. Chronic pancreatitis: maldigestion, intestinal ecology and intestinal inflammation. 
World journal of gastroenterology : WJG. 2009;15(14):1673-1676.
54. Olesen AE, Brokjaer A, Fisher IW, Larsen IM. Pharmacological challenges in chronic 
pancreatitis. World journal of gastroenterology : WJG. 2013;19(42):7302-7307.
55. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. 
American journal of surgery. 2001;182(5A Suppl):11S-18S.
56. Kaufmann RM, Kraft B, Frey R, et al. Acute psychotropic effects of oral cannabis extract 
with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. 
Pharmacopsychiatry. 2009;43(1):24-32.
57. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Advances 
in pharmacology. 2006;54:1-27.
58. Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU. Genuine antihyperalgesia by 
systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain. 
2009;141(3):233-238.
59. Vuilleumier PH, Besson M, Desmeules J, Arendt-Nielsen L, Curatolo M. Evaluation of anti-
hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a 
randomized placebo-controlled study. PloS one. 2013;8(3):e43896.
60. Chapman CR, Feather BW. Effects of diazepam on human pain tolerance and pain sensitivity. 
Psychosom Med. 1973;35(4):330-340.
Chapter 5
Tetrahydrocannabinol Does Not Reduce Pain in 
Patients With Chronic Abdominal Pain in a Phase 2 
Placebo-controlled Study
De Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H. 
Clinical Gastroenterology and Hepatology. 2017 Jul;15(7):1079-1086.e4.
Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study.Chapter 5
9796
5
ABSTRACT
BACKGROUND & AIMS: Delta 9 tetrahydrocannabinol (THC) is the most abundant 
cannabinoid from the plant Cannabis sativa. There is only equivocal evidence that THC 
has analgesic effects. We performed a phase 2 controlled trial to evaluate the analgesic 
efficacy, pharmacokinetics, safety, and tolerability of an oral tablet containing purified 
THC in patients with chronic abdominal pain.
METHODS: Sixty-five patients with chronic abdominal pain for 3 months or more 
(numeric rating scale scores of 3 or more) after surgery or due to chronic pancreatitis 
were randomly assigned to groups given the THC tablet or identical matching placebos 
for 50–52 days. Subjects in the THC group were given the tablet first in a step-up phase 
(3 mg, 3 times daily for 5 days and then 5 mg, 3 times daily for 5 days) followed by a 
stable dose phase (8 mg, 3 times daily until day 50–52). Preceding and during the entire 
study period, patients were asked to continue taking their medications (including 
analgesics) according prescription. Patients reported any additional pain medications 
in a diary. Efficacy and safety assessments were conducted preceding medication intake 
(day 1), after 15 days, and at 50–52 days. Plasma samples were collected on study days 
1, 15, and 50–52; mean plasma concentration curves of THC and 11-OH-THC were 
plotted. The primary endpoint was pain relief, measured by a visual analogue scale of 
the mean pain (VAS mean scores), based on information from patient diaries. Secondary 
endpoints included pain and quality of life (determined from patient questionnaires), 
pharmacokinetics, and safety.
RESULTS: At days 50–52, VAS mean scores did not differ significantly between the THC 
and placebo groups (F(1, 46) =.016; P=.901). Between the start and end of the study, VAS 
mean scores decreased by 1.6 points (40%) in the THC group compared to 1.9 points 
(37%) in the placebo group. No differences were observed in secondary outcomes. 
Oral THC was generally well absorbed. Seven patients in the THC group stopped taking 
the tablets due to adverse events, compared with 2 patients in the placebo group. All 
(possibly) related adverse events were mild or moderate. 
CONCLUSIONS: In a phase 2 study, we found no difference between a THC tablet and a 
placebo tablet in reducing pain measures in patients with chronic abdominal pain. THC, 
administered 3 times daily, was safe and well tolerated during a 50–52 day treatment 
period.
Clinicaltrials.gov no: NCT01562483 and NCT01551511.
INTRODUCTION
Chronic abdominal pain remains a major clinical challenge. Two typical chronic abdominal 
pain etiologies of visceral origin are chronic pancreatitis (CP) and postsurgical pain (PSP). 
Approximately 80–90% of CP patients suffer from chronic abdominal pain during the course 
of their illness.1,2 Incidences of painful post abdominal surgery adhesion development 
vary in literature from 45 to 90%.3-5 Intra-abdominal adhesions are believed to be the most 
likely cause of PSP.4 CP and PSP are both associated with an increased responsiveness 
of nociceptive pathways in the central nervous system, termed central sensitization.6-8 
Central sensitization produces pain hypersensitivity by changing the sensory response in 
the central nervous system, and is associated with the development and maintenance of 
chronic pain.7 Because central sensitization alters the properties of neurons in the central 
nervous system, the pain is frequently no longer reliably coupled to the presence of 
particular peripheral stimuli. Therefore, pharmacologic treatment options that produce 
analgesia by targeting these changes in the central nervous system are required.8
The introduction of cannabinoids offers an interesting alternative for chronic pain 
management. Delta-9-tetrahydrocannabinol (THC) is the principal psychoactive 
compound of the Cannabis sativa plant,9 and interacts with two cannabinoid receptors, 
termed CB1 and CB2. CB1 receptors are predominantly found in the brain and spinal 
cord, while CB2 receptors are located primarily in the periphery, including the immune 
system.10 CB1 receptors are also highly expressed in regions critical for emotion processing 
including the amygdala, hippocampus, and anterior cingulate cortex.11 Brain activity 
within this emotion-related circuitry was found to be increased in patients with chronic 
pain.12,13 Hence, it was suggested that cannabinoids may modulate pain perception by 
disturbing the connectivity within this circuit. This was demonstrated by Lee et al., who 
observed that THC reduced the functional connectivity between the amygdala and the 
primary somatosensory cortex (S1) during pain processing.14 Further research indicated 
that THC does not selectively affect these limbic regions, but rather interferes with sensory 
processing, which in turn reduces sensory-limbic connectivity, leading to deactivation of 
affective regions.15 Thus it may be expected that THC interferes, although not selectively, 
with the affective components of pain.
The majority of clinical trials on the efficacy of THC for pain treatment has been focused on 
cancer related pain, central neuropathic pain syndromes, and acute pain conditions.16-18 
We aimed to investigate the efficacy, pharmacokinetics and safety of a novel cannabinoid-
based product, an oral tablet containing purified natural THC, in patients with chronic 
abdominal pain.
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METHODS
Study design
This phase II study used an equally randomized (allocation ratio 1:1), double-blind, 
placebo-controlled, parallel design. The study initially started as two clinical trials in 
(1) patients with painful CP and (2) patients with chronic abdominal PSP. Integration 
into one study was necessary due to a disappointing recruitment rate. Initial 
trials used identical study designs, treatment schemes and outcome parameters. 
Integration was supported by an independent statistician, who reviewed blinded 
interim data. The medical ethical committee approved both initial studies as well as 
the protocol amendment concerning study integration prior to study closure. The 
study was conducted according to the principles of the Declaration of Helsinki, and in 
accordance with the International Conference on Harmonization guidelines of Good 
Clinical Practice. All subjects provided oral and written consent before conduct of 
any protocol-related procedures. All authors had access to the study data and had 
reviewed and approved the final manuscript. Clinicaltrials.gov identification numbers 
NCT01562483 and NCT01551511.
Study population
Adult patients (age >18 years) suffering from abdominal pain developed after a surgical 
procedure or resulting from chronic pancreatitis were eligible for participation, if 
they had persistent or intermittent abdominal pain (on a daily basis for at least 3 
months) severe enough for medical treatment (average NRS ≥ 3).19 Key exclusion 
criteria were: daily cannabis use in past three years; history of hypersensitivity to 
THC; serious painful conditions other than PSP or CP; significant medical disorder 
or concomitant medication that may interfere with the study or may pose a risk for 
the patient; major psychiatric illness in history; epileptic seizure in history; affected 
sensory input such as diabetic neuropathy; BMI >36.0 kg/m2; significant exacerbation 
in illness within two weeks; positive urine drug screen or alcohol test at screening or 
on study days; clinically relevant abnormalities in ECG or laboratory results; pregnant 
or breastfeeding females; intending to conceive a child; or participation in another 
investigational drug study within 90 days before study entry. Preceding and during 
the entire study period, patients were asked to take their co-medication, including 
analgesics, according prescription. Patients reported additional pain medication 
(taken as needed) in a diary. The study was executed at the Radboud university 
medical center, the Netherlands. Patients were recruited by their physician or via 
advertisements.
Randomization and study treatment
Tablets with standardized Δ9-THC content (Namisol®, Echo Pharmaceuticals, Weesp, the 
Netherlands) or identical matching placebos were administered orally during a 50-52 
days add-on treatment. The study treatment consisted of two phases (supplementary 
figure 1): a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose 
phase (day 11-52: 8 mg TID). It was permitted to taper the dosage to 5 mg TID, when 
8 mg was not tolerated. Independent pharmacists dispensed either active or placebo 
tablets according to a computer-generated randomization list stratified for opioid and 
non-opioid users using separate lists. Treatment allocation was strictly concealed from 
participants, investigators, and all other study personnel involved in the study until end 
of study and database lock.
Study procedures
Efficacy and safety assessments were conducted preceding medication intake on day 1 
(visit 2), after 15 treatment days (visit 3) and 50-52 treatment days (visit 4). Several phone 
calls were performed by the investigators during and after the treatment period (day 
4-5, 9-10, 21-23, 28-30, 38-40 and 59-61) in order to evaluate the tolerability, safety and 
compliance. 
Additional study procedures in supplementary material.
Primary efficacy outcome
The primary endpoint was change in pain intensity at the end of study treatment versus 
baseline of THC compared with placebo. A visual analogue scale was used in order to 
quantify the mean (VASmean), minimal (VASmin) and maximal (VASmax) pain intensity in a 
daily diary, starting five days preceding first medication intake until the end of study 
treatment. The boundaries of these 10 cm lines were 0 for no pain and 10 for unbearable 
pain. 
Statistics primary outcome
VASmean pain was analyzed by an Analysis of Covariance (ANCOVA) of the VASmean at day 
50-52 (last day of diary) between placebo and THC that incorporates VASmean at baseline 
(mean day -5 to -1 pre-treatment) as covariate in the analyses. Possible moderating 
variables such as subpopulation (pancreatitis/postsurgical) and opiate user (y/n) were 
evaluated by observing potential interactions and post hoc subgroup analyses.
Secondary outcomes and statistics are fully described in supplementary material.
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RESULTS
A total of 69 patients were assessed for eligibility during screening, of whom 65 were 
included and randomized (figure 1). Sixty-two patients started study medication, of 
whom 21 (8 CP/ 13 PSP) patients in the THC arm and 29 (15 CP/ 14 PSP) patients in the 
placebo arm were included in the modified intention to treat efficacy analysis. For the 
safety analysis, 30 (12 CP/ 18 PSP) patients were included in the THC arm and 32 (15 
CP/ 17 PSP) patients in the placebo arm. Patient characteristics are shown in table 1. 
Eligible patients were recruited from October 2012 to July 2014, and stopped due to 
poor recruitment.
Assessed for eligibility (n=69) 
Allocated to placebo  treatment (n=34) 
 
Received Placebo (n=32) 
Did not received Placebo (n=2) 
•  Withdrawal of consent (n=2) 
Allocated to THC treatment (n=31) 
 
Received THC (n=30) 
Did not received THC(n=1) 
•  Withdrawal of consent (n=1) 
Lost to follow-up (n=0) 
 
Discontinued intervention <36 days (n=9) 
•  Adverse events (n=7) 
•  Withdrawal of consent (n=2) 
Discontinued intervention >36 days (n=0) 
 
Excluded (n=4) 
•  Not meeting inclusion criteria (n=3) 
•  Decline to participate (n=1) 
Lost to follow-up (n=0) 
 
Discontinued intervention <36 days (n=3) 
•  Adverse events (n=2) 
•  Withdrawal of consent (n=1) 
 
Discontinued intervention >36 days (n=1) 
•  Adverse event (n=1) 
Efficacy analysis (n=29) 
•  Excluded from analysis (n=0) 
 
Safety analysis  (n=32) 
•  Excluded from analysis (n=0) 
Efficacy analysis (n=21) 
•  Excluded from analysis (n=0) 
 
Safety analysis  (n=30) 
•  Excluded from analysis (n=0) 
Randomized (n=65) 
Figure 1: Participant flowchart.
Table 1: Demographic and clinical characteristics.
CP (n=23) PSP (n=27)
THC Placebo THC Placebo
Gender (male/female) 7/1 11/4 2/11 5/9
Age (years) 53.9 (7.5) 53.9 (10.3) 52.2 (11.3) 51.9 (8.2)
BMI (kg/m2) 24.2 (5.0) 24.3 (3.8) 27.0 (4.5) 26.4 (3.5)
Ethnicity
Caucasian 8 14 12 14
Mixed Afro-Caucasian 0 0 1 0
Asian 0 1 0 0
NRS pain at screening 5.3 (1.7) 5.9 (1.6) 6.9 (1.0) 7.0 (0.8)
Concomitant medication
None 0 0 0 2
PCM 3 12 12 10
NSAID 3 2 5 1
Weak opioids 3 6 5 7
Strong opioids 7 11 4 4
Antiepileptics 3 4 1 3
Smoking status
Current smoker 6 6 4 6
Past smoker 1 6 1 5
No smoker 1 3 8 3
Etiology CP
Alcohol 6 3
Hereditary 0 1
Idiopathic 2 7
Neoplasm 0 2
Other 0 2
Continuous data are expressed as mean (SD) and categorical data as numbers (n). Weak opioids were defined as 
codeine and tramadol. Strong opioids were defined as opioid-based therapies such as oxycontin, fentanyl and 
morphine. 
Abbreviations: PCM=paracetamol, NSAID= non-steroidal anti-inflammatory drugs.
Efficacy
For patients in the efficacy analyses, mean (SD) VASmean pain scores at baseline were 4.0 
(1.9) and 5.2 (1.8) for THC and placebo respectively, and for patients in the safety analysis, 
including drop-outs, 4.3 (1.9) and 5.2 (1.9) points respectively. VASmean pain scores during 
THC and placebo treatment are shown in figure 2. Primary efficacy analysis of the average 
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VAS pain at the last day of diary did not reveal significant difference between THC and 
placebo treatment (95% CI of diff [-1.31, 1.16], F(1, 46) =.016, p =.901). Mean VAS pain 
scores were reduced on average of 1.6 points (40%) in the THC arm compared to 1.9 points 
(37%) in the placebo arm. Parallel results were observed for minimal and maximal reported 
VAS pain. Subgroup analyses of CP (95% CI of diff [-2.23, 1.78], F(1, 19) =.056, p =.816) and 
PSP (95% CI of diff [-1.87, 1.70], F(1, 24) =.010, p=.922) patients revealed similar results and 
did not affect these outcomes as covariate. VAS pain outcomes are presented in table 2.
Figure 2: Mean VAS pain at baseline (day -5 to -1) and during study treatment (day 1 to 49) for THC and placebo 
in patients with chronic abdominal pain (n=50), subdivided in chronic pancreatitis (n=23) and postsurgical 
pain (n=27). VASpain scores are shown until day 49, which is the last day of diary for most patients. Grey bars 
represent baseline period.
Table 2: VAS pain scores
Mean VAS pain Minimal VAS pain Maximal VAS pain
Mean SD Mean SD Mean SD
Chronic abdominal pain (n=50 modified ITT analysis)
THC Baseline 4.0 1.85 2,79 1,53 4,61 2,39
Last day 2.4 2.28 1,75 1,97 4,20 2,78
Mean last 5 days 2.9 2.13 1,85 1,76 4,61 2,39
Diff (last day minus baseline) -1.6 1.78 -0,96 1,77 -0,40 0,85
Placebo Baseline 5.2 1.75 3,03 1,85 5,66 2,24
Last day 3.5 2.42 2,54 1,98 5,44 2,63
Mean last 5 days 3.8 2.20 2,61 1,75 5,66 2,24
Diff (last day minus baseline) -1.9 2.18 -0,87 1,14 -0,12 1,50
Chronic abdominal pain (n=62 including drop-outs)
THC Baseline (including drop-outs) 4.3 1.93 3,28 1,98 4,61 2,39
Placebo Baseline (including drop-outs) 5.2 1.89 3,12 2,52 5,66 2,24
Chronic Pancreatitis (n=23)
THC Baseline 3.4 2.32 1,84 1,41 4,64 2,64
Last day 1.7 2.56 1,26 1,65 4,03 3,22
Mean last 5 days 3.1 2.81 1,46 1,71 4,64 2,64
Diff (last day minus baseline) -1.7 1.61 -0,70 0,77 -0,57 0,94
Placebo Baseline 4.9 1.94 2,80 2,23 5,58 2,23
Last day 3.1 2.23 2,25 1,95 4,98 3,06
Mean last 5 days 3.6 2.09 2,31 1,75 5,58 2,23
Diff (last day minus baseline) -2.1 2.28 -1,01 1,31 -0,40 1,76
Postsurgical pain (n=27)
THC Baseline 4.4 1.48 3,26 1,40 4,59 2,34
Last day 2.8 2.08 2,01 2,14 4,28 2,65
Mean last 5 days 2.8 1.70 2,04 1,82 4,59 2,34
Diff (last day minus baseline) -1.5 1.94 -1,07 2,08 -0,30 0,82
Placebo Baseline 5.6 1.54 3,28 1,37 5,74 2,34
Last day 3.9 2.61 2,82 2,03 5,88 2,18
Mean last 5 days 3.9 2.37 2,89 1,78 5,74 2,34
Diff (last day minus baseline) -1.7 2.16 -0,74 0,99 0,13 1,22 
Figure 2: Mean VAS pain at baseline (day -5 to -1) and during study treatment (day 1 to 49) 
for THC and placebo in patients with chronic abdominal pain (n=50), subdivided in chronic 
pancreatitis (n=23) and postsurgical pain (n=27). VASpain scores are shown until day 49, 
which is the last day of diary for most patients. Grey bars represent baseline period.  
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Secondary efficacy outcomes
No statistically significant differences were observed in pain related questionnaires such 
as the patient global impression of change, pain catastrophizing or pain related anxiety. 
Measures of depression and generalized anxiety, quality of life, treatment satisfaction 
did also not change after THC treatment compared with placebo. For the domain pain of 
the SF-36 a trend was observed in favor of THC (F(1, 47) =4.023; p =.051). Additionally, no 
differences were observed in subjective feelings corresponding to alertness, mood and 
calmness nor for psychedelic effects including difficulties in controlling thoughts, feeling 
high and feeling drowsy for THC compared with placebo.
No statistically significant differences between THC and placebo were observed for 
appetite level. Subjects in the THC group gained on average 0.8 kg in weight and 
patients in the placebo group lost on average 0.4 kg during study treatment (NS (F(1, 47) 
=1.711; p =.197)). Balance disturbances were shown in several individuals, but did not 
statistically increase during THC treatment compared with placebo.
Table 3: Pharmacokinetic parameters of THC and 11-OH-THC after 50-52 days oral dosing of 8 mg or 5 mg TID 
THC in patients with chronic abdominal pain
THC 8 mg TID THC 5 mg TID 
N Mean SD N Mean SD
THC
Cmax (ng/mL) 14 5,21 2,51 5 4,35 2,65
tmax (h) 14 1,43 1,52 5 1,78 1,72
AUC 0-Last (ng*h/mL) 14 9,89 3,23 5 8,62 2,96
AUC 0-tau (ng*h/mL) 13 11,01 3,42 3 10,56 2,55
t1/2term (h) 13 3,10 1,27 3 3,32 1,89
11-OH-THC
Cmax (ng/mL) 14 6,89 2,97 5 5,50 1,54
tmax (h) 14 1,58 1,31 5 2,22 1,32
AUC 0-Last (ng*h/mL) 14 19,32 8,44 5 19,03 6,25
AUC 0-tau (ng*h/mL) 12 20,15 8,37 3 22,13 8,04
t1/2term (h) 12 2,82 0,75 3 4,52 2,41
AUC 0-inf, AUC 0-tau , t1/2term and λz were calculated only if there were two or more points (excluding Cmax) in the 
elimination phase of the plasma concentration–time curve with r2 > 0.80.
Pharmacokinetics
PK samples on day 50-52 time-locked after medication intake were analysed for 19 (8 CP/ 
11 PSP) subjects resulting in 14 PK profiles of 8 mg and 5 PK profiles of 5mg THC. Mean 
THC plasma concentration curves of THC and 11-OH-THC were plotted (supplementary 
figure 2). Evaluation of the pharmacokinetics at an individual patient level revealed that 
some patients demonstrate a relatively late tmax accompanied with a relatively low Cmax , 
which cannot be observed in the plasma concentration curves. Table 3 summarizes the 
calculated PK parameters of THC and 11-OH-THC. The tmax of THC was 1.4 hours in patients 
on 8mg TID compared with 1.8 hours in patients on 5mg TID Namisol® regimen, and the 
t1/2term was 3.1 hour and 3.3 hour respectively. Mean (± SD) trough levels for THC were 0.70 
(± .59) ng/mL on day 15 and 0.57 (± .32) ng/mL on day 50-52. One patient demonstrated 
predose concentration levels below the lower limit of quantification on day 15.
Safety
Seven patients administering THC discontinued study treatment due to AEs compared 
with 2 patients in the placebo group. These patients did not tolerate a dosage of 5 mg 
TID THC and withdrew due to mild to moderate AEs. Another 5 patients in the THC arm, 
compared with 2 patients in the placebo arm, tapered their dosage to 5 mg TID.
A summary of (possibly) related AEs are presented in table 4. Five patients experienced 
serious AEs during the study treatment that were all considered not to be related to 
the study drug. Further AEs were mild or moderate. All subjects fully recovered from 
AEs. There were no clinically relevant changes in vital signs, ECG parameters, or safety 
laboratory parameters (hematology, biochemistry, and urinalysis).
Treatment compliance
A mean (± SD) of 97% (± 4%) of all placebo study medication was taken correctly 
compared with 98% (± 2%) in the THC treatment arm. There were no patients with a poor 
compliance (<75%), as measured by the amount of medication returned to the hospital 
after the treatment period. One subject appeared to be not compliant according PK 
predose levels on day 15, but demonstrated regular trough levels on day 50.
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Table 4: Summary of (possibly) related adverse events occurring in ≥10% patients treated with THC or placebo 
included in the safety analyses (n=62). All (possibly) related adverse events were mild to moderate.
THC (n=30) Placebo (n=32)
 Averse events (PT term MedDRA) N % N %
General  
Decreased appetite 6 20% 1 3%
Increased appetite 7 23% 6 19%
 
Nervous system disorders  
Amnesia 4 13% 1 3%
Balance disorder 3 10% 4 13%
Disturbance in attention 4 13%  
Dizziness 24 80% 11 34%
Dysgeusia 3 10% 1 3%
Headache 14 47% 18 56%
Somnolence 15 50% 11 34%
 
Psychiatric disorders  
Confusional state 3 10% 3 9%
Depressed mood 3 10% 2 6%
Euphoric mood 4 13% 2 6%
Irritability 2 7% 2 6%
Sluggishness 3 10%  
 
Gastro-intestinal system disorders  
Abdominal pain 3 10%  
Constipation 4 13% 5 16%
Diarrhoea 3 10% 2 6%
Dry Mouth 9 30% 2 6%
Nausea 13 43% 5 16%
 
Skin and subcutaneous tissue disorders  
Hyperhidrosis 8 27% 5 16%
Rash 5 16%
 
Musculoskeletal and connective tissue disorders  
Tremor 1 3% 4 13%
 
Vision disorders  
Visual impairment 4 13% 1 3%
DISCUSSION
This is the first exploratory study to evaluate the analgesic efficacy, pharmacokinetics 
and tolerability of THC, 1) using an oral tablet with improved bioavailability and optimal 
blinding potential, 2) in patients with chronic abdominal pain, 3) during a relatively long-
lasting treatment period of 50 days.
Contrary to our hypothesis, THC did not show a beneficial effect on chronic abdominal 
pain compared with placebo. Similar results were observed for minimal and maximal 
reported VAS pain, indicating that THC does not affect background pain or pain peaks. 
It should be mentioned that, despite the randomization procedure, patients in the 
THC group demonstrated pain of 1.2 points lower intensity at baseline than patients 
in the placebo group. In addition to the primary outcome, several questionnaires were 
used to evaluate a wide range of secondary efficacy outcomes during and after the 
THC treatment period. No differences were observed in pain related questionnaires or 
measures of depression and anxiety, quality of life and treatment satisfaction.
There are many reasons why clinical trials may fail to demonstrate analgesic efficacy on the 
primary endpoint. In first instance this could be related to insufficient analgesic potency 
of the investigational drug, but it may also be related to 1) an impaired bioavailability, 2) 
a large placebo response, 3) indirect analgesic effects, or 4) an inadequate study design.
The absorption of orally administrated drugs might be affected particularly in patients 
with gastrointestinal deficits.20 In the present study, mean plasma concentration curves 
of patients on both 5 mg as well as 8 mg TID treatment regimen demonstrate that THC 
was generally well absorbed and further metabolized into 11-OH-THC. The tmax of THC 
was 1.4 hour in patients on 8mg TID compared with 1.8 hour in patients on 5mg TID 
THC regimen. This delay in absorption in patients on 5mg TID THC was accompanied 
with an enhanced t1/2term duration, which overall resulted in comparable AUC0-tau between 
the two treatment regimens. It should be mentioned that the PK sampling until 6 hours 
postdose was too short for two patients on 5mg TID THC in order to obtain all elimination 
parameters. So these parameters are probably an underestimation. However, the reliable 
pharmacokinetic profiles observed in our study population do not explain the lack of 
observed efficacy.
A large placebo response of 37% pain reduction was observed in current study, which is 
common in chronic visceral pain studies. A meta-analysis including 8.364 patients with 
irritable bowel syndrome allocated to placebo observed a pooled placebo response of 
37.5%.21 However, a previous RCT of our study group also observed a high reduction 
of average pain score by 24% in the placebo arm, but this did not prevent proof of 
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superiority of pregabalin over placebo using a very similar study design in patients with 
CP.22 Underlying mechanisms of the placebo effect can be derived from psychological 
and neurobiological viewpoints. Two well supported mechanisms from a psychological 
point of view are expectancy and conditioning.23 Factors that influence the magnitude 
of the placebo response in RCTs include type of active medication, randomization ratio, 
and the number of planned face-to-face visits, thereby supporting the expectancy 
hypothesis.24 High expectations toward treatment efficacy of THC might have contributed 
to the substantial placebo response as observed in the present study.
The lack of observed analgesic efficacy can also be considered from a mechanistic 
point of view. Two major mechanisms are currently proposed to underlie chronic pain 
and its development: 1) sensitization of nociceptive processing (central sensitization/ 
hyperalgesia), and 2) alterations in central cognitive and autonomic processing.8,13 
Consequently, the focus of treatment options for chronic pain has been shifting away 
from targeting the anatomical site to targeting changes in the peripheral and central 
nervous system. The anti-hyperalgesic potential of THC is not clearly demonstrated 
in human and should be further evaluated using measurements such as quantitative 
sensory testing or EEG.
Patients with persistent pain demonstrated increased brain activity in areas considered 
to mediate emotion including the perigenual anterior cingulate cortex, the medial 
prefrontal cortex, and parts of the amygdala.13 Thus, the representation of pain in the 
brain shifts over time to areas implicated in cognitive function, particularly emotion.25 
The frontal-limbic distribution of cannabinoid receptors in the brain suggests that 
cannabis may preferentially target the affective qualities of pain. A study conducted by 
Lee et al. demonstrated that dronabinol reduced the reported unpleasantness, but not 
the intensity of ongoing pain and hyperalgesia.14 This suggests a shift in central nervous 
system function from nociceptive to cognitive, affective and autonomic sensitization 
in patients moving from acute to chronic pain. Therefore, an agent targeting particular 
brain areas related to the cognitive emotional feature of chronic pain, such as THC, 
might be efficacious in our chronic pain population, but might be better measured using 
affective outcomes of pain.
In general, THC was well tolerated resulting in only mild to moderate (possibly) related 
adverse events, which were similar to previous studies in CP patients and healthy 
volunteers42.26,27 The considerable number of AEs reported in the placebo group as 
well as the withdrawal of patients because of AEs, despite being in the placebo arm, 
indicate that AEs were partly determined by nonpharmacological effects.28,29 This so 
called nocebo effect induces negative effects due to negative expectations. Cannabis 
is a generally well known product, particularly as recreational drug to induce desired 
psychotropic effects such as euphoria, relaxation, and perceptual alterations. Therefore, 
it is plausible that patients in this study were influenced by expectations, which may 
have influenced the occurrence of AEs.
A major limitation of the present study is the small sample size, which is insufficiently 
large to allow subgroup analyses. However, considering the confidence intervals of the 
effect, it is doubtful that an increased sample size would have been resulted in significant 
differences.
Furthermore, the present study comprises a heterogeneous patient population 
regarding etiology and anatomical site of the pain. However, all patients suffered from 
chronic abdominal pain, which is associated with central sensitization and alterations in 
central cognitive and autonomic processing.8,13 The presence of central sensitization in 
chronic pain patients supports the choice of treatments that reduce pain by normalizing 
hyperexcitable central neural activity, which makes the initial pain etiology or peripheral 
stimulus and past or currently received pain treatments less important. These variables 
and other patient characteristics might have contributed to inter-individual differences 
in treatment effects – while on the other hand enhancing the generalizability of the 
study.
Additionally, it should be mentioned that most patients already had received different 
pain treatments including analgesics, which failed to provide a satisfactory level of pain 
relief. Thus, this study included a selection of patients who did not respond to registered 
analgesics with a proven efficacy.
In summary, we conclude that THC treatment showed acceptable safety and tolerability 
profiles during a 50-52 day add-on treatment period, but did not significantly reduce 
pain scores or secondary efficacy outcomes in patients with chronic abdominal pain 
compared to placebo. Further research should evaluate the the effects of THC on 
secondary and tertiary central pain processing.
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Supplementary material: Methods
Study procedures
Potential participating patients were screened for eligibility within 7-35 days prior 
to start of study treatment (visit 1). Screening included demographics, medical 
history, concomitant medication, smoking habits, physical examination, 12-lead 
electrocardiogram (ECG), standard laboratory blood tests (hematology, biochemistry, 
virology) and urine screening tests (urinalysis, drug screening and pregnancy test). 
Furthermore, all patients received a diary to report pain scores, add-on analgesics and 
adverse events.
Study days were carried out at the clinical research center of the Radboudumc, where 
each patient stayed in a separate quiet room.
Secondary efficacy outcomes
Pain related questionnaires included the patient global impression of change (PGIC)1 
evaluated on day 15 and 50-52, pain catastrophizing scale (PCS)2, 3 evaluated on day 1, 
15 and 50-52, and pain anxiety symptom scale (PASS)4 evaluated on day 1 and 50-52. 
The hospital anxiety and depression scale (HADS)5, and quality of life questionnaire 
(RAND SF-36)6 were filled out at day 1 and 50-52. Treatment satisfaction (TSQM v. II)7 
and the patient appetite level (AppLe) were evaluated at the last study visit. The AppLe 
was a modification of the PGIC to evaluate any change in appetite in the last week and 
compared to before the study period.
Drug effects on alertness, mood, and calmness were explored using the Bond & Lader 
questionnaire, and potential subjective psychotomimetic (psychedelic) effects were 
evaluated using the Bowdle questionnaire.8, 9 Both questionnaires were filled out on day 
1, 4-5, 9-10, 15, and 50-52.
Left-right (roll) and anterior-posterior (pitch) postural movements were measured using 
a gyroscope-based measurement system (SwayStar™, Balance International Innovations 
GmbH, Switzerland), which was attached to the waist of the patient. Patients stood, 
without shoes, as still as possible in a standardized base of support with their arms 
hanging at both sides of their body. Body sway was measured for one minute with eyes 
open, one minute with eyes closed and for 30 seconds with eyes open standing on one 
leg of preference. Patients were asked to fixate at one point during the tasks with eyes 
open. The computerized measures used for analysis reflect the total angular area and 
90% range roll and pitch excursion in degrees from the centre of gravity.
Safety and Tolerability
Safety and tolerability were evaluated using spontaneously reported adverse events (AEs) 
and measurements of vital functions, ECG and laboratory tests. AEs were recorded in a 
daily diary, at study visits and phone calls up to 2 weeks after study drug discontinuation. 
Blood pressure and heart rate were measured at screening and on both study days. ECG, 
hematology, blood chemistry, and urinalysis were performed at screening and at the 
end of the study.
Pharmacokinetics
Plasma concentrations of THC and its active metabolite 11-OH-THC were determined 
predose on day 1, 15 and 50-52 to confirm a baseline state, determine trough levels 
and test the compliance. The PK sampling on day 50-52 was extended with 7 additional 
samples time-locked after medication intake at 0:30, 1:00, 2:00, 3:00, 4:00, 5:00, and 5:55 
hours postdose. Blood samples were collected in 4ml EDTA tubes and immediately after 
collection wrapped in aluminum foil and kept on ice. Samples were centrifuged within 30 
minutes at 2000 g for 10 minutes at 4°C. The handling of THC samples was done avoiding 
direct light. The separated plasma was divided into primary and backup samples, and 
stored at –80°C until bioanalysis. Bioanalysis (Analytisch Biochemisch Laboratorium 
b.v., Assen, the Netherlands) was performed using a validated liquid chromatography/
mass spectrometry/mass spectrometry (LC/MS/MS) assay method according to good 
laboratory practice procedures. The lower limit of quantification for THC and 11-OH-THC 
was 0.100 ng ml−1.
Statistical analysis
The primary outcome of this study was change in pain intensity, measured by the VASmean 
in a daily diary, between THC and placebo treatment. VASmean pain was analyzed by an 
Analysis of Covariance (ANCOVA) of the VASmean at day 50-52 (last day of diary) between 
placebo and THC that incorporates VASmean at baseline (mean day -5 to -1 pre-treatment) 
as covariate in the analyses. Possible moderating variables such as subpopulation 
(pancreatitis/postsurgical) and opiate user (y/n) were evaluated by observing potential 
interactions and post hoc subgroup analyses. Secondary efficacy outcomes were 
analyzed in a similar manner. All participants who received the study medication for at 
least 36 days were included in the efficacy analyses according to the intention to treat 
principle. Dropouts before day 36 were replaced and data of dropouts were excluded 
from further analyses for efficacy. Safety analyses was performed on all randomized 
subjects who received at least one dose of THC or placebo.
For statistical analysis SPSS software for Windows v.20 was used. All statistical tests were 
performed two-tailed, and the limit for statistical significance was set at P<0.05. The initial 
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study in CP patients was powered (α = 0.05, power = 0.80) to detect a decrease of at least 
1.0 VASmean pain in the THC group compared with placebo, resulting in 34 patients per 
group. Variances in pain scores were extrapolated from a similar study with pregabalin.10 
No information was available to estimate the SD in the initial PSP study, therefore, same 
numbers were adopted for this study. Input variances for the integrated study were 
considered to be too unreliable to conduct a sample size calculation. Therefore, no 
sample size calculation was performed for this early phase 2 clinical trial.
Non-compartmental analysis to determine plasma PK parameters of the active 
compounds, THC and 11-OH-THC, was performed using the WinNonlin modeling 
and analysis software (version 2.1 a; Pharsight Inc., Apex, NC). The maximum plasma 
concentration (Cmax), the time to reach Cmax (Tmax), and the AUC from 0 up to the last 
measurement (AUC0–last, using the linear log trapezoidal rule) were calculated from the 
individual plasma concentration-versus-time profiles. The terminal half-life (t1/2 term) was 
calculated only if there were two or more points (excluding Cmax) in the elimination 
phase of the plasma concentration–time curve with r2 > 0.80. For that reason, one patient 
was excluded from this part of the analysis for THC and two patients for 11-OH-THC. 
Subsequently, the areas under the plasma concentration curves extrapolated to the end 
of the dosing period (AUCtau) were calculated using the linear log trapezoidal rule and 
extrapolation to 8 hours.
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Supplementary material: figure 1. After baseline measurements, patients administrated 
3 mg TID THC or placebo from day 1 to 5. On day 5, tolerability was evaluated. The 
dosage of day 6 to 10 was increased to 5 mg TID or, when not tolerated, the patient 
was withdrawn. On day 10, the tolerability was evaluated again. From day 11 to 15, the 
dosage was further increased to 8 mg TID. This dosage could be tapered to 5 mg TID, 
when 8 mg appeared to induce unacceptable adverse events (dotted arrows). At day 15 
the tolerability was evaluated again. If tolerable, patients proceeded with 8 mg TID, but 
if not, the dosage was reduced to 5 mg TID.
Grey filled arrows represent decision points I en II: increased dosage or withdrawal. 
Black filled arrow represents decision point III: continue 8 mg TID, taper to 5 mg TID, or 
withdrawal. Dotted line represents the permitted dose adjustment of minimal 5 mg TID. 
Supplementary material: figure 2. Mean (unilateral SD error bars) plasma concentration 
curves of THC and 11-OH-THC obtained after 50-52 treatment days in chronic abdominal 
pain subjects taking 5 mg versus 8 mg TID THC.
Chapter 6
Dronabinol and chronic pain:
importance of mechanistic considerations
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ABSTRACT
INTRODUCTION: Although medicinal cannabis has been used for many centuries, 
the therapeutic potential of delta-9-tetrahydrocannabinol (D9-THC; international non-
proprietary name = dronabinol) in current pain management remains unclear. Several 
pharmaceutical products with defined natural or synthesized D9-THC content have been 
developed, resulting in increasing numbers of clinical trials investigating the analgesic 
efficacy of dronabinol in various pain conditions. Different underlying pain mechanisms, 
including sensitization of nociceptive sensory pathways and alterations in cognitive 
and autonomic processing, might explain the varying analgesic effects of dronabinol in 
chronic pain states.
AREAS COVERED: The pharmacokinetics, pharmacodynamics and mechanisms of 
action of products with a defined dronabinol content are summarized. Additionally, 
randomized clinical trials investigating the analgesic efficacy of pharmaceutical cannabis 
based products are reviewed for the treatment of chronic nonmalignant pain.
EXPERT OPINION: We suggest a mechanism-based approach beyond measurement of 
subjective pain relief to evaluate the therapeutic potential of dronabinol in chronic pain 
management. Development of objective mechanistic diagnostic biomarkers reflecting 
altered sensory and cognitive processing in the brain is essential to evaluate dronabinol 
induced analgesia, and to permit identification of responders and/or non-responders to 
dronabinol treatment.
INTRODUCTION
Although medicinal cannabis has been used for thousands of years, the therapeutic 
potential of cannabinoids in current pain management is still unclear. Evidence 
supporting the analgesic efficacy of cannabinoids face several difficulties. First, there is 
limited level one evidence of randomized clinical trials (RCTs), which is generally accepted 
as the most reliable evidence of whether a treatment is effective. Second, chronic pain 
patients are a heterogeneous group comprising many different pain syndromes and 
underlying mechanisms.1 Pain is influenced by several aspects other than nociceptive 
input and altered nociceptive processing, such as cognitive, emotional and social factors, 
all contributing to the entire pain experience. Thus acute pain differs from chronic pain 
and cancer related pain differs from non-malignant pain, which makes a comparison 
between these pain populations complicated. Third, a broad range of cannabis based 
products are used including herbal crude with distinct administration forms and 
undefined absorption as well as pharmaceutical products with a known bioavailability.
The International Association for the Study of Pain (IASP) defines pain as chronic if it 
persists beyond the normal tissue healing time, which is usually three to six months.2 
Chronic pain is associated with an abnormal state of responsiveness or increased gain 
of the nociceptive pathways in the central nervous system, termed central sensitization,3 
as well as with alterations in cognitive functioning. Changes to nociceptive signal 
processing in the central nervous system are typically expressed as hyperalgesia, i.e. 
increased pain in response to noxious stimuli, and allodynia, i.e. pain in response to a 
non-nociceptive stimulus. Because central sensitization alters the properties of neurons 
in the central nervous system, the pain is frequently no longer reliably coupled to the 
presence of particular peripheral stimuli. Cognitive neuroplasticity is manifest as shifts 
in brain activity in patients with chronic pain from sensory representation areas to areas 
related to cognitive function and considered to mediate emotion.4
Opioids are frequently prescribed for chronic pain. However, opioids often do not provide 
effective or satisfactory pain relief in chronic pain conditions. Additionally, adverse 
consequences of prolonged opioid use, including addiction, tolerance and opioid 
induced hyperalgesia, call for alternatives in medical pain treatment. The discovery 
and cloning of the endocannabinoid system in the early 1990s increased scientific 
interest in the therapeutic potential of cannabinoids. New pharmaceutical products 
were developed containing either natural or synthesized delta-9-tetrahydrocannabinol 
(Δ9-THC), which is the principal psychoactive compound of the Cannabis sativa plant. 
Dronabinol is the international non-proprietary name (INN) of Δ9-THC. To date, a wide 
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range of products containing Δ9-THC are described in literature: 1) crude herbal cannabis 
for recreational use containing undefined concentrations of active compounds; 2) 
crude medicinal cannabis containing estimated concentrations of active compounds 
used for medical purposes; 3) synthetic analogues interacting with cannabinoid (CB) 
receptors, and 4) pharmaceutical products with standardized natural or synthetic Δ9-
THC content containing whole cannabis plant extract, a defined combination of Δ9-THC 
and cannabidiol (CBD), or pure Δ9-THC. CBD is another non-psychotropic constituent of 
cannabis, which has very low affinity for cannabinoid CB1 and CB2 receptors.5 It may act 
as a high potency antagonist of cannabinoid receptor agonists and an inverse agonist 
at the CB2 receptor.6
For many patients the only way they can use cannabis as a medicine is to obtain 
material that is of variable quality, composition and purity and is illicit. They commonly 
smoke herbal cannabis, which has some obvious disadvantages. Most important is that 
smoking of herbal cannabis results in high plasma levels after inhalation that cause 
immediate side effects and makes it difficult to administer accurate therapeutic dosages. 
Additionally, the smoke produced contains irritants and carcinogens, and additionally, 
patients do not wish to smoke medicines or do not know how to do so. The development 
of pharmaceutical products for oral or sublingual administration with defined Δ9-THC 
content offers a favorable alternative. Psychological and physiologic effects after intake 
of oral dronabinol preparations were similar compared to whole plant drug cannabis.7,8 
However, the effects of dronabinol in whole plant cannabis may be modulated by other 
cannabinoids, mainly CBD, and other cannabis constituents.9,10 This was demonstrated 
by a study in patients with intractable cancer-related pain where a combination of THC 
and CBD showed a more promising efficacy profile than the THC extract alone.11 Potential 
interactions between phytocannabinoids and cannabis terpenoids are extensively 
reviewed by Russo et al.9,10
Several randomized clinical trials have been conducted to investigate the analgesic 
efficacy of cannabis-based products with standardized Δ9-THC content. The aim 
of this review is to provide an overview of these trials, offer a brief description of the 
endocannabinoid system, and the describe the pharmacokinetics and potential 
side effects of dronabinol in the treatment of chronic non-malignant pain. Common 
limitations in current clinical trials and challenges are discussed in the expert opinion 
section of this review. Furthermore, we propose a mechanism-based approach to 
evaluate the therapeutic potential of Δ9-THC in chronic pain management, not only for 
subjective pain relief but also in reducing pain sensitivity.
OVERVIEW OF DRONABINOL CHEMISTRY
The endocannabinoid system 
The endocannabinoid system consists of two cannabinoid receptors, the CB1 and CB2 
receptors,12,13 and the endogenous ligands for these receptors, such as anandamide 
and 2-arachidonoylglycerol (2-AG).14,15 The distribution of CB receptors and the role of 
endocannabinoid-hydrolyzing enzymes within pain modulatory circuits has recently 
been reviewed.16
THC induces pharmacological effects by binding non-selectively to G protein coupled 
CB receptors. CB1 receptors are expressed most densely on neurons in the brain, spinal 
cord and peripheral nervous system, but are also expressed by some non-neuronal cells 
in many peripheral organs and tissues.17,18 In the central nervous system, CB1 receptors 
are most expressed in the cerebral cortex, basal ganglia, cerebellum, hippocampus, 
periaqueductal grey (PAG), rostral ventromedial medulla, certain nuclei of the thalamus, 
amygdala, and dorsal primary afferent spinal cord region.19-21 CB1 receptor expression 
appears to be sparse or absent in the vital centers of the brainstem. In contrast, CB2 
receptors are most densely expressed in the peripheral nervous system and in human 
immune cells, e.g. resident in the spleen, tonsils and leucocytes.22,23 Previous studies 
suggested that CB2 receptors are also expressed in the central nervous system,24-26 but 
many investigators were not able to detect neuronal CB2 receptors in healthy brains.27-29 
Although the expression of CB2 receptors in neurons has remained controversial, 
it is now well accepted that CB2 receptors are expressed in brain microglia during 
neuroinflammation.30
Thus cannabinoid receptors occur in high density in many areas related to pain. They 
densely populate the PAG and the rostral ventrolateral medulla, which are important 
brain areas involved in descending pain modulation. They are also concentrated in 
the superficial layers of the spinal dorsal horn, and they are found in the dorsal root 
ganglion, and peripheral terminals of primary afferent neurons.20,31 Putative analgesic 
effects of cannabinoids may therefore be produced by both central mechanisms, e.g. via 
activation of descending modulatory pathways,32 and peripheral mechanisms, e.g. by 
inhibiting release of neurotransmitters from nociceptive primary afferents.33 In addition, 
a recent study investigated the effect of oral THC on the affective qualities of pain. They 
concluded that amygdala activity contributed to the dissociative effect of dronabinol on 
pain perception.34
Pharmacokinetics 
The pharmacokinetic profile of Δ9-THC varies with route of administration and 
formulation.35,36 After inhalation of the smoke of a cannabis cigarette, Δ9-THC reaches a 
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maximum plasma concentration within minutes. Psychotropic effects commence within 
seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 
hours.35 Bioavailability after oral ingestion of cannabinoids is low compared to inhalation 
and variable among different formulations. Maximal plasma concentrations after oral 
administration are usually reached after 60-120 min,37,38 and in some subjects after up 
to 6 hours.37 Therefore, the onset of pharmacodynamic effects is delayed compared to 
inhalation, but the duration is prolonged because of continued slow absorption from 
the gut.39 Once absorbed, dronabinol and metabolites are rapidly distributed to all 
other tissues at rates dependent on the blood flow. Because they are extremely lipid 
soluble, cannabinoids accumulate in fatty tissues.40 The pharmacokinetics following 
sublingual administration is similar to that after oral administration. In addition, kinetics 
of cannabinoids are much the same for females and males,39 as well as for frequent and 
infrequent users.41
Metabolism
Cannabinoids are metabolized in the liver by microsomal hydroxylation and oxidation 
catalysed by enzymes of the cytochrome P-450 complex.42,43 Hydroxylation results in 
11-hydroxy-THC (11-OH-THC), which is possibly more potent than THC itself and may 
be responsible for some of the effects of cannabis. Further oxidation takes place to 
produce 11-nor-9-carboxy-THC (THC-COOH), which is an inactive metabolite. First-pass 
metabolism in the liver further reduces the oral bioavailability of dronabinol, i.e. much of 
the dronabinol is initially metabolized in the liver before it reaches the sites of action.35 
The excretion of THC and metabolites is slow due to rediffusion of THC from body fat 
and other tissues into the blood.44 Most of the absorbed THC is excreted as metabolites 
in faeces (more than 55%) and in urine (approximately 20%).
Pharmacokinetic interactions may occur due to metabolic interference with the 
cytochrome P450 subsystem in the liver. CYP450 inhibition by THC may lead to delayed 
elimination of other medications metabolized by the same pathway, which can lead to 
raised plasma levels of the medications in question. However, studies of THC inhibition 
and induction of major human CYP-450 isoforms generally reflect a low risk of clinically 
significant drug interactions with most use, but specific human data are lacking.45,46 
Potential side effects
Cannabis and individual cannabinoid receptor agonists such as Δ9-THC have very 
similar, although not identical, side effects.47 These side effects depend on the dose 
and route of administration, composition of the product and treatment indication. A 
systematic review studying the safety of medical cannabinoids found an increased risk 
of nonserious adverse events compared to placebo, but no difference in serious adverse 
events. Additionally, the risk associated with long-term use of cannabinoids is poorly 
qualified in current clinical and observational studies.48 Common side effects for THC 
products in general include dizziness, somnolence, lethargy, abnormal feeling, dry 
mouth, nausea and increased appetite.49,50 
However, most adverse effects appear to be dose-related, and can be avoided by 
adequate dose titrating. Moreover, some side effects could be classified as potentially 
beneficial (e.g. euphoric mood, somnolence, increased appetite), and are not necessarily 
harmful. Sleep parameters were in fact significantly improved in several RCTs performed 
with a THC/CBD combination spray in chronic pain.51
Pharmaceutical formulations
To date, four pharmaceutical preparations with defined dronabinol content have been 
developed and/or are available for selected indications in certain countries.
• Cannador (IKF-Berlin, Germany) is an oral capsule, containing whole cannabis 
plant extract with standardized Δ9-THC and CBD content in approximately a 2:1 
ratio. This product is no longer under investigation in clinical studies and the 
project to bring it on the market has been stopped.
• Marinol (Solvay Pharmaceuticals, Belgium) is an oral capsule containing synthetic 
Δ9-THC. 
• Namisol (Echo Pharmaceuticals, The Netherlands) is an oral tablet containing 
pure, natural Δ9-THC isolated from the Cannabis sativa plant. To date, only phase 
I results are published.
• Sativex (GW Pharmaceuticals, UK) is a whole cannabis based oromucosal spray, 
containing primarily natural THC and CBD in a standardized 1:1 ratio, and minor 
cannabinoids and terpenoids.
Parallel to the development of pharmaceutical cannabis based medicines, governments 
of several countries set up programs to supply quality-controlled herbal cannabis 
(Bedrocan, The Netherlands). Furthermore, Nabilone (Valeant Pharmaceuticals 
International, USA), which is a synthetic analogue of Δ9-THC for oral administration, 
was not included in this review because this agent has different pharmacokinetic and 
pharmacodynamic properties.
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THERAPEUTIC POTENTIAL OF DRONABINOL IN CHRONIC PAIN 
MANAGEMENT
Animal studies using either acute or chronic pain models have demonstrated significant 
analgesic and antihyperalgesic effects of cannabinoids. However, the role of cannabinoids 
in human analgesia or antihyperalgesia is less well documented.52 An increasing number 
of randomized controlled trials have investigated the analgesic efficacy of different 
products containing dronabinol in various pain states. These trials have been evaluated 
in a few good quality reviews.1,50,53-58 In summary, products containing dronabinol 
demonstrated analgesic efficacy in a majority of studies in chronic pain, whereas the data 
in acute pain were less conclusive. No significant difference was found in the summed 
pain intensity difference over 6 hours, nor in the time to rescue analgesia, between Δ9-
THC and placebo in patients undergoing elective abdominal hysterectomy.59 A more 
promising effect in acute pain was found by Holdcroft et al., who demonstrated a 
dose-response effect for decreasing pain intensity at rest in acute postoperative pain.60 
However, (weak) analgesic effects of cannabinoids in acute human experimental pain 
and acute postoperative pain models were also accompanied by hyperalgesic effects, 
suggesting cannabinoid-induced sensitization,61 particular at higher doses.62 The 
analgesic effects of cannabinoids in chronic pain states appear more promising, with 
significant pain reduction being documented in the majority of clinical studies.63-75
Randomized controlled trials in chronic non-malignant pain
An overview of randomized controlled trials with standardized dronabinol products 
in human chronic non-malignant pain treatment is provided in table 1. The majority 
of these studies were conducted in patients suffering from central neuropathic pain in 
multiple sclerosis (MS).
Dronabinol reduced spontaneous pain intensity as measured with a numerical rating 
scale (NRS) over a treatment period of 3 weeks,72 and improved overall pain ratings 
associated with spasm over a treatment period of 15 weeks.75 Additionally, dronabinol 
improved median radiating pain intensity and pressure pain thresholds in MS patients.72 
Five randomized controlled trials (RCTs) compared the analgesic efficacy of the 
oromucosal THC/CBD combination spray with placebo in patients with MS-related pain. 
Rog et al. demonstrated efficacy for up to 4 weeks,70 whereas a 6 week treatment in a 
subsample of MS patients with pain did not show a significant between group effect, but 
only within group effects in both the THC/CBD and placebo group.73 A recent study in 
339 patients with MS-related neuropathic pain failed to show a significant difference in 
the number of responders between THC/CBD spray compared to placebo. The responder 
analysis at week 14 of phase A of this study showed a large proportion of responders to 
THC/CBD treatment, with 50% of patients on THC/CBD spray classed as responders at 
the 30% level, compared to a similarly large number of 45% placebo responders. Phase 
B of this study demonstrated an increased time to treatment failure in the THC/CBD 
spray group compared to placebo.65 Two crossover studies in patients with neuropathic 
symptoms, mainly MS-related, reported significant reductions in VAS pain in favor of 
products containing dronabinol.67,74
In other neuropathic pain conditions, such as peripheral neuropathic pain with allodynia, 
The THC/CBD combination spray produced statistically significant improvements in pain 
levels, dynamic and punctate allodynia.68 A significant pain reduction was also reported 
in patients with central neuropathic pain due to brachial plexus avulsion.63 However, 
a significant pain reduction was observed within the THC/CBD spray group but not 
between the THC/CBD and placebo groups in patients with painful diabetic peripheral 
neuropathy.71 In patients with rheumatoid arthritis, which is an inflammatory rather than 
a neuropathic pain syndrome, morning pain at rest and on movement were improved 
with THC/CBD spray compared to placebo.64
A pilot study that compared the effectiveness of dronabinol with that of an active 
control, diphenhydramine, in patients with pain below the level of spinal cord injury 
found no significant difference in pain intensity ratings.69 The efficacy of dronabinol 
as an adjuvant treatment to opioid therapy for chronic pain patients was assessed by 
Narang et al.66 Patients who received dronabinol experienced decreased pain intensity 
and increased satisfaction compared with placebo. In an extended open-label titrated 
trial of dronabinol as add-on medication to patients on stable doses of opioids, titrated 
dronabinol contributed to significant relief of pain compared with baseline. Thus, the 
use of dronabinol was found to result in additional analgesia among patients taking 
opioids for chronic non-malignant pain.
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EXPERT OPINION
The introduction of cannabinoid medicines offers an interesting alternative approach in 
the area of chronic pain management, particularly for cases in which currently available 
pharmacologic treatments are not sufficient. Scientific literature on clinical research 
regarding medicinal cannabinoids lags far behind the extensive anecdotal experiences 
of both patients and their physicians. The majority of clinical trials in patients with chronic 
non-malignant pain summarized in this review reported improvement in pain scores in 
favor of products containing dronabinol. However, analgesic effects were generally weak 
and placebo effects were considerable in the comparative arm. In addition, the number 
of available studies for any one specific cannabinoid preparation, as well as other study 
factors such as various pain conditions, limited study population size and treatment 
duration, preclude the recommendation of any one specific cannabinoid drug for the 
treatment of any one chronic pain condition. Underlying pain mechanisms, including 
plasticity of nociceptive and cognitive pain processing, may explain the varying analgesic 
effects of dronabinol in particular chronic pain states. To date, regulatory authorities 
still assess the therapeutic potential of new analgesics based primarily on the patient’s 
subjective pain experience. Hence, we suggest a mechanism-based approach beyond 
the measurement of subjective pain relief for future research, to evaluate the therapeutic 
potential of dronabinol in chronic pain management. 
Underlying mechanisms of chronic pain
Two major mechanisms are currently proposed to underlie chronic pain and its 
development: 1) sensitization of nociceptive pathways (central sensitization), and 2) 
alterations in central cognitive and autonomic processing.4,76 
Preclinical and clinical evidence suggests that persistent pain is correlated with 
synaptic plasticity through an increase in excitability and synaptic efficacy of neurons 
in central nociceptive pathways,77 and reduced function in inhibitory pathways resulting 
in a decreased inhibitory efficiency.78 Identification of the presence of such central 
sensitization in chronic pain patients enables a mechanism-based approach to the 
diagnosis and treatment of pain, by choosing treatments that reduce pain experience by 
normalizing hyperexcitable central neural activity,76 or augment descending inhibition.78
A recent prospective study demonstrated a divergence over time in brain signatures 
between subjects with subacute back pain that recovered within a year versus those in 
whom pain persisted.4 All subjects initially exhibited acute pain-specific brain activity, 
including in the insula, anterior cingulate cortex, and thalamus. Patients with persistent 
pain demonstrated increasing brain activity in areas considered to mediate emotion 
including the perigenual anterior cingulate cortex, the medial prefrontal cortex, and 
parts of the amygdale.4 Thus, the representation of pain in the brain shifts over time 
from the classical acute pain matrix to areas implicated in cognitive function, particularly 
emotion.
The frontal-limbic distribution of cannabinoid receptors in the brain suggests that 
cannabis may preferentially target the affective qualities of pain. An earlier mentioned 
study conducted by Lee et al. demonstrated that dronabinol reduced the reported 
unpleasantness, but not the intensity of ongoing pain and hyperalgesia.34 This reduction 
in the unpleasantness of hyperalgesia was positively correlated with right amygdala 
activity. Dronabinol also reduced functional connectivity between the amygdala and 
primary sensorimotor areas during the ongoing pain state. This suggests that dronabinol 
may target preferentially the affective qualities of pain.34 
The shift in central nervous system function from nociceptive to cognitive, affective and 
autonomic sensitization in patients moving from acute to chronic pain is increasingly 
well established. This indicates that the effects of pain on the brain are not uniform but 
differ according to degree of chronicity, and hence explain varying effects of dronabinol 
in different pain conditions and stages. Thus, an agent targeting particular brain areas 
related to the cognitive emotional feature of chronic pain, such as dronabinol, might 
be more efficacious in patients with evidence of this particular form of supraspinal 
neuroplasticity.
Individual treatment tailoring and responder identification
Most analgesics are only effective in a subset of patients and many have adverse 
effects.51 The concept of personalized medicine is based on optimizing medication 
types and dosages for individual patients according to genetic, mechanistic, and other 
patient-related factors.79,80 This mechanism-based approach may help to prevent a long 
undesirable trial and error process of finding an appropriate therapy for the individual 
patient 81. RCTs are the current gold standard for demonstrating analgesic efficacy at the 
group level in patients with a specific diagnosis of chronic pain.80 While the strict sample 
selection criteria, protocol standardization and controlled nature of RCTs are ideal for 
conclusively demonstrating analgesic efficacy and side effects in the average patient, 
they are less ideal at identifying individual patients likely to experience good analgesia 
with low side effects.80 
Several non-invasive techniques, such as quantitative sensory testing (QST), conditioned 
pain modulation (CPM) and encephalography (EEG), have the potential to identify 
patients with a specific pattern of abnormalities in central pain processing, and thus to 
predict treatment outcome of specific analgesic therapy in individual patients suffering 
from a chronic pain disorder.81-83
QST provides information on sensory function at the peripheral and central level of the 
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nervous system by measuring pain thresholds to different external stimuli of controlled 
intensity.84 The effect of pregabalin was associated with pre-treatment sensitivity to 
electric tetanic QST. These results were reported as first evidence that QST predicts the 
analgesic efficacy of pregabalin in patients with painful chronic pancreatitis.81,85 Similar 
findings were reported using EEG measurements, where changes in spectral indices 
caused by slowing of brain oscillations were identified as a biomarker for the central 
analgesic effect of pregabalin.86
Hence, important goals for future research would be to develop objective diagnostic 
tests for efficient screening for defined types of altered pain-related activity in the brain, 
to evaluate dronabinol-induced effects regarding the reversal of such defined brain 
activity abnormalities, and to consequently identify responders and/or non-responders 
to dronabinol treatment.
Interactions between cannabinoids and opioids
Opioids have been and continue to be regularly prescribed in chronic pain treatment, 
but opioid therapy is controversial due to concerns regarding long-term efficacy and 
adverse events including addiction.87 In addition, accumulating evidence suggests 
that in some patients chronic opioid exposure may actually worsen the perception of 
pain. This phenomenon, termed opioid-induced hyperalgesia, is an undesirable effect, 
in that opioid therapy enhances or exacerbates pre-existing pain, while it is originally 
prescribed as an analgesic.88,89
The existence of multiple mechanisms underlying chronic pain, including this opioid-
induced hyperalgesia, may explain a limited analgesic efficacy of pharmacologic agents 
as monotherapy.90 Additionally, dose-related drug side effects, such as somnolence and 
dizziness, may limit the tolerability of higher, more efficacious doses of single analgesic 
drugs. Combining drugs with different pharmacological mechanisms may result in 
greater efficacy by simultaneous and beneficial effects on multiple pain mechanisms.91 
Multimodal analgesic practice is well established in acute pain management and to a 
lesser extent in chronic pain. However, preclinical studies demonstrate that cannabinoids 
act synergistically with opioids.92-101 Administration of low doses of THC in conjunction 
with low doses of opioids seems to be an alternative regimen that reduces the need 
to escalate opioid dose while increasing opioid potency.92 Additionally, Narang et al. 
reported additional analgesia among patients taking opioids for chronic non-cancer 
pain with dronabinol intake.66 
Thus dronabinol may be useful in pain treatment solely, and also in combination with 
opioids if it has synergistic interactions with opioid analgesics and if its use improves the 
efficacy of pain treatment in patients with a tolerance to opioids. Future research should 
study the bidirectional interactions between opioids and cannabinoids and their potent 
effects on pain modulation mechanisms, and investigate the efficacy of novel analgesic 
combination regimens comprising cannabinoids and opioids to treat chronic pain, 
particularly if opioid resistant.
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Article highlights
• Several pharmaceutical products with standardized Δ9-THC content have been 
developed containing whole cannabis plant extract, a defined combination of 
Δ9-THC and cannabidiol, or pure Δ9-THC.
• The therapeutic potential of Δ9-THC to treat chronic non-malignant pain is 
promising.
• Chronic non-malignant pain is associated with an abnormal state of 
responsiveness or increased gain of the nociceptive pathways in the central 
nervous system and with alterations in cognitive functioning.
• Sensitization of nociceptive sensory pathways and alterations in cognitive and 
autonomic processing might explain the varying analgesic effects of Δ9-THC.
• Cannabinoids may preferentially target the affective qualities of pain.
• Δ9-THC may have synergistic interactions with opioid analgesics.
• Several non-invasive techniques, such as quantitative sensory testing, 
conditioned pain modulation and encephalography, have the potential 
to identify patients with a specific pattern of abnormalities in central pain 
processing, and to predict treatment outcome.
PART III
Chapter 7
Single dose tetrahydrocannabinol does not alter pain 
related cortical processing in patients with chronic 
pancreatitis pain
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ABSTRACT
INTRODUCTION: How tetrahydrocannabinol (THC) can exert an effect on chronic 
pain is largely unknown maintaining the debate of therapeutic efficacy. Chronic pain 
is associated with synaptic plasticity through an increased excitability and synaptic 
efficacy of neurons in central nociceptive pathways (i.e. central sensitization). In this 
study, we evaluated the underlying neural mechanisms of THC by investigating pain 
related cortical activity in patients with chronic pancreatic pain.
METHODS: Twenty-four patients with chronic abdominal pain due to chronic pancreatitis 
(CP) participated in this randomized, single-dose, double-blind, placebo-controlled, 
cross-over study. Patients, stratified in opioid and non-opioid users, administered a single 
dose of THC (8 mg) or Diazepam (5mg non-opioid group/ 10mg opioid group) with a 
14-day washout period between study days. Predose until 5h postdose, two types of 
cortical activity were recorded: spontaneous brain activity in a resting state and evoked 
potentials (EPs) to noxious electrical stimuli.
RESULTS: Test-retest reliability of all resting state alpha EEG indices was excellent, and 
evoked EEG parameters showed fair to good agreement. Grand average power spectra of 
the spontaneous EEG did not change over time following THC compared with diazepam. 
EP components demonstrated no significant treatment effects for N1 peak amplitude 
(F(1, 17) =.43; p =.52), N1 latency (F(1, 17) =.10; p =.76), P3 amplitude (F(1, 17) =1.78; p 
=.20) and P3 latency (F(1, 17) =2.79; p =.11). A significant negative correlation (r=-.55; 
p<.05) was observed between changes in VAS pain scores and peak alpha power.
CONCLUSION: A single dose of THC did not affect alpha indices of the resting state EEG 
nor EPs to pain related electrical stimuli in CP patients with chronic abdominal pain. 
Changes in pancreatic pain were negatively correlated with changes in peak alpha 
power, indicating that individual treatment responses were associated with enlarged 
peak power amplitude in the resting state EEG. The test-retest reliability results warrant 
the use of these EEG parameters for further research.
INTRODUCTION
The role of cannabinoids such as Δ9-tetrahydrocannabinol (THC) in chronic pain 
management remains unclear.1 THC is the main psychoactive compound of the Cannabis 
sativa plant. Supposed analgesic effects of THC might be produced by targeting brain 
areas related to central pain processing and pain perception.2,3 However, evidence from 
clinical trials regarding the analgesic efficacy remains equivocal.
Clinical trials generally evaluate the effectiveness of potential analgesics by means of 
subjective measures of pain experience. However, chronic pain is not only an altered 
perceptual state, but is also associated with synaptic plasticity through an increased 
excitability and synaptic efficacy of neurons in central nociceptive pathways (i.e. central 
sensitization).4 Central sensitization is a form of synaptic plasticity, which constitutes 
an abnormal perceptual response to a normal sensory input and results in a spread 
of sensitivity.5 The presence of central sensitization in chronic pain patients asks for 
a treatment that results in pain relief by targeting the hyperexcitable central neural 
activity.6 Electroencephalography (EEG) may be a useful method to detect alterations in 
central pain processing and to study the underlying neural mechanisms of analgesics, 
such as THC, in patients associated with a spread of increased pain sensitivity.7,8
Electrical brain activity recorded in the EEG reflects the summed synaptic potentials of 
many activated neurons located in the cerebral cortex. EEG recordings are commonly 
divided into two types: resting state and evoked EEG. The spontaneous EEG is recorded 
during a state of awake rest and characterized by oscillations in distinct frequency bands, 
such as delta (1-4 Hz), theta (4-7.5 Hz), alpha (7.5-13 Hz), beta (13-32 Hz), and gamma 
(32-80 Hz). The resting state EEG with eyes closed is dominated by oscillations in the 
alpha-band, particularly at the parietal and occipital cortex.9 Several alterations in the 
spontaneous brain activity of chronic pain patients are observed including a shift of peak 
alpha or theta frequency towards lower frequencies and/or a reduction in alpha or theta 
power.10-12 Besides the brains´ resting state, one could also study possible alterations in 
cortical processing by recording evoked potentials (EPs) in the EEG. EPs involve voltage 
polarity changes in the EEG, time-locked to the onset of a stimulus and averaged 
across trials. Early components of EPs depend largely on the physical parameters of the 
stimulus, whereas later components of EPs are related to the manner in which the subject 
evaluates the stimulus.13 Alterations in stimulus processing are associated with chronic 
pain, although these changes in both EP amplitudes and latencies are inconsistent.14,15 
This is likely the consequence of a large variability in stimulation methods, analyzing 
techniques and study populations, making it difficult to draw clear conclusions.
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Current study is part of a larger study investigating the analgesic efficacy, pharmacokinetics 
and safety of a single dose THC in patients with chronic abdominal pain resulting from 
chronic pancreatitis (CP). Patients reported pain relief following both THC and diazepam 
administration, but no significant differences were observed in subjective pain measures 
between both study treatments. THC was generally well absorbed with an average Tmax of 
123 minutes resulting in reliable pharmacokinetic profiles.16 Diazepam was used as active 
placebo to prevent unblinding and to control for indirect pain relief through the sedative 
effects of THC.16 The pathogenesis of pancreatic pain is poorly understood, but neural 
plasticity that results in peripheral and central sensitization seems to play an important 
role in chronic pain due to CP.17 In this study, we evaluated the anti-nociceptive effects 
of THC by investigating underlying pain related cortical activity. We hypothesized that 
clinically effective analgesics can modify or reverse those changes resulting from central 
sensitization. Hence, we investigated whether a single dose of orally administrated THC 
alters 1) the resting state EEG and 2) EPs to pain related electrical stimuli in CP patients 
with chronic abdominal pain. Additionally, individual changes in subjective pain 
scores were correlated with EEG indices to assess whether EEG changes were linked to 
underlying analgesic responses and not caused by confounding factors such as sedation 
and other adverse effects.
METHODS
This was an equally randomized (1:1 ratio), single-dose, double-blind, placebo-
controlled, cross-over study. The primary analysis concerning the analgesic efficacy, 
pharmacokinetics and safety have been reported elsewhere.16 The Medical Ethical 
Committee approved the study (2011/114). The study was conducted according to 
the principles of the Declaration of Helsinki, and the International Conference on 
Harmonization guidelines of Good Clinical Practice. All subjects provided written 
consent. Clinicaltrials.gov identification number NCT01318369.
Subjects
Twenty-four patients with CP participated in the study. All patients had chronic 
abdominal pain, persistent or intermittent on a daily basis during the past 3 months, 
and considered their pain as severe enough for medical treatment (NRS ≥ 3). Patients in 
the opioid subgroup (n=12) took stable doses of prescribed opioids, and patients in the 
non-opioid subgroup (n=12) had not or occasionally taken opioids in the past 2 months. 
Key exclusion criteria were: cannabis use in previous year; history of hypersensitivity 
to THC; BMI <18.0 or >31.2 kg/m2; serious painful conditions other than CP; significant 
medical disorder or concomitant medication that may interfere with the study or may 
pose a risk for the patient; major psychiatric illness in history; epileptic seizure in history; 
diabetic neuropathy; significant exacerbation in illness within two weeks; positive urine 
drug screen or alcohol test at screening or on study days.
Study procedures
Eligible patients were stratified in opioid and non-opioid users and randomly assigned 
into one of two treatment sequences using a computer-generated list of random 
numbers. Patients administrated a single dose Δ9-THC (8 mg) or Diazepam (5mg non-
opioid group/ 10mg opioid group) with a 14-day washout period between both study 
days. With respect to the expected THC-mediated sedative effects of cannabis, Diazepam 
was used as “active placebo” to prevent unblinding of patient and investigator by inducing 
sedative effects. Patients, staff and investigator were all blinded in a double dummy 
design. Oral tablets with standardized Δ9-THC content (Namisol®, Echo Pharmaceuticals, 
Weesp, the Netherlands) have demonstrated reliable bioavailability.16
Patients were not allowed to use illicit drugs, consume alcohol within 24 hours or caffeine 
within 6 hours prior drug administration. Therefore, urine drug screening tests and saliva 
alcohol tests were conducted on both study days. Food intake on the second study day 
was identical with the first study day. Patients used their prescribed medication, including 
analgesics, on both study days. Study days were carried out at the clinical research center 
of the Radboudumc, where each patient stayed in a separate quiet room.
EEG recording
Two types of cortical activity were recorded in the EEG: Spontaneous brain activity 
in a resting state and EPs to noxious electrical stimuli. Both EEG measurements were 
consecutively conducted predose and time-locked at 1:10, 2:10, 3:10, and 5:05 hours 
after administration of study medication. The resting state EEG was recorded for 1 
minute with eyes closed, followed by the ERP stimulation block. EEG was recorded 
using a multi-channel ActiCAP system (BrainVision, Brain Products GmbH, Germany) of 
32 active electrodes. Electrodes were positioned according to the international 10-20 
system. The ground electrode was placed at the forehead and the reference electrode in 
FCz position. Eye movements were detected by horizontal and vertical electrooculogram 
(EOG) recordings. Horizontal EOG was measured at the outer canthus of both eyes and 
vertical EOG above and below the left eye. Electrode impedances were maintained under 
20 kΩ to ensure an optimal signal-to-noise ratio. EEG was recorded with a sampling rate 
of 2000 Hz. During the measurements, patients were sitting in a comfortable chair and 
no further task was given.
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Stimulation protocol
Pain related EPs were extracted from the EEG by averaging repetitive stimulus responses 
within a stimulus block. A concentric surface electrode was attached to the non-
dominant lower arm 10 cm distal from the cubital fossa. This concentric electrode 
delivers electrical stimuli which are limited to the superficial layer of the dermis, and 
therefore activates mainly nociceptive A-delta fibers.18 The stimulus produces a pinprick-
like pain sensation that is typical for A-delta fiber mediated pain, and has been used 
in previous studies.19-21 The individual pain threshold was determined by increasing the 
stimulus amplitude (0,1 mA/sec), starting at zero until the pain threshold was achieved. 
This procedure was repeated for a second time. The stimulus amplitude was adjusted 
to 150% of the mean individual pain threshold. Patients received 20 painful electric 
doubled stimuli (pulse width of 2 ms; fixed inter-stimulus interval of 5 ms) delivered 
with a random inter-pair interval of 7-10 sec. Triggers were communicated to an electric 
constant-current stimulator (Digitimer, model DS7A) using Presentation software 
(version 14.9) and directly positioned into the EEG recording. Experienced stimulus 
intensities were measured using a visual analogue scale (VASstim) from 0 cm (no pain) to 
10cm (unbearable pain). VASstim were obtained at a random moment within a train of five 
doubled pulses, resulting in a total of 4 VAS scores within each stimulation block.
Signal analysis
EEG data were offline processed using Brain Vision Analyzer 2.0 software. The spontaneous 
EEG recordings were down-sampled to 500 Hz, high-pass filtered at 1 Hz, low-pass 
filtered at 80 Hz and a notch filter was applied at 50 Hz. The EEG recordings were then 
segmented into 12 epochs of 5 sec. Ocular correction was performed according to the 
Gratton and Coles algorithm.22 Epochs were inspected for artifacts and semi-automatic 
rejected from further analysis if data exceeded an amplitude of 200 µV or exceeded the 
maximal allowed voltage step of 50 µV. Less than 5% of all epochs were rejected for 
further analysis. The power amplitudes of the EEG frequencies were computed using 
a Fast Fourier Transformation (FFT). To this end, epochs were multiplied by a Hanning 
window, Fourier transformed and spectral distributions were averaged across all epochs 
for each participant and electrode separately. Grand average power spectra were 
computed by averaging all scalp electrodes per treatment for each participant. Alpha 
indices were calculated for each electrode and measurement separately and averaged to 
create four regions of interest (ROI): frontal (Fp1, Fp2, F7, F3, Fz, F4, F8), central (FC5, FC1, 
FC2, FC6, C3, Cz, C4), parietal (CP5, CP1, CP2, CP6, P7, P3, Pz, P4, P8), and occipital (O1, 
Oz, O2). The amplitude of the peak alpha power (PAP) was determined as the maximum 
value between 7.5-13 Hz and the peak alpha frequency (PAF) as the corresponding 
frequency within this alpha band of interest. Additionally, the gravity alpha frequency 
(GAF) was calculated within the 7.5-13 Hz range as more stable alternative compared to 
the peak method. The GAF is the weighted sum of spectral estimates divided by alpha 
power.23
EEG recordings to extract EPs were down-sampled to 500Hz and re-referenced using 
the averaged recordings from all scalp electrodes. EEG data were high-pass filtered at 
1 Hz, low-pass filtered at 80 Hz and a notch filter was applied at 50 Hz. The EEG was 
then segmented into -500 to 1000ms epochs relative to the onset of the stimulus, 
and corrected for ocular artifacts according to the Gratton and Coles algorithm.22 
Subsequently, epochs were inspected for artifacts and rejected from further analysis if 
data exceeded an amplitude of 200 µV or exceeded the maximal allowed voltage step 
of 50 µV. Less than 5% of all segments were removed from each dataset. After baseline 
correction (-100 to 0 ms) all epochs within a stimulus block were averaged for each 
subject individually. The grand average EP for each block and group was calculated.
Based on morphology and latency of the grand average EP, analyzed from the Cz 
electrode, two distinct peaks (N100 and P300) were defined. The N100 was defined as the 
largest negative amplitude value between 80 and 180 ms, and the P300 as the largest 
positive value between 180 and 400 ms. The maximum amplitude and corresponding 
latency of these peaks were calculated for each individual grand average EP.
Statistical analysis
All data were analyzed using SPSS software for Windows, version 22. Initially, data were 
examined descriptively using means, SD, and graphs. Intra-individual stability of EEG 
over recording sessions was evaluated for the alpha indices and EP components using 
the intraclass correlation coefficient (ICC) and 95% confidence interval for the relative 
reliability, and 95% limits of agreement according to Bland-Altman, that contains 
95% of differences between repeated measurements limits, for absolute reliability. 
The ICC parameter ranges from 0 to 1, with values closest to 1 indicating the highest 
reproducibility. An ICC less than 0.4 was considered poor agreement; 0.4 to 0.59, fair 
agreement; 0.6 to 0.75, good agreement; and greater than 0.75, excellent agreement.24
Differences between THC and diazepam within the resting state EEG were statistically 
analyzed using a repeated measures Analysis of Variance (ANOVA) with treatment (2; THC, 
diazepam), ROI (4; frontal, central, parietal, occipital), and the repeated measurements 
(5; predose, 1:10, 2:10, 3:10, and 5:10 hours postdose) as within subject factors, order 
(2) and opioid user (2) as between subject factors, and VASpain at baseline as covariate. 
Repeated measures ANOVA were conducted for statistics of N1 and P3 peak amplitudes 
and latencies with treatment (2; THC, diazepam), and the repeated measurements (5; 
predose, 1:10, 2:10, 3:10, and 5:10 hours postdose) as within subject factors, order (2) and 
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opioid user (2) as between subject factors, and VASpain at baseline as covariate. Degrees 
of freedom were adjusted using Greenhouse-Geisser correction for within-subject 
factors with more than two levels. In order to evaluate the reproducibility of the baseline 
EEG, 95% limits of agreement and Pearson’s correlation coefficients were calculated. 
Correlations were tested using either parametric Pearson or non-parametric Spearman 
test based on data distributions. All statistical tests were performed two-tailed, and the 
limit for statistical significance was set at P<0.05. 
RESULTS
Twenty-five patients were included. One patient dropped-out prior the first study day 
and was replaced. Two patients in the opioid subgroup were lost to cross over after 
the first study day. EEG analysis were performed on 22 fully evaluable patients. Patient 
demographics and baseline characteristics are described in table 1. Baseline VAS pain 
scores measured on both study days (THC vs. diazepam) correlated significantly (r = 0.79, 
p< 0.0001).
Resting state EEG
Overall, reliability of alpha indices obtained from the baseline EEG recordings was 
excellent with ICC=0.95 (95% CI, 0.89-0.98) for PAP, ICC=0.84 (95% CI, 0.65-0.93) for PAF, 
and ICC=0.90 (95% CI, 0.78-0.96) for GAF, corresponding with 95% limits of agreement 
of -1.47 to 2.12 µV/Hz, -0.99 to 1.14 Hz, and -0.21 to 0.22 Hz respectively, reflecting the 
reproducibility of the EEG.
Grand average power spectra of the spontaneous EEG did not change over time after 
THC compared with diazepam administration (figure 1 A-E). Although THC seems to 
produce a small increase in α-activity starting 2:10H hours postdose according the grand 
average power spectra, this could not be demonstrated in alpha power indices. Alpha 
indices calculated per ROI measured at time point 2:10H, which is close to the time to 
reach maximum plasma concentration (Tmax) of THC, are shown in table 2. There were no 
treatment effects for PAP (F(1, 18) =2.92, p =.10), PAF (F(1, 18) =1.90, p =.16), or GAF (F(1, 
18) =.74, p =.40). Additionally, no repeated measurements, opioid or order effects were 
observed, only significant region effects.
Electrical stimulation
Intensities of pain related electrical stimulation ranged from 0.9 to 5.9 mA (mean ± SD: 
2.9 ± 2.0). No treatment effect (NS (F(1, 42) =0.07; p =.7887)) was observed between THC 
and diazepam concerning the VASstim in response to noxious electrical stimuli (figure 2). 
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Figure 2: Average (SD) visual analogue scale (VASstim) scores of pain related electrical stimuli measured predose, 
and postdose at 1:10, 2:10, 3:10, and 5:05 hours after tetrahydrocannabinol (THC) compared with diazepam.
Table 1: patient characteristics
Opioid 
(n=10)
Non-opioid 
(n=12)
Total group
(n=22)
Gender (male/ female), n 7 / 3 7 / 5 14/8
Age (years), mean (sd) 49.4 (5.6) 56.1 (9.5) 53.1 (8.5)
Mean VAS pain diary, mean (sd) 4.4 (1.4) 3.3 (1.6) 3.8 (1.6)
Baseline VAS pain THC, mean (sd) 3.3 (1.7) 2.7 (2.2) 3.0 (1.9)
Baseline VAS pain diazepam, mean (sd) 3.2 (1.5) 2.3 (2.0) 2.7 (1.8)
Pain duration (years), mean (sd) 7.1 (7.0) 8.6 (5.3) 7.9 (6.0)
Concomitant medication, n
None 0 1 1
PCM 5 7 12
NSAID 1 2 3
Weak opioids 1 0 1
Strong opioids 10 0 10
Antiepileptics 4 2 6
Antidepressants 0 0 0
Etiology CP, n
Alcohol 1 2 3
Hereditary 1 1 2
Idiopathic 6 8 14
Neoplasm 1 1 2
Other 1 0 1
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Table 2: Alpha indices of the resting state EEG at time point 2:10H (first time point following Tmax at 122.8 min) 
calculated per region of interest (ROI).
ROI Alpha index THC Diazepam
mean SD mean SD
Frontal PAP (µV/Hz) 3.17 1.85 5.07 2.68
PAF (Hz) 8.45 0.77 8.72 0.90
GAF (Hz) 9.82 0.17 9.91 0.19
Central PAP (µV/Hz) 2.81 1.65 2.87 1.23
PAF (Hz) 8.50 0.71 8.50 0.89
GAF (Hz) 9.86 0.18 9.93 0.24
Parietal PAP (µV/Hz) 8.11 6.39 2.56 1.25
PAF (Hz) 8.86 0.98 8.73 1.00
GAF (Hz) 9.74 0.26 9.77 0.32
Occipital PAP (µV/Hz) 12.41 9.77 7.13 5.11
PAF (Hz) 8.86 1.02 8.79 0.91
GAF (Hz) 9.73 0.31 9.73 0.35
Abbreviations: peak alpha power (PAP), peak alpha frequency (PAF), gravity alpha frequency (GAF), time to 
reach maximum plasma concentration (Tmax), tetrahydrocannabinol (THC)
Evoked Potentials 
Baseline noxious electrical stimulation yielded typical EPs at the central site on the 
scalp (Cz electrode). EPs at Cz and corresponding scalp topographies of the N1 
and P3 components, mapped at their peak latencies, were similar for both predose 
measurements (Figure 3A-E). The reliability was fair for N1 latency (ICC, 0.40; 95% CI, 0.00-
0.70) and good for N1 peak power (ICC, 0.75; 95% CI, 0.48-0.89), P3 latency (ICC, 0.67; 
95% CI, 0.35-0.85), and P3 peak power (ICC, 0.71; 95% CI, 0.41-0.87). Based on these scalp 
topographies demonstrating most prominent activity at the vertex, further EP analyses 
were performed at electrode Cz.
Grand average EPs resulting from noxious electrical stimulation measured pre- and 
postdose after THC or diazepam are shown in figure 4. Statistical analysis of early EP 
components at electrode Cz demonstrated no significant treatment effects for N1 peak 
amplitude (F(1, 17) =.43; p =.52) or N1 latency (F(1, 17) =.10; p =.76), in addition to no 
significant repeated effects for both N1 peak amplitude (F(1, 17) =1.00; p =.35) or N1 
latency (F(1, 17) =.00; p =.98). Furthermore, there were no significant effects of treatment 
observed at electrode Cz for P3 amplitude (F(1, 17) =1.78; p =.20) and P3 latency (F(1, 
17) =2.79; p =.11), nor any repeated effect for P3 amplitude (F(1, 17) =.94; p =.36) and P3 
latency (F(1, 17) =1.38; p =.27). No order, no electrode and no opioid effect was observed 
in the ANOVAs.
Figure 1 A-E: Grand average frequency power distributions averaged over all electrodes measured predose 
(A), and postdose at 1:10 (B), 2:10 (C), 3:10 (D), and 5:05 (E) hours after THC compared with diazepam. The grey 
square represents the area within the α-band.
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Figure 3 A-E: Baseline evoked potentials. (A) Pain related grand average evoked potentials at Cz recorded 
predose in the THC and diazepam condition. (B-E) Corresponding group mean scalp distributions of neural 
activity for the N1 and P3 components (mapped at their peak latencies) recorded baseline in the THC and 
diazepam condition.
Clinical pain and EEG activity
Post hoc analysis of overall alpha indices of EEG in rest did not demonstrate any significant 
correlation with reported pain intensity at baseline (figure 5). Postdose changes close to 
Tmax of THC, demonstrated a significant negative correlation between VAS pain scores 
and PAP, indicating that individual treatment response is associated with enlarged 
peak power amplitude. No statistical correlations were observed between changes in 
reported pain intensity and PAF or GAF.
Figure 4 A-B: Pain related grand average evoked potentials at electrode Cz recorded predose and postdose at 
1:10, 2:10, 3:10, and 5:05 hours after (panel A) tetrahydrocannabinol (THC) and (panel B) diazepam. Lines are 
smoothened for clarity.
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Neither latency nor amplitude of early as well as late EP components measured baseline 
were associated with predose pain. Additionally, no correlation was observed between 
changes in EP components and changes in pain reported intensity.
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Figure 5: Scatter plots of reported pain intensity and alpha indices of EEG in rest. Left panels show baseline 
measurements. Right panels show postdose delta scores at time point 2:10H (EEG) and 2:05H (VAS) after 
tetrahydrocannabinol (THC) minus baseline. Top row: peak alpha power (µV/Hz), middle row: peak alpha 
frequency (Hz) and bottom row: gravity alpha frequency (Hz). Each dot represents a single patient (n=22). The 
line represents the best linear fit to the data from the entire group.
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DISCUSSION
Our primary purpose was to investigate whether THC alters cortical brain activity in 
patients with chronic abdominal pain due to CP. Alpha indices obtained from the 
spontaneous EEG, that have shown to be related to several chronic pain populations 
in previous studies.10,11,25-29 as well as pain related EPs were studied over time following 
THC administration and compared with diazepam. We primarily demonstrated a good 
test-retest reliability of all resting state alpha EEG indices in CP patients. The intra-subject 
variability of evoked EEG parameters showed fair to good agreement, supporting the 
use of these EEG parameters for further research. However, no changes were observed 
in the resting state EEG nor for pain related EPs following THC administration compared 
to diazepam. Behavioral VAS scores of electrical transcutaneous nociceptive stimulation 
maintained stable over time, indicating that acute evoked pain was not affected by 
THC. These results are in line with the subjective experience of pancreatic pain, where 
no analgesic effect of THC could be observed.16 Pancreatic pain was decreased after 
both THC as well as diazepam administration, which was assumed to be a placebo 
response, since no analgesic efficacy is described for diazepam.30 Further analysis of 
subjective measures of individual clinical pain scores in relation to objective measures 
of EEG parameters at baseline did not reveal any correlation. One significant negative 
correlation was found between change in VAS pain scores and change in PAP, which 
may indicate that individual treatment response is associated with enlarged peak power 
amplitude.
Resting state EEG and chronic pain
Chronic pain is related to changes in brain activity reflected in the resting state EEG. 
Pinheiro et al. reported in a systematic review a general trend towards increased alpha 
and theta power among several studies determining EEG patterns in the presence 
of chronic pain.14 Changes in the resting EEG might be explained by the concept of 
thalamocortical dysrhythmia (TCD). TCD is based on reduced excitatory or increased 
inhibitory input of neurons in the thalamus, resulting in the presence of a persistent low-
frequency thalamocortical spiking, causing the increased power at low frequencies.25,31,32 
Affirmatively, Sarnthein et al. observed an enhanced alpha power amplitude and a shift 
towards lower frequencies of the dominant peak in patients with mixed neurogenic 
pain syndromes.25 Two studies in patients with neuropathic pain following spinal cord 
injury demonstrated a shift in peak frequency towards lower frequencies in patients 
with pain compared those without pain, but no differences were observed in power 
amplitudes.26,27 Oppositely, Van den Broeke et al. observed a larger overall alpha 
amplitude in patients with chronic pain after breast cancer treatment, but no slowing.29 
Interestingly, no changes in resting EEG were shown in patients with chronic low back 
pain. It was suggested that only patients with severe pain or neuropathic pain develop 
the typical TCD pattern.33 Previous studies investigating the resting EEG in patients 
with CP reported similar alterations in EEG activity, observed as an increase in power 
amplitude in the theta and alpha frequency band or shift towards lower PAF.10,11,28 
Although not confirmed, it is likely that similar changes in electrical brain activity have 
been developed in our study population. Pharmaco-EEG studies can help us understand 
underlying mechanisms of centrally acting analgesics by studying their cortical effects.
Analgesics and resting state EEG 
A review on analgesia and EEG reported that opioids generally induced slowing of 
the spontaneous EEG, whereas other analgesics such as anticonvulsants produced 
inconsistent results.7 However, most of these pharmaco-EEG studies were performed in 
healthy volunteers and results were not linked to clinical pain outcomes. One study in CP 
patients with pain observed that the analgesic effect of 3 weeks of pregabalin treatment 
was reflected as a slowing of brain oscillations.8 THC has no status as proven analgesic in 
general, and in the current study, THC failed to demonstrate efficacy based on subjective 
outcome measures of pain. Moreover, a large placebo effect was shown, which could 
not be related to alpha indices in the resting state EEG. Graversen et al. did also not 
found a relation between changes in EEG indices and placebo response, suggesting that 
the slowing of EEG in the verum group reflects the underlying analgesic mechanisms of 
pregabalin.8 Considering this may be true, one can propose that the absence of a clinical 
analgesic effect of THC is reflected by the absence of changes in the EEG. Alternatively, 
several studies in healthy subjects have shown that acute administration of THC disrupts 
neural oscillations. For example, Notage et al. demonstrated that delta, theta and high 
alpha amplitudes were all significantly reduced after a single dose of intravenous 
THC,34 and Morrison et al. demonstrated a significant reduction in theta power.35 In this 
light, it should be mentioned that patients in the present study used different types of 
medication, including opioids and other analgesics, with THC as add-on. THC did not 
produce alterations within the alpha spectrum of the resting state EEG in CP patients. 
Although we could not detect differences between subgroups of analgesics, possibly 
due to small subgroups, the variety of analgesics may have affected the EEG and masked 
a potential effect of THC. 
Evoked potentials in chronic pain
Besides spontaneous EEG, chronic pain is associated with significant changes of early and 
late EP components in response to somatosensory and visual pain-related stimulation as 
well as cognitive tasks,36-41 suggesting an abnormal brain functioning linked to cognitive 
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processes such as attention.14 In particular, chronic pain was associated with delayed and 
enhanced stimulus processing of late P3 components using pain related EPs elicited by 
very similar electrical transcutaneous nociceptive stimuli in patients after breast cancer 
treatment and patients with trigeminal neuralgia.20,21 Early components observed in 
the EP after electrical stimulation reflect sensory discriminative processes of stimulus 
perception, whereas these late EP components have been related to cognitive evaluative 
processes, such as attention and distraction and target/non-target responses.42,43
Pharmaco-EEG recorded as EPs, and particularly amplitudes, can be a viable and useful 
tool for analyzing changes in cortical activity following administration of different 
analgesics.44 For example, opioids generally induced a decrease of the late component 
amplitude in EPs evoked by painful stimuli, whereas non-painful somatosensory 
stimuli were unaffected.7 Weak analgesics, such as non-steroidal anti-inflammatory 
drugs, produced a fairly consistent decrease in P3 amplitudes. Most important, these 
changes in EP amplitudes were quite consistent with the clinical effect, i.e. the pain relief 
provided, and a few studies demonstrated dose dependent changes in EP amplitudes.7 
Acute administration of THC has been associated with reduced P3 amplitudes utilizing 
memory and reaction time tasks,45,46 and dose dependently reduced P3 amplitudes using 
an oddball paradigm as neural correlate of cognition.47 In an experimental human pain 
model, THC reduced the reported unpleasantness, but not the intensity of ongoing pain 
and hyperalgesia, that was positively correlated with right amygdala activity.3 THC also 
reduced functional connectivity between amygdala and primary sensorimotor areas 
during the ongoing pain state, indicating that THC may target, although not selectively, 
the affective and more cognitive aspects of pain.1,3
In this context, we hypothesized that THC induces a reduction of P3 amplitude in response 
to painful electrical stimulation, reflecting a cognitive or attention component of pain.48 
However, no changes in amplitudes or latencies of both early and late EP components 
were detected immediately following a single dose of THC. Individual changes in EPs 
could not be associated with individual treatment responses, hampering the prediction 
of treatment outcome in individual chronic pain patients. Hence, the underlying central 
mechanisms and therapeutic potential of THC remain unclear.
Methodological considerations
This study has a number of limitations. First, different types of pain medication may 
have exerted multifarious influences on our results, i.e. other drugs could have affected 
the spontaneous EEG or induced a dampening effect on EPs. The sample size was too 
small to conduct subgroup analysis, and differences might have been missed between 
opioid subgroups due to a type I error. Second, electrical stimulation with the concentric 
electrode recruits predominantly Aδ fibers, but also to some extent Aβ fibers, and thus, 
stimulation was not nociceptive-specific. Mouraux et al. showed that only low intensity 
electrical intra-epidermal stimulation below 2.5 mA are able to evoke Aδ-associated 
evoked brain responses.49 In the present study we used transcutaneous electrical 
stimulation with stimulation intensities ranging from 0.9 to 5.9 mA, which indicates that 
we did not selectively stimulated Aδ fibers in all subjects. On the other hand, even when 
the stimulus is entirely noxious, the EP may not be nociceptive-specific.50 Finally, a wide 
variety of methodologies among pharmaco-EEG studies impede direct comparison 
of results. This diversity involves differences in study procedures, such as electrode 
placement, selection of reference electrode and recording conditions, but involves even 
more a wide range of analysis methods. The analysis techniques used in the present 
study are generally most common, but has disadvantages since only phase-locked 
components of EPs are effectively preserved. Non-phase-locked nociceptive inputs to 
the brain are lost due to the averaging process. Gram et al. proposed a new methodology 
to classify single-sweep EPs recorded in pharmaco-EEG studies, which may provide 
interesting perspectives for future studies, since it reveals additional information to what 
is typically reported.44 
Conclusions and future directions
A single dose of THC did not affect alpha indices of the resting state EEG nor EPs to 
pain related electrical stimuli in CP patients with chronic abdominal pain. Changes in 
subjective experienced pancreatic pain were negatively correlated with changes in 
PAP, indicating that individual treatment response was associated with enlarged peak 
power amplitude in the resting state EEG. Individual treatment responses could not be 
associated with changes in pain related EP components. Further long-term treatment 
studies are required to evaluate the anti-nociceptive effects of THC on pain related 
cortical activity.
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ABSTRACT
The analgesic effectiveness of delta-9-tetrahydrocannabinol (THC), the most abundant 
psychoactive substance in cannabis, is inconclusive. Chronic pain is associated with 
maladaptive changes in neuronal electrical activity. In this study, cortical correlates of 
THC in relation to its analgesic potency are investigated utilizing electroencephalography 
(EEG). EEG recordings of 49 patients with chronic abdominal pain were assessed in a 
randomized, placebo-controlled, double-blind study involving administration of an oral 
tablet containing purified THC or identical matching placebos. THC was administered 
3 times daily during a 50-52 day add-on treatment. Spontaneous EEG at a resting state 
and pain related evoked potentials (EPs) to noxious electrical stimuli were recorded 
prior drug administration on day 1 and last study day. EEG indices were associated 
with subjective measures of pain and analgesia. At day 50–52, THC did not affect the 
resting state EEG nor pain related EPs compared to placebo. A slightly significant delay 
in N1 latency at Cz was observed for THC in a subgroup of patients with postsurgical 
abdominal pain. Cortical correlates of THC could not be associated with its analgesic 
efficacy. However, clinical pain severity was associated with slowing of brain oscillations 
in a resting state, as well as with enhanced N1 and P3 amplitudes elicited by noxious 
electrical stimulation. In conclusion, pain related EEG indices were not affected by THC 
and did not reflect individual treatment responses in patients with chronic abdominal 
pain. More research is necessary to investigate central mechanisms and therapeutic 
potential of THC for individual patients with chronic pain.
INTRODUCTION
Chronic pain of moderate to severe intensity occurs in 19% of the adult Europeans and 30% 
of the US population. One-third of these individuals with chronic pain define their pain 
as severe and 40% reported inadequate management of their pain.1,2 Pharmacological 
drugs are the key components of chronic pain management. However, only a minority of 
patients with chronic pain sufficiently benefits from the currently available treatments. 
This can be to some extent attributed to the variety of pain mechanisms underlying the 
chronic pain condition in each individual patient.
Chronic pain is associated with peripheral reorganization of afferent signalling and 
altered sensitivity for nociceptive afferents. At the level of the spinal cord, central 
sensitization contributes to an abnormal state of responsiveness or increased gain of 
the nociceptive system.3 Furthermore, accumulating evidence shows that chronic pain 
underlies neocortical anatomical reorganization, functional connectivity changes, 
and abnormalities in resting state activity.4 Analgesics targeting the underlying pain 
pathways may affect these abnormalities. Therefore, the relation between clinical drug 
efficacy and alterations in pain pathways should be studied for each drug. Accordingly, 
assessment of abnormalities in pain pathways prior to initiation of pharmacological 
treatment can predict drug effects and help in selecting the appropriate therapeutic 
strategy for individual patients. Thus knowledge of drug effects on neuronal electrical 
activity should be able to help us better understand the pathology underlying chronic 
pain.
So far, the analgesic effectiveness of delta-9-tetrahydrocannabinol (THC), the primary 
psychoactive substance in cannabis, is not evident. Multiple clinical studies have 
demonstrated that THC induces pain relief in patients with chronic pain, but this pain 
reducing effect remained absent in other randomized controlled trials.5 In the current 
study, THC treatment did not reduce chronic abdominal pain compared to placebo 
using subjective outcomes of pain, which has been reported previously.6 Several reasons 
might explain these opposing results, including variability among individual chronic 
pain patients and lack of a mechanism based treatment model. 
THC induces a range of perceptual and cognitive alterations through the activation of 
cannabinoid CB1 and CB2 receptors.7,8 CB1 receptors are predominantly found in the 
central nervous system in areas associated with the activation of an extended pain 
network in the brain,9,10 while CB2 receptors are primarily expressed in immune tissues.11 
It is suggested that pain experience is determined by the integration of neuronal activity 
including but not exclusively involving these pain associated brain areas. In addition, 
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pain is not only associated with a spatially extended network of dynamically recruited brain 
areas, but also with complex temporal patterns of brain activity.12
Electroencephalography (EEG) has been demonstrated to be a useful method to detect 
abnormalities at different levels of the pain pathway in the temporal domain. Changes in EEG 
activity observed in the presence of chronic pain include a general trend towards increased 
alpha and theta power in the spontaneous EEG and low amplitudes of evoked potentials 
(EP) elicited by various stimuli.13 EEG studies have demonstrated that chronic cannabinoid 
use is associated with disrupted oscillations in the theta and gamma band.14 Additionally, 
controlled acute administration of THC resulted in decreased theta power, indicating that 
THC modifies neural brain oscillations.15
In this study, neural correlates of THC in relation to its analgesic potency are elucidated 
utilizing EEG. We investigated the effects of THC on EEG indices during resting state and pain 
related EPs elicited by noxious electrical stimulation in patients with chronic abdominal pain.
METHODS
Study population
Adult patients with chronic abdominal pain arising after a surgical procedure or resulting from 
chronic pancreatitis (CP) were included. Chronic pain was defined as persistent or intermittent 
abdominal pain on a daily basis for at least 3 months and severe enough for medical 
treatment (average numeric rating scale ≥ 3).16 Key exclusion criteria were: daily cannabis 
use in past three years; history of hypersensitivity to THC; serious painful conditions other 
than postsurgical pain (PSP) or CP; significant medical disorder or concomitant medication 
that may interfere with the study or may pose a risk for the patient; major psychiatric illness 
in history; epileptic seizure in history; affected sensory input such as diabetic neuropathy; 
positive urine drug screen or alcohol test at screening or on study days; or participation in 
another investigational drug study within 90 days before study entry. 
Eligible patients were recruited from October 2012 until July 2014, and stopped prematurely 
due to poor recruitment. All patients provided written informed consent. The study was 
performed in accordance with the Declaration of Helsinki, the International Conference on 
Harmonization Guideline on Good Clinical Practice. The study was approved by the medical 
ethical review committee region Arnhem-Nijmegen and the institutional review board. The 
pharmacokinetics, efficacy and safety of THC have been described elsewhere.6 Clinicaltrials.
gov identification numbers NCT01562483 and NCT01551511.
Study design and study treatment
This was an equally randomized (1:1), double-blind, placebo-controlled, parallel study. 
Patients were stratified into opioid and non-opioid users and equally randomized to 
receive THC or placebo treatment. Oral tablets with standardized THC content (Namisol®, 
Echo Pharmaceuticals, Weesp, The Netherlands) or identical matching placebos were 
administrated as add-on treatment. Study treatment lasted for 50-52 days, consisting of a 
step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID) and a stable dose phase (day 11-52: 
8 mg TID). It was permitted to taper the dosage to 5 mg TID, when 8 mg was not tolerated. 
Patients and study personnel were strictly blinded until end of study. Patients were asked to 
continue their regular co-medication, including analgesics, according to prescription. 
Study procedures
Patients were screened for eligibility based on demographics, medical history, concomitant 
medication, smoking habits, physical examination, 12-lead electrocardiogram (ECG), standard 
laboratory blood tests and urine screening tests (drug screening and pregnancy test). 
Several questionnaires were conducted prior study treatment, including Hospital Anxiety 
and Depression Scale (HADS), Pain Anxiety Symptoms Scale (PASS), Pain Catastrophizing 
Scale (PCS). Furthermore, all patients received a diary to daily report pain scores, add-on 
analgesics and adverse events. EEG measurements were conducted predose on day 1 and 
approximately 4 hours after administration of study medication on the last treatment day. 
Study days were carried out at the clinical research center of the Radboudumc. 
EEG recording
Two types of EEG were recorded: spontaneous brain activity in a resting state and pain related 
EPs to noxious electrical stimuli. The resting state EEG was recorded for 1 minute with eyes 
closed. EEG was recorded using a multi-channel ActiCAP system (BrainVision, Brain Products 
GmbH, Germany) of 32 active electrodes according to the international 10-20 system. The 
ground electrode was placed at the forehead and the reference electrode in FCz position. EEG 
was recorded with a sampling rate of 2000 Hz and electrode impedances were maintained 
under 20 kΩ to ensure an optimal signal-to-noise ratio. Horizontal electrooculogram (EOG) 
was measured at the outer canthus of both eyes and vertical EOG above and below the 
left eye for artefact detection. Patients stayed in a separate quiet room sitting upright in a 
comfortable chair.
Stimulation protocol
Pain related EPs were extracted from the EEG by averaging repetitive stimulus responses 
within a stimulus block. A concentric surface electrode was attached to the non-dominant 
lower arm 10 cm distal from the cubital fossa. This concentric electrode activates mainly 
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nociceptive A-delta fibers in the superficial layer of the dermis, producing a pinprick-
like pain sensation that is typical for A-delta fibers.17 The individual pain threshold 
was determined by increasing the stimulus amplitude (0.1 mA/sec), starting at zero, 
until the pain threshold was achieved. This procedure was repeated for a second time. 
The stimulus amplitude was adjusted to 150% of the mean individual pain threshold. 
Patients received 20 painful electric doubled stimuli (pulse width of 2 ms; fixed inter-
stimulus interval of 5 ms) delivered with a random inter-pair interval of 7-10 sec. Triggers 
were applied with an electric constant-current stimulator (Digitimer, model DS7A) using 
Presentation software (version 14.9). Experienced stimulus intensities were measured 
using a visual analogue scale (VASstim) from 0 cm (no pain) to 10cm (unbearable pain). 
VASstim were obtained at a random moment within a train of five doubled pulses, resulting 
in a total of 4 VAS scores within each stimulation block. 
Signal analysis
EEG data were offline processed using Brain Vision Analyzer 2.0 software (band-pass 
filters: 1.0 and 80 Hz; notch filter: 50 Hz; sampling rate: 500 Hz; average reference 
montage; ocular correction18). The spontaneous EEG recordings were segmented into 
12 epochs of 5 sec. Epochs were inspected for artifacts and semi-automatic rejected 
from further analysis if data exceeded an amplitude of 200 µV or exceeded the maximal 
allowed voltage step of 50 µV. Less than 2% of all epochs were rejected for further 
analysis. The power amplitudes of the EEG frequencies were computed using a Fast 
Fourier Transformation (FFT). To this end, epochs were multiplied by a Hanning window, 
Fourier transformed and spectral distributions were averaged across all epochs for each 
participant and electrode separately. Grand average power spectra were computed 
by averaging all scalp electrodes per treatment for each participant. Additionally, four 
regions of interest (ROI) were created by grouping the following electrodes: frontal (Fp1, 
Fp2, F3, Fz, F4), central (C3, Cz, C4), parietal (P3, Pz, P4, P8), and occipital (O1, Oz, O2). 
Both power spectra and peak frequency analyses were performed on the spontaneous 
EEG. Spectral EEG power was calculated for selected frequency bands (theta: 4.0–7.5 Hz; 
alpha: 7.5–13.0 Hz; and beta: 13.0–30 Hz) by extracting the mean activity per ROI and per 
measurement. Peak alpha power (PAP) amplitudes were determined as the maximum 
value between 7.5-13 Hz and the peak alpha frequency (PAF) as the corresponding 
frequency. The gravity alpha frequency (GAF) was calculated by the weighted sum 
of spectral estimates divided by alpha power within the 7.5-13 Hz range.19 The GAF is 
considered as more constant alternative compared to the more fluctuating peak method.
EP recordings were segmented into -100 to 1000ms epochs time locked to stimulus 
onset. Less than 1% of all segments were removed by semi-automatic artifact rejection. 
After baseline correction (-100 to 0 ms) all residual epochs within a stimulus block were 
averaged for each subject individually. Subsequently, the grand average EP for each 
block and group was calculated. Based on morphology and latency of the grand average 
EP, two distinct peaks (N100 and P300) were defined for the midline electrodes Fz, Cz, 
Pz and Oz. The N100 was defined as the largest negative amplitude value between 80 
and 180 ms, and the P300 as the largest positive value between 180 and 400 ms. The 
maximum amplitude and corresponding latency of these peaks were calculated for each 
individual grand average EP.
Statistical analysis
SPSS software for Windows v.20 was used for statistical analysis. Repeated measures 
Analysis of Variance (RM-ANOVA) analysis were performed to test whether there were 
statistically significant differences between THC and placebo (between factor; 2 levels: 
THC and placebo) with respect to period (within factor; 2 levels: baseline and day 50) and 
EEG parameters, such as power spectra density per ROI (within factor; 5 levels: frontal, 
central, parietal, occipital and overall) and frequency band (within factor; 3 levels: theta, 
alpha and beta). VASpain at baseline and subgroups (chronic pancreatitis (CP)/ postsurgical 
pain (PSP)) were incorporated as covariates. Degrees of freedom were adjusted using 
Greenhouse-Geisser correction for within-subject factors with more than two levels. All 
EEG outcomes were analysed in a similar manner. No correction for multiple comparison 
was applied for explorative post hoc testing. Additionally Pearson’s correlations or non-
parametric Spearman tests were used, based on the data distributions, to investigate 
the relation between differential effects on EEG parameters and subjective outcomes of 
pain intensity. All statistical tests were performed two-tailed, and the limit for statistical 
significance was set at P<0.05. 
RESULTS
Demographics and clinical outcomes
Forty-nine patients (22 CP/ 27 PSP) were included in the EEG analysis. Clinical and 
demographic characteristics of these patients are described in Table 1. As reported, no 
differences were observed regarding subjective outcomes of VAS pain between THC 
and placebo treatment 6. Mean VAS pain scores reported on average were 1.6 cm (40%) 
after THC treatment compared to 1.9 cm (37%) after placebo treatment. A significant 
difference in VAS pain scores at baseline was observed between the THC and placebo 
group, corresponding to a mean (SD) of 4.0 (1.9) and 5.2 (1.8) cm respectively.
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Table 1: Demographic and clinical characteristics.
THC (n=21) Placebo (n=28)
Gender (male/female) 9 / 12 15 / 13
Age (years) 53.0 (9.8) 53.2 (9.3)
Etiology of pain (CP/ PSP) 8 / 13 14 / 14
Concomitant medication
None 0 0
PCM 3 11
NSAID 3 2
Weak opioids 3 5
Strong opioids 7 10
Antiepileptics 3 4
VAS pain baseline 4.0 (1.9) 5.3 (1.7)
VAS pain last day 2.4 (2.3) 3.5 (2.4)
VAS pain change -1.6 (1.8) -1.9 (2.2)
HADS anxiety 6.5 (3.6) 6.7 (4.5)
HADS depression 6.5 (4.5) 6.8 (4.0)
HADS total 12.9 (7.0) 13.3 (7.5)
PCS total 20.4 (9.7) 23.0 (12.0)
PASS total 63 (29) 64 (30)
Continuous data are expressed as mean (SD) and categorical data as numbers (n). Weak opioids were defined 
as codeine and tramadol. Strong opioids were defined as opioid-based therapies such as oxycontin, fentanyl 
and morphine. Abbreviations: CP= chronic pancreatitis, PCM=paracetamol, NSAID= non-steroidal anti-
inflammatory drugs, VAS= visual analogue scale, HADS= hospital anxiety and depression scale, PASS= pain 
anxiety symptoms scale, PCS= pain catastrophizing scale.
Figure 1: Mean (SD) absolute power spectra, expressed as mean activity (µV) averaged across all electrodes, 
within the theta (4.0–7.5 Hz), alpha (7.5–13.0 Hz) and beta (13.0–30 Hz) frequency bands at baseline and last 
day of treatment shown for THC (n=21) and placebo (n=28).
Table 2: Mean (SD) alpha indices per ROI measured baseline on study day 1 and at the last day of study 
treatment on day 50 for the THC and placebo group.
Alpha index Day ROI THC (N=21) Placebo (N=28)
mean SD mean SD
PAP (µV/Hz) 1 Frontal .15 .12 .16 .13
1 Central .21 .18 .18 .18
1 Parietal 1.70 1.95 1.37 1.38
1 Occipital 2.47 3.48 2.58 3.05
50 Frontal .17 .14 .17 .14
50 Central .25 .25 .18 .18
50 Parietal 1.77 1.99 1.47 1.64
50 Occipital 4.10 6.24 2.13 2.73
PAF (Hz) 1 Frontal 8.88 1.02 9.16 1.16
1 Central 9.34 1.09 9.07 1.04
1 Parietal 9.59 .81 9.23 1.11
1 Occipital 9.57 1.03 9.27 1.03
50 Frontal 8.96 1.14 8.91 .90
50 Central 10.51 3.62 9.05 1.28
50 Parietal 9.54 .95 9.30 .97
50 Occipital 9.47 .94 9.08 1.05
GAF (Hz) 1 Frontal 9.60 .42 9.55 .43
1 Central 9.72 .46 9.70 .42
1 Parietal 9.66 .51 9.58 .60
1 Occipital 9.64 .50 9.57 .64
50 Frontal 9.62 .50 9.52 .45
50 Central 9.77 .64 9.66 .40
50 Parietal 9.73 .68 9.59 .59
50 Occipital 9.68 .61 9.55 .63
Abbreviations: peak alpha power (PAP), peak alpha frequency (PAF), gravity alpha frequency (GAF), and region 
of interest (ROI)
Table 3: Mean (SD) electrical stimulation parameters for THC and placebo
THC (N=21) Placebo (N=28)
mean SD mean SD
Mean electrical pain threshold (mA) 2.47 1.60 2.72 1.89
Stimulus intensity (mA) 3.70 2.41 4.06 2.86
VAS stimulus baseline (cm) 5.70 1.43 5.65 1.62
VAS stimulus day 50 (cm) 5.16 1.48 5.15 1.91
Pain-related cortical activity during tetrahydrocannabinol treatment in patients with chronic abdominal painChapter 8
177176
8
THC effect on resting state EEG
Grand average spectral density powers obtained from the resting state EEG and calculated 
per frequency band separately are shown in figure 1. No significant differences were 
observed between THC compared to placebo treatment (F(1, 47) =0.752; p =.390) and 
between last day of treatment compared to baseline (F(1, 47) =0.215; p =.645). Significant 
within subject effects were observed for ROI (p<.001) and frequency band (p<.001).
Regarding all alpha indices, no significant between subject effects were observed 
between THC and placebo treatment, and no significant within subject changes were 
observed between last study day and baseline measurements. PAP, PAF and GAF 
outcomes per ROI are presented for THC and placebo treatment in table 2.
Resting state EEG and clinical pain 
No correlations were observed between power spectral densities and VAS pain scores at 
baseline in patients with chronic abdominal pain. However, PAF (r=-.31; p=.03) and GAF 
(r=-.36; p=.01) demonstrated significant negative correlations and PAP (r=.27; p=.06) 
a nearly significant positive correlation with VAS pain as shown in Figure 2, indicating 
that increased pain severity is associated with lower peak frequencies. Furthermore, no 
significant differences at baseline were observed in power spectral densities or alpha 
indices between the THC and placebo group.
Figure 2: Correlations between clinical VAS pain scores and alpha EEG indices at baseline. Alpha indices include 
peak alpha power (PAP) shown in upper left panel, peak alpha frequency (PAF) shown in lower left panel, and 
gravity alpha frequency (GAF) shown in lower right panel.
Pain related electrical stimulation
Electrical pain thresholds were similar between treatment groups, overall resulting in 
mean stimulus intensities of 3.9 mA (range 0.9 – 12.8 mA). Both study groups showed 
a similar non-significant reduction in VASstim (F(1, 46) =0.103; p =.750) at the end of 
study treatment compared to baseline (Table 3). Additionally, no treatment effect (F(1, 
46) =0.009; p =.927) was observed between THC and placebo concerning the VAS in 
response to pain related electrical stimuli.
THC effect on pain related Evoked Potentials
No changes were observed in pain related grand average EPs after 50-52 days of 
treatment compared to baseline (Figure 3 A-D). Corresponding scalp distributions of 
neural activity for N1 and P3 peaks demonstrate the largest activity at the vertex and 
stable topographic maps over time. No significant within subject effects over time were 
observed in peak amplitudes and latencies (F(1, 46) =0.583; p =.449), and no significant 
effect was found between THC and placebo treatment (F(1, 46) =2.518; p =.119) recorded 
over midline electrodes Fz, Cz, Pz and Oz. However, a significant subgroup effect was 
observed between CP and PSP patients (F(1, 46) =5.607; p =.022). Further explorative 
post hoc analysis of subgroups revealed a significant treatment effect (F(1, 25) =6.729; p 
=.016) in PSP patients, but no repeated measurement effect. Apparently, this treatment 
effect derived from N1 latency measured at Cz (F(1, 25) =6.037; p =.021), representing a 
delay in the THC treatment group.
Baseline EPs and clinical pain
Baseline N1 amplitude at Cz were significantly correlated with clinical pain scores (r=-
.34; p=.017), indicating that severe subjective pain is associated with enhanced N1 
amplitudes. Additionally, baseline VAS pain scores demonstrated significant correlations 
with P3 amplitudes measured at Pz (r=.300; p=.037) and Oz (r=.296; p=.039), suggesting 
that clinical pain severity is also associated with enhanced P3 amplitudes.
Treatment response and EEG parameters
Changes in clinical pain scores at the last study day compared to baseline were not 
associated with alterations in EEG band activity nor with alpha EEG indices in both 
treatment groups. Additionally, this subjective measure of treatment response was 
also not correlated with changes in N1 or P3 components of the pain related EP. Hence, 
individual treatment responses, produced by THC and/ or placebo, were not reflected by 
alterations in the resting state EEG nor pain related EPs.
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Figure 3 A-D: Pain related grand average evoked potentials at Cz recorded baseline and at day 50-52 in the 
THC group (panel A) and the placebo group (panel B). Corresponding group mean scalp distributions of neural 
activity for the N1 (panel C) and P3 (panel D) components, mapped at their peak latencies, recorded baseline 
and at day 50-52 in the THC and placebo condition.
DISCUSSION
This is the first study to our knowledge to evaluate the pharmacodynamic effects of a 50 
days THC treatment on pain related EEG indices in patients with chronic abdominal pain. 
We demonstrated that THC did not affect spontaneous brain activity nor evoked pain 
processing compared to placebo after 50 days of treatment. Solely in PSP patients, a delay 
in N1 latency at Cz was observed for THC treatment compared to placebo. Moreover, 
cortical correlates of THC could not be associated with its analgesic efficacy, and thus, did 
not reflect individual treatment responses. However, clinical pain severity was associated 
with slowing of brain oscillations in a resting state, as well as with enhanced N1 and P3 
amplitudes elicited by noxious electrical stimulation.
No therapeutic effects of THC 
In the current study, THC did not show a beneficial effect on clinical pain experience after 
a 50-day treatment period compared with placebo in patients with chronic abdominal 
pain. Remarkably, subjective pain relief of approximately 40% was observed in both 
treatment arms.6 A lack of observed analgesic efficacy on the clinical endpoint could 
be related to insufficient analgesic potency of the investigational drug, but can also be 
considered from a mechanistic point of view.
Chronic pain modulates neuronal activity
Pain results from the integration of nociceptive and contextual information (i.e. 
cognitive, emotional, and motivational) mediated by dynamic processes in the brain.12 
Two mechanisms are proposed to underlie chronic pain and its development: 1) 
increased responsiveness of nociceptive neurons in the central nervous system (central 
sensitization), and 2) alterations in central cognitive and autonomic processing.3,20 
In addition, a close relationship between chronic pain and psychological factors 
indicates that brain function plays a central role in chronic pain. This is supported by 
several neurophysiologic and functional imaging studies demonstrating changes in 
the frequency spectrum of the brain, that are believed to be causally involved in the 
development and maintenance of chronic pain 12. In the current study, PAF and GAF were 
negatively correlated with VAS pain scores at baseline, indicating that increased pain 
severity was associated with slowing of brain oscillations in a default state. Several studies 
have shown this slowing of PAF in chronic pain compared to controls, including patients 
with chronic abdominal pain.21-24 Moreover, multiple studies on EEG power spectra at rest 
reported that chronic pain patients displayed an increase of theta oscillations compared 
to controls.23,25 Although these results are not fully consistent, chronic pain is generally 
associated with alterations in brain oscillations recorded at rest, which are attributed 
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to plasticity of the central nervous system. Similar signs of plasticity were observed in 
the current research population, enabling the study of potential antinociceptive effects 
of THC utilizing maladaptive EEG outcome parameters in this group of chronic pain 
patients.
THC and neuronal oscillations
In this study, we did not observe THC induced changes in resting state brain activity, 
whereas several other EEG studies have demonstrated that chronic cannabinoid use 
is associated with disrupted oscillations in the theta and gamma band.14 Additionally, 
controlled acute administration of THC resulted in decreased theta power in healthy 
subjects,15 demonstrating that THC has the ability to modify neural brain oscillations. We 
hypothesized that THC induces antinociceptive effects by reversing the increased theta 
activity or slowed alpha peak power in patients with maladaptive alterations resulting 
from chronic pain. Various explanations can be considered for the lack of EEG changes 
in our study. First, the analgesic efficacy of THC, evaluated by means of clinical pain 
experience, is still unclear and the optimal therapeutic dosage is not defined. Question 
is if in the absence of clinical efficacy, as also shown in this study, antinociceptive effects 
can be expected? Changes in the EEG could still occur, but these might be independent 
from clinical or antinociceptive drug efficacy. Second, placebo effects on pain perception 
are associated with decreased neural activities in pain modulatory brain regions and 
pain related EPs. A recent study using tonic muscle pain in healthy subjects revealed that 
placebo analgesia induced significant increases in alpha oscillations.26 These changes 
in alpha amplitudes were strongly correlated with the placebo effect on pain reported 
experience. In the current study, a considerable placebo effect on clinical pain perception 
was observed, which may have affected brain oscillation of chronic pain patients in both 
treatment arms.
Pain related EPs 
Chronic pain is frequently associated with changes of early and late EP amplitudes in 
response to somatosensory and visual pain related stimuli.27 Delayed and enhanced P3 
amplitude, using equivalent electrical noxious stimulation, was shown in patients with 
chronic pain after breast cancer treatment.28 In the current study, we observed significant 
correlations between clinical pain experience and enhanced N1 and P3 amplitudes, 
suggesting that clinical pain intensity is associated with an increased responsiveness of 
pain related EPs. Early EP components are generally related to early preconciousness 
processes, reflecting somatosensory afferent input. By contrast, later components of EPs 
may reflect discomfort or emotional-motivational aspects, related to the manner in how 
the subject evaluates the stimulus.29,30 These cognitive functions are also known to be 
affected by cannabinoids. Furthermore, the frontal-limbic distribution of CB1 receptors 
in the brain suggests that cannabis may preferentially target the affective and more 
cognitive qualities of pain. This was supported in an experimental human pain model, 
where THC reduced the reported unpleasantness, but not the intensity of ongoing pain 
and hyperalgesia.31 Contrary to our hypothesis, we could not detect changes in pain 
related EPs elicited by noxious electrical stimulation after THC treatment. A slightly 
significant delay in N1 peak was shown for THC in only a subgroup of PSP patients, though 
no correction for multiple testing was applied. Thus, a potential type I error needs to be 
taken into account. Additionally, other factors such as the observed clinical inefficacy 
on VAS pain, as well as selected study population and stimulation paradigm may have 
complicated this study. Acute administration of THC has been reported to reduce P300 
amplitudes to auditory stimuli in healthy volunteers.32 Therefore, it would be interesting 
to study pain related mechanisms of THC in an experimental human pain model utilizing 
nociceptive specific stimuli in order to increase the internal validity.
Methodological considerations
Several limitations to the current study have to be addressed. The sample size is susceptible 
to both type I and type II statistical errors, which cannot be ruled out completely. Besides, 
the study population was too small to conduct a reliable prediction analyses based on 
responders and non-responders in both treatment groups. Suppose that only a minor 
part of chronic pain patients benefits from THC treatment, then it is important to develop 
a method to predict its effect in an individual. Future studies are necessary in order to 
develop a clinical pharmaco-EEG model, based on underlying maladaptive mechanisms, 
to predict the efficacy of THC in individual chronic pain patients. 
Furthermore, it should be mentioned that most patients continued regular prescribed 
pain medication during study treatment, as decided by the ethical committee. Hence, 
central acting drugs, such as frequently prescribed opioids and anticonvulsants, have 
an effect on the spontaneous as well as evoked EEG.33 Overall, opioids induce increased 
activity in the delta band and a decrease of late component EP amplitudes evoked 
by painful stimuli, while the few studies on anticonvulsants such as pregabalin show 
inconsistent results.33 Additionally, these drugs can induce sedative effects, which also 
influence EEG characteristics. 
Finally, noxious transcutaneous electrical stimulation using the concentric electrode 
is not nociceptive-specific. Only low intensity electrical intra-epidermal stimulation 
below 2.5 mA are able to evoke Aδ-associated evoked brain responses,34 while larger 
stimulation intensities were applied in this study. Therefore, it should be mentioned that 
beside Aδ fibers, also tactile Aβ fibers were stimulated, producing pain related EPs. 
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In conclusion, THC did not affect these alterations in spontaneous brain activity nor 
evoked pain processing. Correlations between clinical pain intensities and objective EEG 
outcomes suggest that chronic abdominal pain alters central pain processing recorded 
by EEG. Moreover, cortical correlates of THC could not be associated with its analgesic 
efficacy, and so, did not reflect individual treatment responses. Future studies are 
necessary to further explore underlying mechanisms and therapeutic potential of THC 
for individual patients with chronic pain.
ACKNOWLEDGMENTS
The authors thank all participating patients. The research project was supported by a grant 
from the European Union, the European Fund for Regional Development (EFRO, ‘Here is 
an investment in your future’) in a consortium with Echo pharmaceuticals conducting 
investigator-initiated phase 2 drug studies with Namisol®. The Investigational Medical 
Product was provided by Echo Pharmaceuticals, Weesp, The Netherlands. The authors 
declare no competing financial interests.
REFERENCES
1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: 
prevalence, impact on daily life, and treatment. European journal of pain. 2006;10(4):287-333.
2. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in 
United States adults: results of an Internet-based survey. The journal of pain : official journal 
of the American Pain Society. 2010;11(11):1230-1239.
3. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 
2011;152(3 Suppl):S2-15.
4. Baliki MN, Apkarian AV. Nociception, Pain, Negative Moods, and Behavior Selection. Neuron. 
2015;87(3):474-491.
5. de Vries M, van Rijckevorsel DC, Wilder-Smith OH, van Goor H. Dronabinol and chronic 
pain: importance of mechanistic considerations. Expert opinion on pharmacotherapy. 
2014;15(11):1525-1534.
6. de Vries M, van Rijckevorsel DC, Vissers KC, et al. Tetrahydrocannabinol Does Not Reduce 
Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. 
Clinical gastroenterology and hepatology : the official clinical practice journal of the American 
Gastroenterological Association. 2016.
7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for 
cannabinoids. Nature. 1993;365(6441):61-65.
8. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid 
receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-564.
9. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain 
perception and regulation in health and disease. European journal of pain. 2005;9(4):463-484.
10. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed 
anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human 
brain. Neuroscience. 1997;77(2):299-318.
11. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. 
International journal of obesity. 2006;30 Suppl 1:S13-18.
12. Ploner M, Sorg C, Gross J. Brain Rhythms of Pain. Trends in cognitive sciences. 2017;21(2):100-
110.
13. Pinheiro ES, de Queiros FC, Montoya P, et al. Electroencephalographic Patterns in Chronic 
Pain: A Systematic Review of the Literature. PloS one. 2016;11(2):e0149085.
14. Skosnik PD, Cortes-Briones JA, Hajos M. It’s All in the Rhythm: The Role of Cannabinoids in 
Neural Oscillations and Psychosis. Biological psychiatry. 2016;79(7):568-577.
15. Morrison PD, Nottage J, Stone JM, et al. Disruption of frontal theta coherence by Delta9-
tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharma-
cology: official publication of the American College of Neuropsychopharmacology. 2011;36(4):827-836.
Pain-related cortical activity during tetrahydrocannabinol treatment in patients with chronic abdominal painChapter 8
185184
8
16. International Association for the Study of Pain (IASP) TWG. Classification of chronic pain. 
Descriptions of chronic pain syndromes and definitions of pain terms. Second Edition (Revised) 
ed. Seattle: IASP press; 1986.
17. Katsarava Z, Ayzenberg I, Sack F, Limmroth V, Diener HC, Kaube H. A novel method of eliciting 
pain-related potentials by transcutaneous electrical stimulation. Headache. 2006;46(10):1511-
1517.
18. Gratton G, Coles MG, Donchin E. A new method for off-line removal of ocular artifact. 
Electroencephalogr Clin Neurophysiol. 1983;55(4):468-484.
19. Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: a 
review and analysis. Brain research. 1999;29(2-3):169-195.
20. Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain: chronification of back pain shifts 
brain representation from nociceptive to emotional circuits. Brain : a journal of neurology. 
2013;136(Pt 9):2751-2768.
21. de Vries M, Wilder-Smith OH, Jongsma ML, et al. Altered resting state EEG in chronic 
pancreatitis patients: toward a marker for chronic pain. Journal of pain research. 2013;6:815-
824.
22. Boord P, Siddall PJ, Tran Y, Herbert D, Middleton J, Craig A. Electroencephalographic slowing 
and reduced reactivity in neuropathic pain following spinal cord injury. Spinal Cord. 
2008;46(2):118-123.
23. Sarnthein J, Stern J, Aufenberg C, Rousson V, Jeanmonod D. Increased EEG power and slowed 
dominant frequency in patients with neurogenic pain. Brain. 2006;129(Pt 1):55-64.
24. Schmidt S, Naranjo JR, Brenneisen C, et al. Pain ratings, psychological functioning and 
quantitative EEG in a controlled study of chronic back pain patients. PloS one. 2012;7(3):e31138.
25. Stern J, Jeanmonod D, Sarnthein J. Persistent EEG overactivation in the cortical pain matrix of 
neurogenic pain patients. NeuroImage. 2006;31(2):721-731.
26. Li L, Wang H, Ke X, et al. Placebo Analgesia Changes Alpha Oscillations Induced by Tonic 
Muscle Pain: EEG Frequency Analysis Including Data during Pain Evaluation. Frontiers in 
computational neuroscience. 2016;10:45.
27. Pinheiro ES, Queiros FC, Montoya P, et al. Electroencephalographic Patterns in Chronic Pain: A 
Systematic Review of the Literature. PloS one. 2016;11(2):e0149085.
28. van den Broeke EN, de Vries M, van Goor H, Vissers KC, van Rijn CM, Wilder-Smith OH. Patients 
with persistent pain after breast cancer surgery show both delayed and enhanced cortical 
stimulus processing. Journal of pain research. 2012;5:139-150.
29. Sur S, Sinha VK. Event-related potential: An overview. Industrial psychiatry journal. 
2009;18(1):70-73.
30. Zaslansky R, Sprecher E, Katz Y, Rozenberg B, Hemli JA, Yarnitsky D. Pain-evoked potentials: 
what do they really measure? Electroencephalography and clinical neurophysiology. 
1996;100(5):384-391.
31. Lee MC, Ploner M, Wiech K, et al. Amygdala activity contributes to the dissociative effect of 
cannabis on pain perception. Pain. 2013;154(1):124-134.
32. D’Souza DC, Fridberg DJ, Skosnik PD, et al. Dose-related modulation of event-related potentials 
to novel and target stimuli by intravenous Delta(9)-THC in humans. Neuropsychopharmacology 
: official publication of the American College of Neuropsychopharmacology. 2012;37(7):1632-
1646.
33. Malver LP, Brokjaer A, Staahl C, Graversen C, Andresen T, Drewes AM. Electroencephalography 
and analgesics. British journal of clinical pharmacology. 2014;77(1):72-95.
34. Mouraux A, Iannetti GD, Plaghki L. Low intensity intra-epidermal electrical stimulation can 
activate Adelta-nociceptors selectively. Pain. 2010;150(1):199-207.
Chapter 9
General discussion
Partly based on: 
Systematic mechanism-orientated approach to 
chronic pancreatitis pain
Bouwense SA, de Vries M, Schreuder LT, Olesen SS, Frøkjær JB, Drewes AM, van Goor H, 
Wilder-Smith OH.
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After tissue healing, pain may persist as chronic pain. Chronic pain has a major impact 
on quality of life.1 Although the majority of publications on chronic pain address the 
treatment of this pain, an adequate approach to the prevention and treatment of chronic 
pain is still lacking. A key insight has been that nervous system processing of pain is not 
hard-wired: sensory processing in the nervous system typically changes as a result of 
noxious sensory inputs.2 Acute nociception initially results in increased pain sensitivity 
(hyperalgesia) affecting the peripheral and central nervous system. When ongoing 
nociception (due to ongoing damage to tissues and nerves) is present, peripheral nervous 
system sensitization may occur. Furthermore, this nociceptive barrage will continuously 
excite the brainstem and brain leading to central sensitization. In the end the whole 
nervous system may become sensitized, leading even minor stimuli to become painful 
or to the presence of pain without nociceptive input.2-4 This phenomenon of maladaptive 
plasticity of the nervous system manifests itself as altered pain processing in chronic 
pain patients.
A systematic approach to diagnosing altered pain processing in chronic pain
A suitable tool is required in order to facilitate a systemic approach to diagnose altered 
pain processing in patients with chronic pain. This tool should document:4
1. The function of the central nervous system
2. Changes in the function and structure of the central nervous system
Application of such a tool in the systematic approach to chronic pain permits a 
mechanism-orientated management enabling: (1) proper diagnosis and follow-up of 
chronic pain, (2) rationale for treatment choice and responder identification and (3) 
monitoring of pain treatment.4
Quantitative sensory testing (QST), electroencephalograpy (EEG) and magnetic 
resonance imaging (MRI) have increasingly been used in chronic pain disorders to describe 
maladaptive changes in (peripheral) nerves and the central nervous system. Increasing 
evidence from studies using these tools has provided us with important information 
on central pain processing and how it can be influenced by disease progression and 
treatments. Each tool has its own strengths and limitations, although the potential of 
EEG is largely unclear. We focused in this thesis on EEG to further investigate cortical 
sensory processing in the presence of chronic pain.
Rationale for EEG as diagnostic tool for chronic pain
As early as 1953, the EEG was being studied by Kirschbaum and colleagues in patients 
with pain due to peptic ulcers and functional gastric disorders.5 Their study is an early 
example of the recognition of the brain-gut axis as a possible substrate for visceral pain 
syndromes. In the more recent literature, studies using EEG in visceral pain syndromes 
mostly address chronic pancreatitis. Although the use of EEG can be demanding and 
complex, this technique is a potentially useful non-invasive tool for clinical practice. 
EEG has a poor spatial resolution, but superior millisecond-range temporal resolution 
compared to other neurodiagnostic instruments such as PET or (f )MRI, enabling direct 
measurements of neuronal processing.6 EEG can be used in chronic pain conditions to 
study the brains’ default state reflected by the resting state EEG (static element) and 
brain activity due to external stimuli reflected by event related or evoked brain potentials 
(dynamic element).6
Changes in resting state EEG activity associated with chronic pain
Alterations in the brains’ default state as reflected by resting state EEG, particularly in the 
alpha band, have been observed in multiple studies in various chronic pain conditions. 
These changes typically consist of a shift of peak alpha or theta frequency to lower 
frequencies and/or a reduction in alpha or theta power.7-11 Similar results were shown 
in our study investigating novel potential markers of chronic pain in the resting state 
EEG in patients with chronic pancreatitis. We observed that chronic pancreatitis pain is 
associated with alterations in the spontaneous brain activity, observed as a shift towards 
lower peak alpha frequencies (PAF). This shift correlates with the duration of pain, 
suggesting that PAF has the potential to be a clinically feasible biomarker for chronic 
pain (chapter 3).
Accordingly, Olesen et al. reported an increase in amplitude strength in the theta and 
alpha band in patients with chronic pancreatitis compared to healthy controls, and 
concluded that their findings reflected a slowed EEG rhythmicity in patients compared 
to controls.12 In irritable bowel syndrome (IBS) patients, power spectrum analysis of the 
resting EEG also showed a decrease of alpha power percentage together with an increase 
of beta power percentage compared to healthy subjects.13 These findings are similar to 
findings in other non-visceral (e.g. neurogenic) chronic pain syndromes, indicating that 
slowing of brain rhythmicity as a reflection of altered resting state CNS function may 
be a hallmark of the chronic pain state. Additionally, baseline results as obtained in our 
clinical parallel study (chapter 8), demonstrated that clinical pain severity was associated 
with slowing of brain oscillations in a resting state, as well as with enhanced N1 and P3 
amplitudes elicited by noxious electrical stimulation. However, it is still unclear whether 
alpha activity is directly related to subjective pain experience, given that equivocal 
results are observed among clinical studies. 
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Alterations in evoked brain potentials associated with chronic pain
Evoked potentials (EPs) have been used to describe changes in the central nervous 
system, although the heterogeneity among previous studies impedes identification 
of a characteristic maladaptive pattern of chronic pain. We aimed to investigate brain 
processing in response to painful electrical stimuli in patients with chronic pain after 
breast cancer treatment (chapter 2). In this group of patients, we observed that persistent 
pain was associated with both delayed and enhanced stimulus processing as reflected in 
an increased latency and enhanced amplitude of the late EP component between 250–
310 ms. From this study the key question raised: are these alterations in evoked brain 
potentials similar for all types of chronic pain including (postsurgical) abdominal pain?
Dimcevski et al. recorded EPs after painful stimuli given with a constant current electric 
stimulator at the three different sites of the upper gastrointestinal tract. Patients with 
chronic pancreatitis had a significantly decreased latency for the N1 and P1, while N2 
latency was borderline significant compared to healthy subjects. No differences were 
found in amplitudes of the N1, P1, and N2 potentials.14 Patients with chronic pancreatitis 
also showed hyperalgesia to electrical stimulation and prolonged latencies of early 
visceral EPs components in the frontal region of the cortex compared to healthy controls. 
Moreover, scalp distributions of EP amplitudes were more scattered and more posteriorly 
located in this patient group.15 These changes are generally compatible with our findings 
in patients with non-visceral postsurgical pain (chapter 2). In contrast, stimulation of 
vagal nerve afferents in patients with gastroesophageal reflux disease did not reveal any 
difference in peak latencies or EP amplitude between gastroesophageal reflux disease 
(GERD) patients and controls.16 IBS patients showed an altered generation or transmission 
of rectal EPs observed as a higher prevalence of cerebral evoked potential early peaks, 
and shorter latencies compared to healthy subjects.17 Another study in IBS reported 
a shorter latency and a smaller amplitude of the early EP component after electrical 
painful stimulation in the sigmoid colon in IBS patients compared to healthy subjects.18 
These data suggest that central processing of painful stimuli is altered in different types 
of chronic (abdominal) pain. However, typical maladaptive characteristics could not be 
identified probably due to the heterogeneity in clinical (pain) characteristics, stimulation 
modalities and EEG analyzing methods.
Different stimulus modalities produce different cortical scalp potentials
In order to obtain EPs that are specific to nociceptive input, such input should be the 
result of physiological processing of nociceptive stimuli, i.e. involving selective activation 
of nociceptive Aδ/C-fibers in the periphery and recording resultant EPs generated in the 
cortex.19 Brain mapping studies have established a positive relationship between the 
intensity of pain reported to nociceptive selective laser stimuli and EP amplitude.20 In 
the context of evoked EEG studies, it must be noted that in general the experimental 
visceral electrical stimulation of large and small peripheral afferents in different gut 
segments is painful, but not nociception specific.21 Whether EPs resulting from stimuli 
entirely selective for nociceptive peripheral afferents represent the experience of pain 
or a more generalized response of heightened attention or arousal to afferent stimuli 
is current topic of debate.20,22-25 Mouraux and Iannetti demonstrated that laser-evoked 
EEG responses reflect neural activities equally involved in processing nociceptive and 
non-nociceptive sensory inputs.24 Thus, a stimulus entirely selective for nociceptive 
peripheral afferents does not imply that the elicited brain activity is nociception specific. 
However, even if EPs reflect neuronal activities that are unspecific for the nociceptive 
system, their generation still relies on the consequences of nociceptive activation and 
resultant changes in CNS state at both peripheral and central levels.24
EEG as tool to detect altered brain processing associated with chronic pain
To summarize, studies in chronic pain investigated both the resting state as well as the 
evoked EEG. The broad range of applied analysis techniques and stimulation methods 
hampers direct comparison of results. However, alpha activity in the resting state 
EEG has been shown to be affected in multiple chronic pain states, including chronic 
pancreatitis as demonstrated in our study, suggesting a change in the default state of 
the brain as a result of chronic pain. In addition, we observed that chronic pain was 
associated with delayed and enhanced stimulus processing in response to electrical 
noxious stimuli in patients after breast cancer treatment. Pain-evoked EEG studies in 
chronic pancreatitis patients also demonstrated alterations in dynamic pain processing 
reflected by prolonged latencies of visceral EPs and higher theta activity with prolonged 
persistence of the signal at a lower frequency during experimental visceral pain. Taken 
together, these EEG findings further support the concept that chronic (abdominal) pain 
conditions are associated with significant and ubiquitous alterations in resting state and 
evoked central pain processing, both nociceptive and non-nociceptive, interpreted as 
a sign of maladaptive plasticity.26 The challenge now is to improve the sensitivity and 
specificity of EEG to allow the development as diagnostic tool for individual patients. 
Additionally, future EEG research should monitor fluctuations of perceived pain in 
longitudinal studies.
Treatments for chronic abdominal pain are lacking
Opioids are among the most prescribed and effective drugs for the treatment of 
moderate to severe pain in general. Although there is a consensus on their utility as a 
treatment for chronic cancer pain, their long-term use for chronic non-malignant pain 
remains controversial due to concerns about side effects, long-term efficacy, functional 
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outcomes, chronic toxicity and the potential for drug abuse. 27 Additionally, chronic 
administration of opioids can result in decreased pain thresholds and produce opioid-
induced hyperalgesia. Opioid-induced hyperalgesia is a paradoxical effect, in that opioid 
therapy enhances or exacerbates pre-existing pain, while it is originally prescribed as 
analgesic.28,29 This unintended and undesirable consequence of prolonged opioid 
exposure is likely the result of neural plasticity of the nervous system.29 In addition, 
opioids may affect the absorption of other drugs by changes in gastrointestinal motility, 
sphincter function, intestinal fluid secretion and drug metabolism.30-32 It is thus desirable 
to avoid prolonged opioid prescription, but the question arises: What are the alternatives 
for patients suffering from chronic abdominal pain?
As addressed in the first part of this thesis, chronic pancreatitis and chronic postsurgical 
pain display both visceral and neuropathic pain components, which are associated with 
maladaptive plasticity of the peripheral and central nervous system. Medical therapy 
is increasingly focused on a combination of medications by targeting different pain 
pathways. Over the past few years, several (psycho)pharmacological drugs, that are not 
normally considered analgesics, such as tricyclic antidepressants and anticonvulsants, 
have been investigated as adjuvant treatment option. Despite this, effective, safe and 
sustainable treatment options for chronic pain are still lacking.
The therapeutic potential of THC
Despite a long history of medicinal cannabis use in the treatment of pain, the analgesic 
properties of cannabis or THC are still ill-defined, particularly for chronic abdominal pain 
conditions. We did not observe any analgesic effect of a single dose of THC compared 
to diazepam, with no difference between opioid users and non-opioid users, in chronic 
pancreatitis patients (Chapter 4). Although pain was decreased after THC administration, 
a similar effect was observed after diazepam, which might be the result of placebo or 
sedative effects. Subsequent clinical trials by our group were designed to evaluate the 
efficacy of THC during a relatively long-lasting treatment period of 50-52 days (Chapter 
5). In this parallel design study, THC also did not show a beneficial effect on chronic 
abdominal pain compared with placebo. Between the start and end of the study, VAS 
mean scores decreased by 1.6 points (40%) in the THC group compared to 1.9 points 
(37%) in the placebo group. Our findings are in contrast with other studies, since most 
previous studies in chronic non-malignant pain conditions demonstrated analgesic 
efficacy using a single dose or treatment periods of 2 to 15 weeks. 33-45 However, the 
majority of studies with cannabis-based medicines were conducted in patients suffering 
from central neuropathic pain in multiple sclerosis. The lack of observed analgesic efficacy 
in our clinical trials can be related to insufficient analgesic potency of the investigational 
drug, but it may also be related to 1) the selected study design and treatment dose, 2) 
inter-individual variation in pharmacokinetic profiles, 3) a large placebo response, and 
4) indirect anti-nociceptive effects. These aspects are further discussed in the following 
paragraphs.
Selecting the optimal study design and treatment dose
Randomized clinical trials are traditionally performed double-blinded, whereby both 
patient and investigator theoretically do not know or cannot distinguish the assigned 
treatment. However, the psychoactivity of cannabinoids may unmask their presence 
through the occurrence of recognizable side effects and consequently may result in poor 
concealment of group allocation.46 This may bias participants toward their expectations 
and/or conditioning of pain relief, which can lead to incorrect assumptions regarding 
the efficacy of the drug. This is particularly so in studies utilizing self-reported subjective 
outcomes.46 For this reason, low dose Diazepam was used as active placebo to prevent 
unblinding of patient and investigator in the single dose crossover study. However, 
interpretation of (secondary) outcomes appeared to be more complicated comparing 
two psychoactive substances. Therefore, we decided to use an inactive placebo in the 
parallel group study, which is less prone to unblinding for the reason that patients 
cannot compare both treatment arms in a parallel design. The observed pain relief in 
each treatment arm of both clinical trials were probably induced by placebo effects, 
which supports that we gained adequate blinding of patients. However, we should have 
evaluated the preservation of the blind-to-treatment allocation by asking participants 
whether or not they believed they received active study medication or placebo. It is 
important that future studies of psychoactive compounds use methodologies designed 
to counteract unmasking and incorporate blindness assessments in their study protocols.
In the single dose study, the THC dose was primarily based on the PK and PD results of 
an earlier phase I study with Namisol® in healthy young volunteers 47. Previous studies 
with other cannabis-based compounds were inappropriate to select the optimal dose, 
because PK profiles depend among different formulations and administration routes. 
We used a novel tablet formulation of pure THC that was produced using an emulsifying 
drug delivery technology to improve the uptake of poorly soluble lipophilic compounds. 
This oral tablet demonstrated an improved bioavailability in healthy subjects. Previous 
studies of other cannabis-based compounds demonstrated linear dose-response 
curves for multiple pharmacodynamic parameters. Extrapolating these linear effects, 
we selected the maximal tolerable dose of THC as shown in the phase I study in order 
to induce the largest analgesic effect. However, it appears that a single dose might be 
insufficient to achieve adequate exposure duration. A lipophilic substance such as THC 
will diffuse to the fatty tissues immediately, and therefore, the THC concentration at 
the target site might be insufficient to modulate pain after single dose, explaining the 
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comparable effects between the experimental and control condition.
Subsequently, the single dose concentration-time curves were used to simulate multiple 
dosing strategies in order to determine the most optimal dosage regimen for a relatively 
long term treatment period. The treatment scheme, consisting of a step-up phase to 
habituate and a stable dose phase to induce the desirable effects, was semi-fixed only 
allowing dosage tapering in the stable dose phase with one step. Future studies should 
adjust the dosage for individual patients according to individual pharmacokinetic 
profiles and clinical effects 48,49.
Inter-individual variation in pharmacokinetic profiles
The underlying pathophysiology of chronic pancreatitis potentially alters the 
pharmacokinetics of orally administrated drugs, and consequently, the efficacy of a 
pharmacological treatment. Fibrotic destruction of the pancreas in chronic pancreatitis 
or after pancreatic surgical resections induces exocrine insufficiency and results in a 
decreased release of pancreatic enzymes and bicarbonate.50 The pancreatic gland normally 
produces more than 2 L of secretions per day which is composed of water, bicarbonates 
and enzymes.51 The impaired secretion of digestive enzymes into the duodenum leads 
primarily to fat malabsorption, which is clinically recognized as steatorrhea. Impaired 
pancreatic bicarbonate secretion in the intestines results in changes in the intraluminal 
pH, because of insufficient buffering of gastric acid by the bicarbonate. Reduction in 
duodenal pH results in inactivation of trypsine, amylase, and particularly lipase enzymes, 
and consequently leads to further impairment of fat digestion.52,53 Fat malabsorption 
also results in a deficit of fat-soluble vitamins, 54 and may affect absorption of lipophilic 
drug formulations.55 Additionally, opioid use, malnutrition and a history of alcohol 
abuse, common featured in chronic pancreatitis patient, may potentially influence the 
pharmacokinetics. We observed a delay in time to reach maximal plasma concentration 
and a spread in maximal plasma concentrations in chronic pancreatitis patients compared 
to healthy volunteers. These changes in pharmacokinetics of THC might be direct and 
indirect consequences of exocrine and endocrine pancreatic insufficiency. Several other 
factors, such as antidiabetics, cytochromes P450 enzyme polymorphism and pancreatic 
surgery, potentially enhanced inter-individual variations in the pharmacokinetics of THC, 
and accordingly, contributed to inter-individual variations in efficacy.
The problem of placebo responses
A large number of novel analgesics have failed to prove superiority over placebo in 
clinical trials, which has been ascribed to a large placebo response.56 In our clinical trials, 
we observed 20% pain reduction after a single dose of diazepam, which was used as 
active placebo in the cross-over study, and 37% pain reduction in the placebo arm after 
50-52 days of study treatment. Large placebo responses are quite common in chronic 
(abdominal) pain studies. A meta-analysis in patients with irritable bowel syndrome 
allocated to placebo observed an average placebo response of 38%.57 Additionally, the 
placebo response rate in clinical trials evaluating treatment of pain in chronic pancreatitis 
was 20%. Factors that were associated with higher placebo responses in chronic 
pancreatitis patients were a multicenter design, a run-in period of less than two weeks, 
and absence of a washout in crossover trials.58 Type of active medication, randomization 
ratio, and the number of planned face-to-face visits are expectancy mediating factors also 
influencing the degree of the placebo response.56 The effect of baseline pain intensity on 
the placebo response is not clear, however, patients experiencing more fluctuations in 
pain demonstrate larger placebo responses compared to patients with less variability 
in pain over time.59 Fluctuating pain patterns are typical for chronic pancreatitis, which 
might have enhanced the placebo effect.
Underlying mechanisms mediating the placebo effect can be derived from psychological 
and neurobiological perspectives. Two well supported psychological mechanisms are 
expectancy about the therapeutic benefit and conditioning from earlier experiences.60 
High expectations toward treatment efficacy of THC might have contributed to the 
substantial placebo response as observed in our studies. In clinical practice, placebo 
effects can be utilized by influencing patients’ expectations in order to improve 
treatment effects. However, in clinical trials, placebo effects should be minimized to 
optimize differences between verum and placebo. Modifiable study characteristics 
that potentially affect placebo responses should be identified and optimized in order 
to increase the probability that a clinical study will show superiority of the study drug 
compared with placebo. Of these, increased sample size, longer trial duration and more 
frequent face-to-face visits were significantly associated with larger placebo response.56,58 
In retrospect, we should have reduced the number of study contacts between patient 
and study staff in our trials. In future clinical trials, patients’ expectations should be 
assessed as an important factor affecting the magnitude of the placebo response. 
Baseline attitudes can be used as stratification factor in the randomisation procedure or 
patients’ expectations can be used as co-variables.61 Prior identification of high placebo 
responders and potential determinants of the placebo response can also improve 
study designs in order to separate specific treatment from non-specific contextual (i.e. 
placebo) effects. Improved study designs and outcome measurements are required 
for appropriate drug evaluation and personalized health care in chronic (visceral) pain 
research.
A mechanism-orientated approach to evaluate anti-nociceptive effects of THC
The number of chronic pain clinical trials reporting negative findings has increased.62 
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The explanation for these unsuccessful outcomes may involve selection, analysis, and 
interpretation of outcome measures as well as shortcomings in the design of these trials. 
For these reasons, several Initiative on Methods, Measurement, and Pain Assessment 
in Clinical Trials (IMMPACT) recommendations have been developed which should be 
considered in future clinical trials.62-64 Additionally, it is possible that poor understanding 
of patient heterogeneity in pathophysiologic mechanisms (i.e. maladaptive plasticity of 
the CNS) and treatment responses are a reasonable explanation for unsuccessful trials. In 
the first part of this thesis, we focused on the pathophysiology of chronic abdominal pain 
and identified several pain related changes in EEG outcomes. In part III, we evaluated 
these maladaptive changes in EEG outcomes during THC treatment. The ultimate goal 
was to provide a foundation for a mechanism-oriented treatment approach in which 
THC targets the specific mechanisms of a patient’s pain as we proposed in Chapter 6. 
Therefore, resting state EEG and EPs to pain related electrical stimuli were recorded in 
both clinical drug studies, but we observed no THC effects on these EEG indices after 
a single dose of THC (Chapter 7) nor during a treatment period of 50-52 days (Chapter 
8). It is nevertheless too early to draw conclusions regarding the potential of EEG based 
on these negative findings. According to the mechanism-oriented treatment approach, 
pharmacologic treatments can alternatively aim to suppress sensitization or other 
maladaptive neuroplastic changes with the secondary ultimate aim to reduce pain or to 
postpone more severe pain at the long run. If we were able to detect THC effects resulting 
in normalisation of EEG indices, it was interesting to perform long-term follow-up of 
these patients’ subjective pain outcomes. For now, we can conclude that THC did not 
target underlying pathophysiologic mechanisms as identified in several EEG indices in 
this study population. Furthermore, patients’ individual treatment responses could also 
not be linked to individual changes in EEG indices, which suggest that these EEG indices 
do not reflect treatment response utilizing subjective outcomes. This is reasonable, since 
these outcome measures are not similar reflecting different domains related to pain.
Clinical versus neurophysiological assessment of pain and drug efficacy
Because pain is a subjective experience and not only an objective bodily state, the 
choice of an adequate instrument to measure pain is critical to evaluate the efficacy 
of an analgesic. Pain is traditionally measured by means of subjective ratings of pain 
intensity. In contrast, nociception does not describe psychological pain, but refers to the 
physiological processing of information about the internal or external environment, as 
generated by the activation of nociceptors. Thus we have two types of pain assessments, 
reflecting different mechanistic processes and utilizing different instruments, but to a 
certain extent related to each other. Moreover, both assessments can provide essential 
insight in each other’s underlying mechanisms.
In assessing the efficacy of analgesics in clinical trials, several confounders can bias 
subjective pain outcomes. Experimental pain outcomes, such as EEG, are without many 
confounders and therefore a valuable tool for evaluating analgesics in clinical trials.65 
Additionally, assessing analgesic effects by EEG in chronic pain patients may contribute 
to a mechanism-oriented classification of pain and thereby to a better understanding of 
the underlying symptoms. However, it should be mentioned that changes in pharmaco-
EEG monitoring central analgesic mechanisms are not consistent, and experimental 
pain studies using EEG to identify patients who may benefit from treatment strategies 
targeting central pain mechanisms are limited. Moreover, there is a gap between scientific 
relevance of experimental pain models in clinical trials versus implementation of these 
neurophysiologic tools in clinical practice. Diagnostic instruments for both clinical and 
neurophysiological assessments of pain so far lack documented reliability for use in the 
individual patient.
Recommendations for future research
Although the negative results as observed in our clinical drug trials could also be 
explained by a lack of efficacy of THC or limitations in the design of the trials, it should 
be mentioned that multiple chronic pain trials report negative outcomes these days. 
Rather, a lack of knowledge regarding the cause underlying chronic pain and poor 
understanding of patient heterogeneity in pathophysiologic mechanisms and treatment 
response are important explanations for the negative outcomes in trials. 
Ongoing research needs to focus on the mechanisms underlying different chronic pain 
conditions, devise methods for reliably identifying these mechanisms in individual 
patients, and develop treatments that target these mechanisms. A way to increase our 
knowledge in this respect is to measure the effect of pain and nociception on central pain 
processing in large-scale clinical studies using neurophysiological tools, such as QST, EEG 
or fMRI, before and after interventions and during disease progression.[77] Longitudinal 
data collections will help us understand pain related adaptations and evaluate therapies 
and guide us to the proper treatment for a specific patient at a specific disease stage. 
Developments in (f )MRI and EEG hold the most promise to add to our understanding of 
maladaptive plasticity of the central nervous system related to chronic pain. Moreover, 
combining these two techniques to obtain simultaneous high-spatial and high-temporal 
resolution scans offers exciting opportunities. Standardization of stimulation modalities, 
recording procedures and signal analysis is required. The challenge is then to improve the 
sensitivity and specificity of these techniques to allow their development as diagnostic 
tools for the individual patient.
Further research is required to investigate the analgesic potential of THC more 
comprehensively. However, it makes no sense to perform a new classical randomized 
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controlled trial. Future studies need more advanced methods, considering: 1) appropriate 
study designs to manage large placebo responses, 2) adequate patient (responder) 
selection, 3) individual treatment dosages based on inter-individual variation in 
pharmacokinetic profiles, 4) reliable neurophysiological outcomes to evaluate anti-
nociceptive effects. Certainly, THC can also be an ineffective cannabinoid, but this 
cannot be confirmed from our studies. Therefore, advanced clinical studies are necessary 
in order to evaluate if THC might be effective for a certain pain condition and a selective 
group of patients using an individually determined treatment dosage.
Recommendations for clinical practice
To improve pain treatment in the long term, it is important to study the underlying (patho-) 
physiological mechanisms of pain as well as the underlying pharmacological mechanism 
of actions of new and existing analgesics. One aim of such research is that clinicians 
may be better equipped to choose the optimal analgesic and dose or to make informed 
decisions regarding analgesic rotation strategies in efforts to achieve the best individual 
patient outcome. Clinical practice can be very useful to obtain these data for scientific 
evaluation and to apply population-based evidence-based medicine subsequently. 
However, both subjective and experimental outcomes obtained in individual patients 
should be interpreted with caution, due to several limitations concerning validity and 
reliability of the diagnostic instruments. EEG has currently no proven added value for 
clinical practice. Until more objective measurements of (maladaptive) pain processing 
are perfected, clinical practice rely on the use of self-reported outcomes such as quality 
of life or pain scores.
Conclusions
We observed several changes in evoked EEG utilizing pain related EPs to noxious electrical 
stimuli in patients with chronic postsurgical pain and chronic pancreatitis. Alterations in 
resting state EEG were also observed in patients with painful chronic pancreatitis. These 
EEG findings further support the concept that chronic (abdominal) pain conditions are 
associated with significant and ubiquitous alterations in resting state and evoked central 
pain processing, suggesting that chronic pain involve changes in central pain processing 
mediated through mechanisms of neural plasticity. The ultimate goal of these efforts 
is to provide the foundation for a mechanism-based treatment approach in which 
therapeutic interventions target the specific mechanisms of a patient’s pain. 
In our studies, THC was not efficacious as add-on pain treatment in reducing chronic 
abdominal pain compared to placebo utilizing subjective pain outcomes. Future clinical 
studies should optimize study designs to adequately handle large placebo responses 
and choose advanced treatment outcomes to apply a systematic approach to chronic 
pain. EEG can be a useful diagnostic instrument to analyze central pain processing 
and help us in understanding optimal mechanism orientated treatments for chronic 
abdominal pain. Future research should define the presence and pattern of altered pain 
processing for specific chronic pain disorders in individual patients, devise methods for 
reliably identifying these mechanisms in individual patients, and develop treatments 
that target these mechanisms.
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SUMMARY
The objectives of this thesis were to investigate maladaptive mechanisms of neural 
plasticity underlying chronic pain, and to evaluate the analgesic and anti-nociceptive 
potency of oral tetrahydrocannabinol (THC).
The studies described in this thesis focused on three subjects:
1. To investigate potential neuroplastic changes in brain activity associated with 
 chronic (postsurgical) pain using both spontaneous and evoked EEG recordings 
 (Part I).
2. To evaluate the therapeutic potential of a novel oral tablet containing purified 
 THC for the treatment of chronic abdominal pain (Part II).
3. To evaluate potential anti-nociceptive effects of THC utilizing pain related 
 neuroplastic changes in spontaneous and evoked EEG (Part III).
PART I: Cortical processing in chronic (postsurgical) pain
Women who undergo breast cancer surgery have a high risk of developing persistent 
pain. In chapter 2, we investigated brain processing of painful stimuli using evoked 
potentials (EPs) recorded in the electroencephalography (EEG) in patients with persistent 
pain after breast cancer treatment. Nineteen patients (8 women with pain, 11 without 
pain), treated more than one year ago for breast cancer via surgery (mastectomy or 
lumpectomy and axillary lymph node dissection) and/or chemo/radiotherapy were 
recruited and compared to eleven healthy female volunteers. Changes in cortical 
processing were recorded in the EEG utilizing pain related EPs to noxious electrical 
stimuli. The presence of chronic pain was associated with delayed and enhanced 
stimulus processing as reflected by an increased latency and enhanced amplitude of 
the EP positivity between 250-310 ms (P260). Compared to healthy volunteers, breast 
cancer patients had a speeding of (reduced P260 latency) and a tendency towards a less 
intense (smaller P260 amplitude) stimulus processing. These results suggest that the two 
conditions, i.e. treatment and pain persistence, have opposite effects regarding cortical 
responsiveness. The main conclusion of this study is that persistent pain after breast 
cancer treatment is associated with neuroplastic changes in cortical activity shown as 
delayed and enhanced stimulus processing.
Changes in spontaneous EEG activity have been observed in several chronic pain 
populations, suggesting that chronic pain involve changes in central pain processing 
mediated through mechanisms of neural plasticity. However, this was not yet 
investigated for chronic visceral pain conditions. We observed alterations in the resting 
state EEG of patients with painful chronic pancreatitis compared to matched healthy 
controls, which is described in chapter 3. Chronic pancreatic pain was associated with 
slowing of the spontaneous brain activity, observed as a shift toward lower peak alpha 
frequencies (95% CI diff [−.68 to −.01 Hz]; P<0.05). No significant group differences were 
found in peak power amplitudes between chronic pancreatitis patients and healthy 
controls. The shift in peak alpha frequencies was correlated with the duration of pain, 
showing increased reductions with longer pain durations, and suggesting that peak 
alpha frequency is a potential biomarker for disease progression of chronic pain. These 
findings help us understanding the underlying pathology of chronic pain and assisting 
in diagnosis, establishing optimal treatment, and studying efficacy of new therapeutic 
drugs in chronic pain patients.
PART II: Efficacy and safety of tetrahydrocannabinol in chronic abdominal pain
The second part of this thesis focused on the therapeutic potential of a novel oral tablet 
containing purified tetrahydrocannabinol (THC) for the treatment of chronic abdominal 
pain. We performed two phase 2 clinical drug studies evaluating the clinical efficacy, 
pharmacokinetics, pharmacodynamics, pharmacogenetics, safety and pain related 
neuroplastic changes in spontaneous and evoked EEG after oral THC. In chapter 4, the 
results of a randomized, single dose, double-blinded, placebo controlled crossover study 
in patients suffering from abdominal pain related to chronic pancreatitis are presented. 
We found that a single dose of oral THC was not efficacious in reducing chronic pancreatic 
pain compared with the active placebo diazepam (mean diff THC - diazepam -.17; 95% 
CI diff [-.95 to .61]; p=.65). THC was absorbed with an average Tmax of 123 minutes, which 
was similar for opioid and non-opioid users. The absorption of THC was delayed in several 
chronic pancreatitis patients, resulting in an increased variability compared to healthy 
volunteers, most probably due to underlying pathology and concomitant medication 
use. Overall, oral THC produced reliable pharmacokinetic profiles and was generally 
well tolerated with mild to moderate adverse events. Long term treatment effects of 
THC during a treatment period of 50-52 days were further evaluated in a second study. 
The results of this randomized, double-blind, placebo-controlled study evaluating the 
analgesic efficacy, pharmacokinetics, and tolerability of oral THC in patients with chronic 
abdominal pain, are described in chapter 5. Sixty-five patients with chronic abdominal 
pain after surgery or due to chronic pancreatitis were randomly assigned to groups 
given the THC tablet or matching placebos. Subjects in the THC group were given the 
tablet first in a step-up phase (3 mg, 3 times daily for 5 days and then 5 mg, 3 times 
daily for 5 days) followed by a stable dose phase (8 mg, 3 times daily until day 50–52). 
Preceding and during the entire study period, patients were asked to continue taking 
their own medications (including analgesics) according prescription. Contrary to our 
hypothesis, THC did not show a beneficial effect on chronic abdominal pain compared 
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with placebo (F(1, 46) =.016; P=.901). Between the start and end of the study, VAS mean 
scores decreased by 1.6 points (40%) in the THC group compared to 1.9 points (37%) 
in the placebo group. Additionally, no differences were observed in secondary efficacy 
outcomes such as quality of life, appetite level and pharmacodynamic parameters. Oral 
THC was generally well absorbed resulting in reliable pharmacokinetic curves. Seven 
patients administrating THC discontinued study treatment due to adverse events 
compared with two patients in the placebo group. All (possibly) related adverse events 
were mild or moderate.
We demonstrated that THC, administered 3 times daily during a 50-day treatment period, 
was safe and well-tolerated, however, did not relief pain. A large placebo response was 
present in this study, a finding that is in concordance with other chronic visceral pain 
studies. We advised designing future studies in a more optimal way, avoiding these large 
placebo effects.
Chapter 6 provides an overview of clinical trials that have been conducted to investigate 
the analgesic efficacy of various cannabis-based products with standardized THC content 
for chronic non-malignant pain. The majority of these trials reported improvement in 
pain scores in favour of products containing D9-THC (dronabinol). However, analgesic 
effects were generally weak and placebo effects were considerable in the control 
arms. Common limitations of these trials, that potentially bias treatment outcomes, are 
discussed in this review.
Underlying pain mechanisms, including plasticity of nociceptive and cognitive pain 
processing, may explain the varying analgesic effects of dronabinol in particular chronic 
pain states. To date, regulatory authorities assess the therapeutic potential of new 
analgesics based primarily on the patient’s subjective pain experience. We discussed 
a mechanism-based approach beyond the measurement of subjective pain relief for 
future research, to evaluate the therapeutic potential of dronabinol in chronic pain 
management.
PART III: Neuronal mechanisms of tetrahydrocannabinol
In the first part of this thesis, we concluded that chronic abdominal pain can be to 
some extent attributed to maladaptive mechanisms of neural plasticity underlying 
chronic pain. In the second part, we could not observe clinical efficacy of oral THC and 
recommended a mechanism-based approach to evaluate the anti-nociceptive effects of 
THC in chronic pain management. In the studies reported in the last part of this thesis, 
we investigated the underlying pain processing mechanisms of THC by evaluating pain 
related neuroplastic changes in spontaneous and evoked EEG as described in chapter 
2 and 3.
Chapter 7 addressed the potential anti-nociceptive effects of THC by investigating 
underlying pain related cortical activity in the crossover study reported in chapter 4. 
We investigated whether a single dose of orally administrated THC alters 1) the resting 
state EEG and 2) EPs to pain related electrical stimuli in patients with chronic pancreatic 
pain. A concentric electrode delivering electrical stimuli at the lower arm was used, 
which activates mainly nociceptive A-delta fibers and produces a pinprick-like pain 
sensation. Both EEG measurements were consecutively conducted predose and time-
locked at 1:10, 2:10, 3:10, and 5:05 hours after administration of study medication. 
We primarily demonstrated a good test-retest reliability of all resting state alpha EEG 
indices in CP patients. The intra-subject variability of evoked EEG parameters showed 
fair to good agreement, supporting the use of these EEG parameters for further 
research. However, we could not detect THC-related effects on alpha indices of the 
resting state EEG nor on EPs to pain related electrical stimuli in chronic pancreatitis 
patients. VAS scores of electrical transcutaneous nociceptive stimulation maintained 
stable over time, indicating that acute evoked pain was also not affected by THC. These 
results are in line with the overall subjective experience of pancreatic pain patients, in 
whom no analgesic effect of THC was observed (chapter 4). Furthermore, individual 
changes in subjective pain scores were correlated with EEG indices to assess whether 
EEG changes were linked to underlying analgesic responses and not caused by 
confounding factors such as sedation and other adverse effects. A significant negative 
correlation was found between change in VAS pain scores and change in peak alpha 
power, indicating that individual treatment response is associated with enlarged peak 
power amplitude.  Further analysis of subjective measures of individual clinical pain 
scores in relation to objective measures of EEG parameters at baseline did not reveal 
any correlation.
Cortical correlates of THC were further elucidated and reported in chapter 8. We 
explored the effects of THC after a 50-day treatment period on pain related EEG indices 
in patients with chronic abdominal pain. We demonstrated that clinical pain severity 
was associated with slowing of brain oscillations in a resting state, as well as with 
enhanced N1 and P3 amplitudes elicited by noxious electrical stimulation. Correlations 
between clinical pain intensities and objective EEG outcomes suggest that chronic 
pain alters central pain processing recorded by EEG. Utilizing these maladaptive EEG 
outcome parameters in chronic pain, THC did not affect spontaneous brain activity 
nor evoked pain processing compared to placebo after 50 days of treatment. Solely 
in postsurgical pain patients, a delay in N1 latency was observed for THC treatment 
compared to placebo. Moreover, cortical correlates of THC could not be associated 
with its analgesic efficacy, and thus, did not reflect individual treatment responses.
Chapter 10
213212
10
Samenvatting
The main findings of this thesis are discussed with respect to recent literature in Chapter 
9. Part of this general discussion is a mechanism-oriented approach to pain in chronic 
pancreatitis. Recommendations are addressed for future research and clinical practice. 
Future clinical studies should optimize study designs to adequately handle large placebo 
responses and choose advanced diagnostic tools to apply a systematic approach to 
chronic pain. The presence and pattern of altered central pain processing for specific 
chronic pain disorders in individual patients needs further investigation. Additionally, 
methods for reliably identifying these mechanisms in individual patients and treatments 
that target these mechanisms are required.
SAMENVATTING
Pijn is een onplezierige, sensorische en emotionele ervaring, die geassocieerd is met 
actuele of potentiële weefselschade. Acute pijn heeft een belangrijke beschermingsfunctie 
voor ons lichaam en verdwijnt normaal gesproken zodra de weefselschade hersteld is. 
Acute pijn kan door onverklaarde redenen blijven bestaan en overgaan in chronische 
pijn. Chronische pijn is een persisterend, multifactorieel gezondheidsprobleem en staat 
onder invloed van lichamelijke, psychische en sociale factoren. Ongeveer 19% van de 
Europese volwassen bevolking kent een periode van matige tot ernstige chronische pijn.
Hoewel de oorzaak van chronische pijn nog onduidelijk is, lijkt centrale sensitisatie een 
belangrijke rol te spelen in het ontstaan en aanhouden van persisterende pijnklachten. 
Centrale sensitisatie gaat gepaard met een toegenomen respons van nociceptieve 
neuronen in het centrale zenuwstelsel op normale afferente input of zelfs door afferente 
input onder het drempelniveau van de neuron. Hierdoor is pijn niet langer gekoppeld 
aan de aanwezigheid, intensiteit of duur van een specifieke perifere stimulus, maar is pijn 
het gevolg van neuronale veranderingen in het centrale zenuwstelsel. Pijn werkt dan niet 
langer als effectief alarmsignaal, maar is heviger dan te verwachten of ontstaat spontaan. 
Wanneer centrale sensitisatie is opgetreden wordt de behandeling en genezing van 
de pijnklachten lastiger. Huidige pijnbehandelingen schieten vaak te kort of zijn niet 
geschikt voor langdurige toepassing. Cannabinoiden, waaronder tetrahydrocannabinol 
(THC), bieden een potentiele nieuwe toegang voor de behandeling van chronische pijn. 
De doelstelling van dit proefschrift was om de onderliggende maladaptieve neuronale 
veranderingen van  chronische pijn te onderzoeken, alsmede de pijnstillende en anti-
nociceptieve eigenschappen van orale THC te evalueren.
De studies beschreven in dit proefschrift concentreerden zich rondom drie onderwerpen:
Deel I  neuroplastische veranderingen in hersenactiviteit geassocieerd met 
chronische (postoperatieve) pijn onderzocht door analyse van het 
spontaan elektro-encefalogram (rustEEG) en opgewekte potentialen 
(evoked potentials (EP’s)).
Deel II  therapeutisch potentieel van een nieuwe orale tablet bestaande uit pure 
THC voor de behandeling van chronische buikpijn.
Deel III  anti-nociceptieve effecten van THC onderzocht door middel van rust EEG 
en pijn gerelateerde EP’s.
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DEEL I: Corticale verwerking van pijnlijke stimuli in patiënten met chronische (postoperatieve) 
pijn
Vrouwen die een borstkankeroperatie moeten ondergaan, hebben een hoog risico 
op het ontwikkelen van chronische pijn. In hoofdstuk 2, hebben we de verwerking 
van pijnlijke stimuli in de hersenen van patiënten met persisterende pijnklachten na 
een borstkanker behandeling onderzocht door gebruik te maken van EP’s in het EEG. 
Negentien patiënten (8 vrouwen met pijn, 11 zonder pijn), die meer dan één jaar geleden 
zijn behandeld voor borstkanker middels een borstbesparende operatie (lumpectomie) 
of volledige borstamputatie (mastectomie), inclusief volledige okselklierdissectie en/
of chemoradiatie, werden vergeleken met elf gezonde vrouwen van ongeveer dezelfde 
leeftijd. Veranderingen in corticale verwerking op pijnlijke elektrische stimuli werden 
in het EEG geregistreerd door middel van pijn gerelateerde EP’s. De aanwezigheid van 
chronische pijn was gerelateerd aan een vertraagde en versterkte stimulus verwerking, 
wat zich uitte als een verhoogde latentietijd en verhoogde amplitude van de positieve 
piek tussen 250-310 ms (P260) van de EP. In vergelijking met gezonde vrijwilligers liet de 
gehele groep borstkankerpatiënten echter een vervroegde P260 piek en tendens naar 
kleinere P260 amplitude zien.
Deze resultaten suggereren dat de twee condities, borstkankerbehandeling en 
chronische pijn, tegenovergestelde effecten laten zien in corticale respons. De 
belangrijkste conclusie van deze studie is dat chronische pijn na borstkankerbehandeling 
geassocieerd is met neuroplastische veranderingen in corticale activiteit, zichtbaar als 
een vertraagde en verstrekte stimulus respons.
Veranderingen in spontaan EEG zijn in een aantal chronische pijn populaties reeds 
geobserveerd, wat suggereert dat chronische pijn veranderingen in de centrale 
pijnverwerking met zich meebrengt door neuroplasticiteit van het centraal zenuwstelsel. 
Deze hypothese was echter nog nooit onderzocht voor chronische buikpijn. In hoofdstuk 
3 hebben wij het rust EEG van patiënten met chronische buikpijn als gevolg van 
chronische pancreatitis vergeleken met vergelijkbare gezonde proefpersonen. Hiervoor 
werd een Fast Fourier Transformatie (FFT) toegepast op het EEG signaal, wat verdere 
analyse in het frequentiespectrum mogelijk maakt. Wij observeerden in patiënten een 
verschuiving van het EEG naar lagere piek alfa frequenties. Chronische pancreatitis 
pijn bleek dus geassocieerd met een vertraging van de spontane hersenactiviteit. Er 
werden geen significante verschillen gevonden in piek alfa amplitude tussen chronische 
pancreatitis patiënten en gezonde proefpersonen. De verschuiving in piek alfa 
frequentie was gecorreleerd met de duur van de pijn, waarbij langdurigere pijn grotere 
verschuiving liet zien, wat suggereert dat piek alfa frequentie een potentiële biomarker 
is voor ziekteprogressie van chronische pijn.
Deze bevindingen helpen ons de onderliggende pathologie van chronische pijn te 
begrijpen, aanvullende diagnoses te stellen en de optimale behandeling te kiezen. 
Daarnaast biedt het EEG een alternatieve methode om de effectiviteit van nieuwe 
analgetica te onderzoeken in patiënten met chronische pijn.
DEEL II: Effectiviteit en veiligheid van THC in chronische buikpijn
Het tweede deel van dit proefschrift concentreert zich op de therapeutische 
toepassing van een nieuwe tablet, bestaande uit pure THC geïsoleerd uit de cannabis 
sativa plant, voor de behandeling van chronische buikpijn. We hebben twee fase 2 
geneesmiddelenstudies uitgevoerd om de klinische effectiviteit, farmacokinetiek, 
farmacodynamiek, farmacogenetica, veiligheid en pijn gerelateerde neuroplastische 
veranderingen in spontaan en opgewekt EEG van orale THC te onderzoeken. De resultaten 
van een gerandomiseerde, dubbelblinde, placebo gecontroleerde studie met een 
eenmalige dosering THC in patiënten met buikpijn als gevolg van chronische pancreatitis 
zijn beschreven in hoofdstuk 4. We vonden dat een eenmalige dosering orale THC niet 
effectief is in het reduceren van chronische pancreatitis pijn in vergelijking tot de actieve 
controle diazepam. De THC werd geabsorbeerd met een gemiddelde tijd tot maximale 
plasmaconcentratie van 123 minuten, wat vergelijkbaar was tussen opiaat gebruikers en 
niet opiaat gebruikers. De absorptie van THC was in een aantal chronische pancreatitis 
patiënten vertraagd, wat resulteerde in een verhoogde variabiliteit tussen patiënten 
in vergelijking met gezonde proefpersonen. Dit is meest waarschijnlijk het gevolg van 
de onderliggende pathologie en het gebruik van comedicatie. Wij concludeerden dat 
orale THC betrouwbare farmacokinetische profielen liet zien en goed getolereerd werd 
met alleen milde tot matige bijwerkingen. De lange termijn effecten van THC tijdens 
een behandeling van 50-52 dagen werden verder onderzocht in een tweede studie. 
De resultaten van deze gerandomiseerde, dubbelblinde, placebo gecontroleerde 
studie, naar de effectiviteit, farmacokinetiek en tolerantie van orale THC in patiënten 
met chronische buikpijn, zijn beschreven in hoofdstuk 5. Vijfenzestig patiënten met 
chronische buikpijn als gevolg van chirurgie of chronische pancreatitis werden at random 
in twee groepen verdeeld om THC tabletten of overeenkomstige placebo tabletten te 
krijgen. Proefpersonen in de THC groep begonnen met een opstapfase (3 mg, 3 maal 
per dag voor 5 dagen en dan 5 mg, 3 maal per dag voor 5 dagen) gevolgd door een 
stabiele doseringsfase (8 mg, 3 maal per dag tot dag 50–52). Patiënten werden tijdens 
de gehele studieperiode gevraagd hun bestaande medicatie (inclusief pijnstillers) 
volgens voorschrift te blijven gebruiken.  In tegenstelling tot onze hypothese liet THC 
geen voordeliger effect zien op chronische buikpijn in vergelijking met placebo. Tussen 
start en einde van de studie gingen pijnscores (visual analoge scale (VAS)) in de THC 
groep met 1.6 punten (40%) omlaag in vergelijking met 1.9 punten (37%) in de placebo 
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groep. Daarnaast werden er geen verschillen gevonden in secundaire uitkomstmaten 
zoals kwaliteit van leven, eetlust en farmacodynamische parameters. Orale THC werd 
over het algemeen goed geabsorbeerd resulterend in adequate farmacokinetische 
plasma concentratie profielen. Zeven patiënten in de THC groep hebben voortijdig de 
studiebehandeling beëindigd wegens bijwerkingen in vergelijking met twee patiënten 
in de placebo groep. Alle (mogelijk) gerelateerde bijwerkingen waren mild tot matig van 
aard.
Wij hebben in deze studie kunnen aantonen dat THC, bij 3 maal daags gebruik voor 
een behandelperiode van 50-52 dagen, veilig was en goed getolereerd werd, maar 
geen pijnstillende werking heeft. Een aanzienlijk placebo effect werd waargenomen, 
wat frequenter geobserveerd wordt in studies met chronische (buik)pijn patiënten. Wij 
adviseerden toekomstige studies alternatieve studiedesigns te kiezen om dit placebo 
effect te reduceren.
Hoofdstuk 6 geeft een overzicht van klinische studies die gedaan zijn naar de 
effectiviteit van diverse op cannabis gebaseerde producten met gestandaardiseerde 
THC inhoud voor chronische niet kanker gerelateerde pijn. Het merendeel van deze 
studies rapporteert een verbetering in pijnscores bij producten van THC (dronabinol). 
De analgetische werking was echter zwak en er werden substantiële placebo effecten 
gevonden. De zwakke kanten van deze studies, welke mogelijk de behandeluitkomsten 
hebben beïnvloed, worden in deze review besproken.
Onderliggende pijnmechanismen, waaronder plasticiteit van nociceptieve en 
cognitieve pijnverwerking, verklaren mogelijk de variatie in analgetisch effect van 
THC in specifieke chronische pijn condities. Tot op heden beoordelen regelgevende 
instanties het therapeutisch potentieel van nieuwe analgetica voornamelijk op basis van 
de subjectieve pijnervaring van de patiënt. Wij bediscussieerden een op mechanismen 
gebaseerde aanpak die verder gaat dan het meten van subjectieve pijnverlichting, om 
voor toekomstig onderzoek het therapeutisch potentieel van THC bij chronische pijn te 
evalueren.
DEEL III: Neuronale mechanismen van THC
In het eerste deel van dit proefschrift concludeerden we dat chronische buikpijn in 
zekere mate kan worden toegeschreven aan maladaptieve mechanismen van neurale 
plasticiteit, die ten grondslag liggen aan chronische pijn. In het tweede deel konden we 
de klinische werkzaamheid van orale THC niet observeren en werd een op mechanisme 
gebaseerde aanpak aanbevolen om de anti-nociceptieve effecten van THC bij chronische 
pijn te evalueren. In de studies die in het laatste deel van dit proefschrift zijn beschreven, 
hebben we de onderliggende pijnverwerkingsmechanismen van THC onderzocht door 
pijn gerelateerde neuroplastische veranderingen in het spontane en opgewekte EEG te 
evalueren, zoals beschreven in hoofdstuk 2 en 3.
Hoofdstuk 7 ging in op de mogelijke anti-nociceptieve effecten van THC door de 
onderliggende pijn gerelateerde corticale activiteit te onderzoeken in de cross-over studie 
gerapporteerd in hoofdstuk 4. We onderzochten of een enkele dosis oraal toegediende 
THC effect heeft op de rusttoestand van het EEG en EP’s op pijnlijke elektrische stimuli 
bij patiënten met chronische pancreatitis. Er werd een concentrische elektrode gebruikt, 
die voornamelijk nociceptieve A-delta vezels activeert middels elektrische stimuli op 
de onderarm en hierbij een naaldachtige pijnsensatie produceert. Beide EEG metingen 
werden achtereenvolgens uitgevoerd voor inname van studiemedicatie en op 1:10, 2:10, 
3:10 en 5:05 uur na toediening van de studiemedicatie. Allereerst hebben we een goede 
test-hertest betrouwbaarheid aangetoond van alfa indices in het rust EEG in chronische 
pancreatitis patiënten. De intra-individuele variabiliteit van de EP componenten 
op baseline vertoonde een redelijk tot goede overeenkomst en ondersteunde het 
gebruik van deze EEG parameters voor verder onderzoek. We konden echter geen 
THC gerelateerde effecten op alfa indices van het rust EEG of EP’s detecteren op pijn 
gerelateerde elektrische stimuli. Pijnscores van de elektrische transcutane nociceptieve 
stimulatie bleven stabiel in de tijd, wat aangeeft dat acute opgewekte pijn ook niet 
door THC werd beïnvloed. Deze resultaten komen overeen met de algehele subjectieve 
ervaring van patiënten met pancreaspijn, bij wie geen analgetisch effect van THC 
werd waargenomen (hoofdstuk 4). Bovendien werden individuele veranderingen in 
subjectieve pijnscores gecorreleerd aan EEG parameters om te beoordelen of individuele 
veranderingen in het EEG verband hielden met onderliggende pijnstillende effecten en 
niet werden veroorzaakt door verstorende factoren zoals sedatie of andere onbedoelde 
effecten. Een significante negatieve correlatie werd gevonden tussen de verandering 
in pijnscores en verandering in piek alfa amplitude, wat aangeeft dat individuele 
behandelingsrespons geassocieerd is met een verhoogde alfa activiteit. Verdere analyse 
van individuele subjectieve pijnscores op baseline in relatie tot objectieve metingen van 
EEG parameters leverde geen correlaties op.
Corticale correlaten van THC werden verder onderzocht en gerapporteerd in hoofdstuk 
8. We onderzochten de effecten van THC na een behandelperiode van 50-52 dagen 
op pijn gerelateerde EEG indices bij patiënten met chronische buikpijn. We toonden 
aan dat de klinische pijnscore geassocieerd was met vertraagde hersenoscillaties in 
rusttoestand, evenals met versterkte N1- en P3-amplitudes opgewekt door nociceptieve 
elektrische stimulatie. Deze correlaties tussen klinische pijnintensiteit en objectieve EEG 
uitkomsten suggereren dat chronische pijn de centrale pijnverwerking beïnvloedt, wat 
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door middel van EEG kan worden geregistreerd. Gebruikmakend van deze maladaptieve 
EEG uitkomstparameters bij chronische pijn, had THC na 50-52 dagen behandeling 
geen invloed op de spontane hersenactiviteit noch op de pijnverwerking. Alleen bij 
patiënten met postoperatieve pijn werd een vertraging in N1-latentie waargenomen 
voor THC behandeling in vergelijking met de placebo. Bovendien konden corticale 
correlaten van THC niet geassocieerd worden met de analgetische werkzaamheid ervan 
en weerspiegelden ze dus niet het individuele behandelingseffect.
De belangrijkste bevindingen van dit proefschrift worden besproken met betrekking 
tot recente literatuur in hoofdstuk 9. Een deel van deze algemene discussie is 
een mechanisme-georiënteerde benadering van pijn bij chronische pancreatitis. 
Aanbevelingen zijn gericht op toekomstig onderzoek en de klinische praktijk. 
Toekomstige klinische studies zouden studiedesigns moeten optimaliseren om 
adequaat om te gaan met potentiële placebo effecten en geavanceerde diagnostische 
hulpmiddelen kiezen om een systematische aanpak op chronische pijn toe te passen. De 
aanwezigheid en het patroon van maladaptieve centrale pijnverwerking voor specifieke 
chronische pijnstoornissen moet verder worden onderzocht. Daarnaast zijn methoden 
voor het identificeren van deze maladaptieve mechanismen bij individuele patiënten en 
behandelingen die op deze mechanismen zijn gericht essentieel voor een succesvolle 
behandeling van chronische pijn.
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Dankwoord
Het is alweer 8 jaar geleden dat ik met dit onderzoeksproject begonnen ben en ik 
heb er altijd met veel plezier aan gewerkt. De veelzijdigheid van het project, zowel 
inhoudelijk als projectmatig, lag mij goed, maar ook de mensen om mij heen hebben 
hier een belangrijke rol in gespeeld. Ik wil graag iedereen bedanken die op eigen wijze 
een bijdrage heeft geleverd aan de totstandkoming van mijn proefschrift. Een aantal 
mensen wil ik graag in bijzonder bedanken.
Prof. dr. van Goor, beste Harry, natuurlijk moet jij hier als eerste genoemd worden. 
Je hebt mij altijd de ruimte en het vertrouwen gegeven om te leren en het op m’n 
eigen manier te doen. We moesten in het begin een beetje aan elkaar wennen en 
waren het lang niet altijd met elkaar eens. Fijn dat ik altijd open het gesprek met je 
kon aangaan en er ruimte was voor discussie. Het heeft onze samenwerking versterkt. 
Ik wil je ontzettend bedanken voor alle kansen die je mij hebt gegeven en kijk uit naar 
de komende jaren met weer mooie en ambitieuze projecten in het voorruitzicht.
Prof. dr. Vissers, beste Kris, dank voor de prettige en constructieve overleggen. In het 
begin bespraken we hoofdzakelijk projectgerelateerde onderwerpen, maar je kende 
m’n interesse in de organisatie en nam me daar later geregeld in mee. Dank voor het 
positieve meedenken, de razendsnelle correcties en het bewaken van mijn doelen.
Dr. Wilder-Smith, beste Oliver, je was als pijnexpert en bedreven wetenschapper nauw 
betrokken bij dit project. Jouw visie op chronische pijn heeft een belangrijke stempel 
gedrukt op de studies binnen dit proefschrift. Dank dat je altijd de tijd voor me nam en 
me nooit zonder oplossing weer liet vertrekken. Ik waardeer je oprechte interesse voor 
de persoon en de wetenschap.
Leden van de manuscriptcommissie: prof. dr. Burger, prof. dr. Roozendaal en 
prof. dr. Huijgen, hartelijk dank voor het beoordelen van mijn proefschrift op zijn 
wetenschappelijke inhoud.
Graag wil ik alle gezonde proefpersonen en patiënten bedanken voor hun deelname 
en inzet. In totaal hebben 157 proefpersonen minimaal één, maar meestal diverse 
bezoeken gebracht aan het Radboudumc voor mijn onderzoek. Veel dank daarvoor!
Het zaadje van mijn wetenschappelijke interesse voor neurofysiologisch pijnonderzoek 
werd gepland tijdens mijn afstudeerstage op de afdeling anesthesiologie, pijn en 
palliatieve geneeskunde. Hans en Emanuel, wat een voorrecht om 9 maanden met 
jullie een kamer te mogen delen. Ik heb ontzettend genoten van de inhoudelijke 
discussies, foute grappen en wederzijdse betrokkenheid. Helemaal tof dat we vrienden 
zijn geworden en nog altijd bij elkaar terecht kunnen voor een goed advies (oplossing: 
er moet altijd meer gedronken worden). Vanaf heden is het dr. Mooi voor jullie.
Beste collega’s van het Donders Instituut, afdeling biologische psychologie, ik heb 
me als vreemd eendje altijd erg welkom gevoeld. De congressen naar Krakau waren 
iedere keer weer fantastisch.  Dr. Tineke van Rijn, dank voor je tijd en moeite om je in 
de EEG analyse te verdiepen. Prof. dr. Gilles van Luijtelaar, dank dat je in mijn corona 
wilt zitten. De samenwerking wordt voortgezet met dr. Joukje Oosterman. Zeg Joukje, 
wanneer gaan wij naar Krakau?
Diverse afdelingen zijn betrokken geweest in de uitvoer van de geneesmiddelen 
studies. In bijzonder wil ik Simone Hins-de Bree, Jackie van Gemert en Hettie Maters 
van het CRCN bedanken voor hun ondersteuning en het GCP-proof maken van onze 
studies. Ook zonder onze consortiumpartners, Echo Pharmaceuticals en afdeling 
Geriatrie van het Radboudumc, hadden we dit project niet kunnen uitvoeren. Het 
ging niet altijd makkelijk, maar met vallen en opstaan hebben we toch een prachtig 
resultaat neergezet. Emanuel, Luuk en Dagmar, dank voor jullie directe inzet op dit 
project. Helaas bleek het voor beperkte periodes, maar je bent nooit te laat om je 
ambities bij te stellen.
Beste onderzoekers van de afdeling Heelkunde, ik heb ondertussen heel wat collegae 
onderzoekers voorbij zien komen, maar de goede sfeer in de groep blijft een constante 
factor. Het begon op kamer 3.47, waar meestal hard gewerkt werd, maar op z’n tijd ook 
een hoop onzin verkondigd werd. Tjarda, je hebt het maar zwaar met ons te stellen 
gehad (en nog steeds wil je een kamer met me delen). Chema, Dagmar, Willem en 
Sander, leuk dat we af en toe nog onderzoeksherinneringen oprakelen, want goede 
imitaties kunnen oneindig herhaald worden.
Ook nu is er weer een enthousiaste en ambitieuze groep onderzoekers. Ik vind het 
ontzettend leuk om mijn kennis en ervaring met jullie te delen en op die manier deel uit 
te maken van jullie opleiding tot onderzoeker. Gelukkig wordt er naast hard gewerkt, 
ook hard ontspannen. Dank voor alle biertjes, bitterballen en brakke ochtenden.
Staf en secretariaat van de afdeling Heelkunde, dank voor de steun en het prettige 
werkklimaat. Het onderzoek bloeit en ik ben blij dat ik hier een rol in mag spelen.
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Lieve familie en vrienden, bedankt voor jullie belangstelling en gezelligheid. Heerlijk om 
in de avonden en weekenden de ontspanning op te zoeken en het werk even daar te 
laten. Dat is waar ik voor leef!
Lieve papa en mama, wie had ooit gedacht dat ik zou promoveren. Dank voor de vrijheid 
die jullie me hebben gegeven om mijn eigen keuzes te maken. Deze leken op het eerste 
gezicht misschien niet altijd de meest verstandige, maar jullie stonden toch altijd achter 
me. Dit proefschrift was er niet geweest zonder jullie onvoorwaardelijke steun en liefde. 
De laatste paar zinnen zijn voor Martijn, op wie ik blindelings kan vertrouwen en die 
me elke dag aan het lachen maakt. Wat hebben we het fijn samen! Dank dat je er altijd 
voor me bent. Ik kijk uit naar een mooie toekomst met jou en met ons prille gezin. De 
allerlaatste zin is voor onze nieuwste aanwinst. Benthe, heerlijk dat je er bent meisje, 
want met jou is elke dag weer een feestje!
About the Author
Marjan de Vries was born August 28th 1983 in Havelte, The 
Netherlands. After high school in 2002 (CSG Dingstede, 
Meppel), she decided to move to Nijmegen to study 
physical therapy at HAN University of Applied Sciences. 
She became particularly interested in neurophysiology 
of pain and did her first scientific work on collateral 
involvement of sensory nerves in patients with peripheral 
facial paralysis (dr. Carien Beurskens at Radboud University 
Medical Center). After graduation in 2006, she started 
working as physiotherapist, but she struggled with the 
limited evidence available in clinical practice. She went travelling to South Africa and 
did voluntary work as physiotherapist in HIV clinics in Durban. In 2007, she started 
Biomedical Sciences at Radboud University Nijmegen and focused on clinical human 
movement sciences. She obtained her master’s degree in 2010 after a major internship on 
neurophysiology of pain under supervision of dr. Emanuel van den Broeke (Department 
of Anaesthesiology, Pain and Palliative Medicine at Radboud University Medical Center 
and Donders Institute for Brain, Cognition and Behaviour).
In the fall of 2010, prof. dr. Harry van Goor asked her for a research position on a 
European funded project aimed to perform phase II clinical drug studies with cannabis 
based tablets (Department of Surgery at Radboud University Medical Center). This 
research project offered ample opportunities to develop herself in a broad field of 
pharmacology, neuroscience and (experimental) pain. Additionally, she became familiar 
with the comprehensive laws and regulations applicable to studies with non-registered 
medicines, and assumed the role of project manager. In 2014, the Department of 
Surgery offered her a position as research manager, in which she can expand and share 
her knowledge and experience in all aspects of research up till now.
Marjan is living together with her husband Martijn Duinkerke and their daughter Benthe. 
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Stellingen behorende bij het proefschrift:
Tetrahydrocannabinol in Chronic Pain
Cortical Mechanisms of Pain and Analgesia
Marjan de Vries
1. Chronische pijn na een borstkankerbehandeling leidt tot een versterkte maar 
vertraagde verwerking van pijnlijke stimuli in het centraal zenuwstelsel. Dit 
proefschrift
2. Chronische pancreatitis pijn leidt tot een vertraagde hersenactiviteit in rust. Dit 
proefschrift
3. Het pijnstillend effect van THC bij chronische pancreatitis patiënten berust op een 
placebo respons. Dit proefschrift
4. Er is onvoldoende goed bewijs van effectiviteit van cannabis ‘medicatie’ op 
chronische pijn. Dit proefschrift
5. THC in een orale tablet geeft een betrouwbaar farmacokinetische profiel en is veilig 
in gebruik voor patiënten met chronische pijn. Dit proefschrift
6. Het grote placebo effect van de ‘wietpil’ in een trial bij patiënten met chronische 
buikpijn wordt veroorzaakt door de hoge verwachtingen die deze patiënten hebben 
van deze pil. Dit proefschrift
7. EEG is een betrouwbare methode om de gevolgen van centrale sensitisatie in 
patiëntengroepen met chronische pijn te detecteren. Dit proefschrift
8. Wetenschappers zouden moeten worden beloond om negatieve resultaten open 
access te publiceren.
9. ‘Dokter. Feit dat hij komt is halve genezing.’ Herman Pieter de Boer, schrijvend kunstenaar
10. Een investering in kennis betaalt zich terug met de hoogste rente. Benjamin Franklin, 
1750, Poor Richard’s Almanac

